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Abstract 
BCC is the commonest cancer in European-derived populations and Australia has the 
highest recorded incidence in the world, creating enormous individual and societal cost in 
management of this disease. The incidence of this cancer has been increasing 
internationally, with evidence of a 1 to 2% rise in incidence in Australia per year over the 
last two decades. 
The main four epidemiological risk factors for the development of BCC are ultraviolet 
radiation (UVR) exposure, increasing age, male sex, and inability to tan. The pattern and 
timing of UVR exposure is important to BCC risk, with childhood and intermittent UVR 
exposure both associated with an increased risk. The complex of inherited characteristics 
making up an individual’s ‘sun sensitivity’ is also important in determining BCC risk. 
Very little is known about population genetic susceptibility to BCC outside of the rare 
genodermatosis Gorlin syndrome. Mutations in the tumour suppressor gene patched 
(PTCH) are responsible for this BCC predisposition syndrome and the molecular 
pathway and target genes of this highly conserved pathway are well described. 
Derangments in this pathway occur in sporadic BCC development, and the PTCH gene is 
an obvious candidate to contribute to non-syndromic susceptibility to BCC. 
The melanocortin 1 receptor (MC1R) locus is known to be involved in pigmentary traits 
and the cutaneous response to UVR, and variants have been associated with skin cancer 
risk. Many other genes have been considered with respect to population BCC risk and 
include p53, HPV, GSTs, and HLAs. There is preliminary evidence for specific familial 
aggregation of BCC, but very little known about the causes. 
56 individuals who developed BCC under the age of 40 in the year 2000 were recruited 
from the Skin and Cancer Foundation of Australia’s database. This represents the 
youngest 7 – 8% of Australians with BCC from a database that captures approximately 
10% of Sydney’s BCCs. 212 of their first degree relatives were also recruited, including 
89 parents and 123 siblings of these 56 probands.  
17 
All subjects were interviewed with respect to their cancer history and all reports of cancer 
verified with histopathological reports where possible. The oldest unaffected sibling for 
each proband (where available) was designated as an intra-family control. All cases and 
control siblings filled out a questionnaire regarding their pigmentary and sun sensitivity 
factors and underwent a skin examination by a trained examiner. Peripheral blood was 
collected from these cases and controls for genotyping of PTCH. All the exons of PTCH 
for which mutations have been documented in Gorlin patients were amplified using PCR.  
PCR products were screened for mutations using dHPLC, and all detectable variants 
sequenced. 
Prevalence of BCC and SCC for the Australian population was estimated from incidence 
data using a novel statistical approach. Familial aggregation of BCC, SCC and MM 
occurred within the 56 families studied here. The majority of families with aggregation of 
skin cancer had a combination of SCC and BCC, however nearly one fifth of families in 
this study had aggregation of BCC to the exclusion of SCC or MM, suggesting that BCC-
specific risk factors are also likely to be at work. Skin cancer risks for first-degree 
relatives of people with early onset BCC were calculated: sisters and mothers of people 
with early-onset BCC had a 2-fold increased risk of BCC; brothers had a 5-fold increased 
risk of BCC; and sisters and fathers of people with early-onset BCC had over four times 
the prevalence of SCC than that expected. For melanoma, the increased risk was 
significant for male relatives only, with a 10-fold increased risk for brothers of people 
with early-onset BCC and 3-fold for fathers. 
On skin examination of cases and controls, several phenotypic factors were significantly 
associated with BCC risk. These included increasing risk of BCC with having fair, easy-
burning skin (ie decreasing skin phototype), and with having signs of cumulative sun 
damage to the skin in the form of actinic keratoses. Signs reflecting the combination of 
pigmentary characteristics and sun exposure - in the form of arm freckling and solar 
lentigines - also gave subjects a significantly increased risk BCC. Constitutive red-green 
reflectance of the skin was associated with decreased risk of BCC, as measured by 
spectrophotometery. Other non-significant trends were seen that may become significant 
in larger studies including associations of BCC with propensity to burn, moderate tanning 
18 
ability and an inability to tan. No convincing trend for risk of BCC was seen with the 
pigmentary variables of hair or eye colour, and a non-significant reduced risk of BCC 
was associated with increasing numbers of seborrhoeic keratoses. 
Twenty PTCH exons (exons 2, 3, 5 to 18, and 20 to 23) were screened, accounting for 
97% of the coding regions with published mutations in PTCH. Nine of these 20 exons 
were found to harbour single nucleotide polymorphisms (SNPs), seen on dHPLC as 
variant melting curves and confirmed on direct sequencing. SNPs frequencies were not 
significantly different to published population frequencies, or to Australian general 
population frequencies where SNP database population data was unavailable. Assuming a 
Poisson distribution, and having observed no mutations in a sample of 56, we can be 
97.5% confident that if there are any PTCH mutations contributing to early-onset BCC in 
the Australian population, then their prevalence is less than 5.1%. 
Overall, this study provides evidence that familial aggregation of BCC is occurring, that 
first-degree relatives are at increased risk of all three types of skin cancer, and that a 
combination of environmental and genetic risk factors are likely to be responsible. The 
PTCH gene is excluded as a major cause of this increased susceptibility to BCC in 
particular and skin cancer in general. The weaknesses of the study design are explored, 
the possible clinical relevance of the data is examined, and future directions for research 
into the genetics of basal cell carcinoma are discussed. 
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Chapter 1: Introduction and Background 
 
1.1. Introduction 
Basal cell carcinoma (BCC) is the commonest cancer in fair-skinned populations. Non-
melanoma skin cancers (NMSC) make up 80% of all new cancers in Australia, presenting 
an enormous individual and financial cost to Australians: treating these cancers 
accounted for 42% of cancer related medical costs in 1993 and cost the Australian 
community $280 million that year. Great gains have been made over recent decades 
regarding the understanding of epidemiological associations and risks for BCC, with 
much of this research based in Australia where the incidence is the highest in the world. 
Yet, unlike other common cancers such as breast and colon cancer, very little is known 
about population genetic susceptibility to BCC outside one rare familial syndrome. This 
project studies early-onset cases and their relatives in an attempt to further elucidate the 
causes of BCC, the commonest of cancers. 
The term NMSC encompasses both BCC and squamous cell carcinoma (SCC): both are 
common tumours derived from the same keratinocyte cell population in the skin, 
although they have distinct biological and pathological features. There are other NMSCs 
apart from these including Merkel’s cell carcinoma and atypical fibroxanthoma, however 
as these are so rare, the term NMSC is usually used to refer to BCC and SCC only. 
BCC is more than twice as common as SCC in Australia [1], and although very locally 
destructive, rarely metastasizes. SCC does metastasize, usually after a long latency, and is 
responsible for nearly all the 400 deaths per year attributable to NMSC. Neither cancer 
has any direct biological relationship with malignant melanoma (MM), which arises 
instead from neural crest-derived pigment producing cells that migrate into the skin 
during early development. 
Sunlight is known to be one of the major causes of all three types of skin cancer, through 
the mutagenic effects of ultraviolet radiation (UVR). Other major epidemiological 
associations include advancing age, male sex (especially in older groups), and a 
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decreased ability to tan. Pigmentary characteristics such as skin, hair, and eye colour also 
contribute to risk. The timing and pattern of sun exposure are known to be important for 
BCC risk: exposure in childhood and teenage years increase an individual’s later risk, and 
intermittent exposure such as that received on summer holidays increases risk more than 
continuous exposure such as that encountered in an outdoor occupation. Knowledge of 
these important epidemiological associations allowed the Australian government to 
mount an important public health preventative campaign in the early 1980’s called ‘slip, 
slop, slap’ that encouraged awareness of the dangers of sun exposure, and the importance 
of preventative measures (‘slip on a t-shirt, slop on some sunscreen and slap on a hat’). 
This message appears to have permeated the community’s consciousness over the last 
few decades: some attribute the decline of skin cancer in younger age groups to the 
success of such campaigns [1]. 
Most chronic diseases are found to have both genetic and environmental aetiological 
components, with multiple factors interacting in complex ways and often expressed as 
risk phenotypes. There is no reason to believe why BCC would not be subject to the same 
aetiological forces. Familial aggregation studies have been important bases to explore the 
combination of inherited and exogenous risk factors in cancer [2]. Historically, there 
seems to have been a reluctance to approach family studies of NMSC. Perhaps the 
obvious importance of sun exposure in the aetiology of BCC has discouraged interest in 
additional genetic influences, or it has been assumed that any familial aggregation of 
BCC would merely reflect sharing of high-risk skin types. There are also methodological 
difficulties in such studies. First, the high burden of disease makes mandatory reporting 
of NMSC to cancer registries cumbersome, and makes it harder to demonstrate increased 
incidence in relatives. Second, the fact that NMSC are often destructively treated reduces 
the available data from histological confirmation, which is important in verifying cancer 
reports in probands and relatives. 
Although much work has been done on rare genodermatoses involving BCC, very little is 
known about genetic susceptibility to BCC outside these settings. A small Australian 
study looking at familial clustering of NMSC that noted apparent differences in 
susceptibility to BCC versus SCC between NMSC pedigrees, suggesting differing genetic 
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influences [3]. However, there have been no larger-scale studies of this phenomenon. 
Gorlin syndrome is one of the rare familial syndromes that has received research 
attention, and involves autosomal dominant inheritance of marked susceptibility to BCC 
and a range of developmental defects. Mutations in the cell growth regulatory gene 
patched (PTCH), when present in the germline are responsible for this disorder. They 
have also been found in a high percentage of sporadic tumours, suggesting a critical 
involvement of this pathway in BCC tumour development generally. Furthermore, mice 
with Gorlin syndrome-like knockouts of one copy of PTCH develop BCCs if exposed to 
UVR, mimicking the human situation [4]. No studies have yet investigated whether 
germline mutations or less highly penetrant variants of this gene might account for part of 
non-syndromic BCC susceptibility in the general population. 
1.2. BCC and its management 
1.2.1. Cell of origin 
BCCs are composed of lobules of basaloid cells with hyperchromatic nuclei and scant 
cytoplasm that are pluripotential cells derived, or closely related to, basal keratinocytes 
and follicular or epidermal stem cells [5]. The cell of origin of the basal cell carcinoma 
has been contentious however typing of cytokeratins within tumour cells suggests a 
follicular origin [6, 7]. Metastasis occurs rarely, at a rate of 1 in 1000 to 35000 and this 
infrequency is probably due in part to the dependency of the tumour for a specific dermal 
connective tissue stroma for its growth [8, 9]. 
1.2.2. Body sites affected 
BCC virtually never arises in stratified squamous epithelium other than the skin and only 
extremely rarely affects the mucosal surfaces of the body [10, 11]. All over the world, 
BCC is most commonly seen on the skin of the head and neck [12, 13] and is almost 
always more common in men than in women [14]. In fact, in light-skinned European-
derived populations the rate is between 18% and 40% higher in men than women [15, 
16]. Recent studies in Australia have shown that rates of BCC may be higher in women 
of younger age groups and in men of older age groups [1]. Detailed body-site specific 
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rates of BCC incidences are usually adjusted for the actual surface proportion covered by 
the site to allow comparison and are thus also called ‘relative body densities’ [14]. The 
relative body densities of BCC incidences in Australia can be seen in a large series from a 
population based study in Townsville in Northern Queensland [17]. Highest densities of 
BCC for both genders in this series were on the lip, orbit, and nasolabial fold. The next 
highest were on the ear, nose, and cheek, then forehead, eyebrow, chin, jaw and pre-
auricular region. Following these regions, the neck and shoulders showed high densities 
as did the posterior trunk in men and the sun-exposed surface of the arms in women. For 
both genders the less sun-exposed body sites such as heels and thighs showed the lowest 
incidence rates. For all body sites except buttocks and genital region, incidence rates for 
women were lower than for men. Male preponderance was especially noticeable for the 
scalp which may be reasonably attributed to hair loss in men giving rise to increased 
exposure of the scalp to solar radiation. The near absence of BCC from the backs of the 
hands has generally assumed to be due to the nature of the skin rather than to complex 
effects of sun exposure.  
1.2.3. BCC classification 
There is no generally agreed classification of BCC in Australia however the commonest 
subtypes reported are grouped by histological growth pattern [18]; nodular, superficial, 
and morpheaform/sclerosing. BCCs are more likely to be nodular on the head and neck 
and superficial spreading on the trunk and upper limbs [19, 20].  The most common is the 
nodular type which appears as a dome-shaped shiny transluscent (pearly) papule with a 
telangiectatic surface, often with surrounding actinic damage. It may become crusted, 
ulcerated or pigmented, and usually has a firm consistency.  Superficial BCC presents as 
a bright pink, shiny, usually well defined erythematous scaly plaque, with a rolled edge 
that shows slow centrifugal growth; areas of erosion or crusting may also arise in these 
lesions. Morpheaform or sclerosing BCC tends to be more aggressive with a whitish 
colour, poorly defined margins and an indurated consistency. It is often more difficult to 
detect clinically and therefore more extensive upon diagnosis, often with wide subclinical 
extension [21]. 
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1.2.4. BCC treatment 
1.2.4.1. Treatment options 
BCCs often become more aggressive with recurrence and therefore the first priority in the 
treatment of BCC is complete eradication of the tumour. This is done with the additional 
goals of restoration of function and optimal cosmetic result. Shave or punch biopsies may 
be obtained for a tissue diagnosis prior to destructive or excisional therapy, however in 
practice, a prior tissue diagnosis is often not obtained. Surgical excision remains the gold 
standard treatment against which other treatments are judged, and may be done with or 
without Moh’s micrographic surgery. Other surgical treatments include curettage and 
diathermy, and cryotherapy. Non-surgical treatment options include radiotherapy, topical 
treatments such as 5-fluorouracil, photodynamic therapy, laser therapy, imiquimod 5% 
cream, and intralesional/perilesional cytokines. The choice of therapy depends on the 
characteristics of the individual tumour, patient preference, and the resources available 
[19, 21]. 
1.2.4.2. Surgical treatments 
Surgical excision can often be done by excising a simple ellipse around the tumour under 
local anaesthetic with a margin of 3-4mm. Moh’s microscopically controlled excision is 
considered the treatment of choice if the tumour is very large, recurrent, poorly defined, 
or displays an aggressive histological pattern. It is also indicated for tumours in locations 
associated with a high risk of recurrence such as the periorbital and facial areas, and for 
those in areas of cosmetic importance. In this technique, frozen sections of the lesion 
undergo histopathological examination during surgery allowing the entire excision 
margin to be visualised. These are interpreted by the operator to better allow for complete 
excision and to minimise removal of normal surrounding tissue [21]. Curettage and 
diathermy give good results when reserved for small, well-defined, relatively superficial 
tumours and its success is highly operator-dependent. Cryotherapy also tends to be used 
on small superficial tumours. These destructive treatments are simpler than excision 
however they prevent the histopathological verification of these cancers and also 
verification of the adequacy of excision by visualization of tumour margins. Furthermore, 
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destructive treatments and the concomitant uncertainty of diagnosis make the estimation 
of true incidence of this type of cancer very difficult. The resulting wound can take 
longer to heal from curettage or cryotherapy than wounds resulting from excision. Five 
year cure rates for primary BCC with surgical techniques are in the order of 95% [22, 
23], and closer to 99% for Moh’s micrographic surgery on a primary tumour [24]. 
1.2.4.3. Non-surgical treatments 
Non-surgical techniques are increasingly employed for the treatment of BCC. 
Radiotherapy has been used on all stages of BCC with results comparable to surgery [25-
27]. It requires a number of weeks for receiving then healing, and is associated with some 
long term sequelae including scarring and increased neoplasia risk. It is therefore usually 
reserved for either: (a) extensive lesions where major surgery is not appropriate, or (b) 
elderly patients in sites that are difficult to reconstruct and would be associated with 
considerable morbidity, as the concerns regarding long term sequelae of radiotherapy are 
small [28]. Radiotherapy can be also be used to complement surgery for cases of 
persistent, recurrent or advanced tumours [5]. Topical treatments for BCC can give good 
cosmetic results and can be effective treatment in superficial BCCs. 5-fluorouracil cream 
is useful in the management of multiple superficial BCCs on the trunk and limbs [29]. 
Imiquimod functions as an immune system modulator and has recently shown to be 
efficacious in the treatment of superficial BCC [27, 30, 31]. Its antitumour properties are 
related to its stimulation of interferons and other cytokines, and of antigen presenting cell 
function. Intralesional injection of recombinant interferon-α has been only partially 
successful with reported cure rates varying between greatly [5, 31, 32]. Topical 
photodynamic treatment may be useful for the treatment of superficial BCC where 
standard surgical intervention poses difficulties, for example in patients who have 
bleeding disorders or pacemakers. It involves the application of a systemic or topical 
photsensitising chemical which leads to photodestruction when the skin is subsequently 
exposed to light [33]. Laser therapy may offer some advantages in the precision of tissue 
removal; however the majority of tumours are better managed by the less expensive 
commonly available techniques. Intralesional interferon, photodynamic therapy, and laser 
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therapy should be considered investigational until confirmed and reproducible outcomes 
are established in prospective trials [5]. 
1.3. Incidence 
1.3.1. World burden of NMSC 
Basal cell carcinoma of the skin is the most common malignancy in populations of 
European origin including North America and Australia. The world burden of 
nonmelanoma skin cancer (NMSC; BCC and squamous cell carcinoma or SCC) is 
enormous: worldwide, NMSC is three times more common than lung cancer, the next 
most common cancer [34]; the incidence of NMSC alone in the United States is 
approximately equal to that of all non-cutaneous cancers combined [35]. Nonmelanoma 
skin cancer is by far the most common cancer in Australia where it outnumbers all other 
forms of cancer by 3 to 1. We spend more on treating NMSC than any other cancer, 
costing the Australian health sector $280 million in 1993/1994 [36]. Australia has the 
highest incidence of NMSC in the world with Western Australia having the highest ever 
recorded incidence [16].  
1.3.2. Australian incidence and prevalence data 
1.3.2.1. Methods of data collection 
Data on the prevalence and incidence of NMSC in Australia has been collected using a 
variety of methodologies and with different subsections of the Australian population, 
making the results very difficult to compare directly. These include national surveys, 
state-based surveys, analysis of state-based cancer registry data, and smaller regional 
community studies. One of the most important differences in methodology between 
studies is the decision to include lesions treated destructively prior to histopathological 
confirmation. The inclusion of lesions treated destructively reduces the risk of 
underestimation of incidence figures, but it does so at an increased risk of inclusion of 
misdiagnosed lesions; the misdiagnosis rate by experienced Australian dermatologists has 
been estimated at as high as 41% for BCC and even higher for SCC [37, 38]. 
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Periodic surveys such as the Australia-wide survey of NMSC by Staples [1] can provide 
good estimates of incidence and prevalence in broad groupings of histological type and 
population characteristics. The series by Staples et al [1] is the most recent and extensive 
national survey of NMSC incidence in Australia giving figures for the incidence of BCC 
and SCC age-adjusted to the World standard population. This series also allows data 
analysis by individual States and by three zones of latitude. It looked at all cancers 
reported over one year including those with a clinical diagnosis only. National telephone 
surveys of households randomly selected by the electoral roll were performed in 1985, 
1990, and 1995, and reports of treated skin cancer in the previous 12 months were 
verified clinically and histopathologically if possible.  
Cancer registries provide a sufficient sample size over extended time periods to permit a 
detailed description of skin cancer patterns and time trends at specific body sub sites, 
within narrow demographic categories and at different latitudes. Unfortunately, NMSC is 
unsuitable for routine cancer registration in Australia due to the sheer numbers of them 
within the Australian community, the way that many lesions are treated destructively 
without histopathological confirmation, and the fact that this often occurs outside a 
hospital setting. The only cancer registries to have recorded NMSC in Australia were 
State based and have since ceased recording these cancers [39-41]. The Tasmanian 
Cancer Registry collected data between 1978 and 1987 [39]. It only included 
histopathologically confirmed lesions or those referred for radiotherapy, and only the first 
BCC treated per year. The Queensland state-based study involved reporting all treated 
NMSCs during a six month period in 1984 by general practitioners and hospital 
outpatient departments in four representative areas of the State [40]. Cancers that were 
confirmed histopathologically as well as those treated destructively were included.  
Studies of small communities such as those performed in Townsville in Queensland [17], 
Maryborough in Victoria [42], and Geraldton in Western Australia [16] have the 
advantage of allowing longitudinal assessment including detailed skin examination and 
risk factor assessments. Individuals can be screened and then followed up over time to 
detect any incident malignant lesions. This method may give a more accurate assessment 
of the incidence within that population than relying on subjects’ recall of treated lesions 
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because it less likely to miss unreported or undiagnosed tumours. It is an expensive and 
time consuming method of data collection and therefore impractical for larger studies.  
1.3.2.2. Comparison of Australian incidence data 
Important information about the incidence, epidemiology and risk factors for BCC have 
been obtained by combining information from all of these studies. A comparison of the 
figures can be seen in table 1.1, with a summary of the national survey data in figure 1.1. 
These incidence figures are alarmingly high and differ quite dramatically according to 
location, sex, and methodology of the study. The figures from the carefully-screened 
community studies include the largest reported incidence for BCC in the world to date 
from Geraldton in Western Australia. Where incidence was measured over time it is clear 
that incidence figures of both BCC and SCC in Australia have been increasing, with a 
rise of 1 to 2% per year over the periods studies. Interestingly, the national survey 
showed a slight decrease in incidence of BCC in people under 40 years of age which may 
reflect changes in attitude and behaviour towards sun exposure, perhaps due in part to 
extensive public health campaigns operating in Australia for the last 20 years [43]. 
All of the Australian studies show increasing incidence with age and higher incidences 
for men than for women with the exception of a slightly larger incidence in women than 
men in the under-40s. This sex difference may be influenced by differences in ultraviolet 
radiation (UVR) exposure between younger men and women and/or by differences in rate 
of presentation for medical treatment. All studies also showed higher incidence of BCC 
than SCC, with incidence of BCC ranging from between 2.5 and 4 times the incidence of 
SCC. A latitudinal gradient emerged within the national survey and between the State-
based surveys where incidence is clearly greater for populations closer to the equator.  
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Table 1.1 Comparison of measured incidences of BCC found in Australian studies 
Population studied Type of study Time period  Males per 
100,000* 
Females per 
100,00* 
Australia [1] National survey 1995 955 629 
Tasmania [39] State cancer registry 1978-1987 219 110 
Queensland [40] State cancer registry 1984 1474 713 
Nambour, QLD [44] Community survey 1986 2074 1579 
Townsville, North 
QLD [17] 
Community survey 1996-1997 2058 1195 
Maryborough, VIC 
[42] 
Community survey 1982-1986 2244 1069 
Geraldton, WA [16] Community survey 1987-1992 7067 3379 
*age-standardised rate 
 
Figure 1.1 Observed rates and age-specific incidence curves with 95% confidence intervals for BCC and 
SCC for males and females from 1995 Australia. 
 (Created with permission from corrected raw data by M Staples from data reported in [1]) 
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1.3.3. International incidence and prevalence data 
1.3.3.1. International cancer registry data 
There are more cancer registries that include NMSC in countries other than Australia 
which is likely to be due to the lower incidence and therefore reduced burden of 
diagnosis and reporting. Despite this reduced burden, these registries sometimes still have 
difficulty obtaining accurate records for NMSC [45]. The incidence figures for NMSC 
determined internationally are universally lower than those seen in Australian populations 
although a trend towards increasing incidence is also seen in these disparate populations. 
Cancer registries that include data on NMSC have operated in Nordic countries[46], 
Southern European regions [47], Slovakia [13], New Hampshire [48] and Southeastern 
Arizona [49]in the United States, the Swiss canton of Vaud [50], Singapore[51], and the 
Netherlands [52]. Smaller population based incidence studies have also been performed 
on populations in every continent.  
Table 1.2 Comparison of incidence BCC worldwide per 100,000 * 
Location BCC Men BCC Women 
Australia [1] 955 629 
United States [53] 247 150 
United Kingdom [54] 128 105 
Finland [55] 49 45 
Switzerland [50] 52 38 
Netherlands [52] 53 38 
Slovakia [13] 38 29 
Hawaii [56] 576 298 
*World age-standardised rate 
 
 
1.3.3.2. Differences between Australian and International incidence 
data 
The most dramatic difference between the data collected in these countries compared 
with Australian data is the 5-100 times lower rate of BCC incidence seen in European-
derived populations outside Australia (see table 1.2). For instance the incidence of BCC 
in Slovakia in the period 1993 to 1995 was estimated at 38 per 100,000 for men and 29 
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for women [13]. In Finland from 1991 to 1995 it was 49 per 100,000 for men and 45 for 
women [55]. We can compare this to the national Australian survey which reported a 
combined (men and women) figure of 788 for the same time period. The Australian 
national survey figures are likely to be larger than Australian cancer registry figures by a 
factor of three. For BCC in 1985 Staples et al [1] report an overall age-standardised 
incidence of 333 per 100,000 for greater than 37°S latitude. Tasmania lies in a region 
entirely greater than 40°S latitude and the registry’s comparable total incidence figure 
from a similar time in history was 111, exactly one third the nationally estimated figure. 
We should therefore reduce the survey figure from 788 to 263 to make it comparable to 
any cancer registry estimate. This estimate still remains at least five-fold larger than those 
seen in Northern Europe.  
Another difference between the Australian and international data on incidence is the 
variation in male to female ratios. Most studies conducted on Australian populations 
show greater male than female incidence, although there is evidence that this ratio is 
reversing in younger cohorts [1, 57]. The only populations to record incidences greater in 
women than in men are in Asia, and include studies on Korean [58] and Japanese 
populations [12]. This may be due to differences in genetic or environmental risk factors 
between the different populations, or more likely, a combination of both. 
1.3.3.3. Similarities between Australian and international incidence data 
Similarities also exist between Australian and international studies, the most striking of 
which is a trend towards increasing incidence of BCC. Annual percentage increases of 
three to 6% have been reliably recorded across a number of studies of European-derived 
populations, with similar rates of increase for BCC and SCC [59]. The New Hampshire 
Skin Cancer Study Group from the United States of America report an increase of more 
than 80% in incidence from 1979 to 1994 in both men and women [60]. Incidence data 
from the Eindhoven Cancer Registry in the Netherlands collected between 1973 and 2000 
also show a rapid increase in incidence for both sexes with figures doubling over this 
period [61]. Over these last few decades, figures have doubled in Sweden [62], increased 
by 70% in men and 65% in women in Slovakia [13], and increased steadily in Singapore 
at a rate of 3% per year for nearly 30 years [63].  
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It is clear that people with darker pigmentation have a lower incidence of BCC than 
lighter-skinned people living in the same environment. For example, in Kenya the 
incidence of BCC is 0.65 per 100,000 for residents with darkly pigmented skin and 585 
per 100,000 for the European-derived Africans living in the same community, indicating 
a substantially increased risk in the fairer-skinned residents [64]. In Qatar in the Middle 
East, the incidence of BCC is also higher in Europeans living in there compared with 
locally born residents [65]. Non-Hispanic whites in Southeastern Arizona have 11 times 
the incidence of BCC compared with Hispanic whites [49]. 
An obvious trend that emerges from incidence studies is that the risk of BCC increases as 
one gets closer to the equator. Within Australia, the nationwide survey by Staples et al [1] 
gives the most conclusive evidence of this as it samples population from the entire 
continent of Australia and looks specifically at this question. Over the decade studied, a 
latitudinal gradient in incidence of BCC remains evident with a trend to significantly 
higher BCC incidence as latitude decreases. Incidence in latitudes less than 29°S 
remained approximately three times higher than those greater than 37°S, and in 1995 this 
difference was 3.1:1 for men and 4.2:1 for women. Other within-study latitudinal trends 
are evident in the Queensland state-based study [40] which shows a significantly 
increased incidence of BCC in the Northern as opposed to the Southern parts of the State. 
The only exception to this is the Gold Coast which has been estimated to have an 
incidence similar to that of the Northern part of the State. This is likely to be due to the 
complex nature of the Gold Coast population which is affected by the selective migration 
of sun-lovers and by year-round tourism with the sun and beach the main attractions. The 
differences in incidences quoted in the separate community studies also display a 
latitudinal gradient although these studies are not ideally suited to looking at such 
relationships due to the vast differences in collection and measurement between them.  
This inverse relationship between latitude and BCC incidence is also evident overseas, 
with greater incidences reported with lower latitudes in Sweden, Norway and Finland 
[66]. The incidence in Southeastern Arizona is estimated to be between three and six 
times higher than that in Northern parts of the country [49]. Japanese studies also show a 
latitudinal difference however the numbers here are small [67]. Very convincing data 
from the United States in the 1970s show a latitudinal gradient of NMSC incidence 
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across the country [53]. The study involved ten USA metropolitan populations from 
47.5°N (Seattle) to 30.0°N (New Orleans) with a statistically significant gradient of 
incidence rates inversely related to latitude across the cities studied.  
NMSC is an immensely common and costly tumour to European-derived populations, 
and incidence is increasing internationally at an alarming rate. A better understanding the 
complex causes of these cancers should translate into valuable gains in the quality of life 
of millions of people worldwide. 
1.4. Epidemiology and Risk Factors 
Much has been learned about epidemiological risk factors for BCC in the last few 
decades. The main four epidemiological risk factors for the development of skin cancers 
(including basal cell carcinomas) are ultraviolet radiation exposure, increasing age, male 
sex, and inability to tan. Increasing age is one of the strongest risk factors for the 
development of BCC, and as with other cancers, the risk of developing the disease each 
year of life combines to give a rising cumulative risk. Increasing age could be considered 
an indicator of cumulative exposure to environmental risk factors [39, 68-71]. In addition 
to the the likely effect of cumulative UV exposure, increasing risk with age may reflect 
the normal decline in DNA-repair capacity [72] and the effect of age on the ability of 
immune surveillance to eliminate micro-tumours [73]. It is evident from international 
incidence data already described, that in most countries at most points in time measured, 
men have a greater incidence of BCC than women, but that in younger persons (< 40 
years old) with BCC there may be a reversal of this sex ratio [1, 57, 74], a phenomenon 
also seen in measures of melanoma incidence [75]. It is possible that the reduction in 
incidence in the younger age groups has been influenced by public health campaigns on 
skin cancer prevention. 
1.4.1. Ultraviolet radiation 
1.4.1.1. Aetiological role in skin cancer 
Exposure to ultraviolet radiation (UVR) is associated with the incidence of all three 
major types of skin cancer; BCC, SCC, and melanoma. As an aetiological factor in skin 
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cancer initiation, its role is inferred indirectly from a variety of sources. One of the first to 
associate BCC with UVR exposure was Molesworth [76], a Sydney Dermatologist at 
Royal Prince Alfred Hospital in 1927 who noticed that there was a much greater 
incidence of “rodent disease” (as BCC was also known) in Australia as compared with 
England. He noted that the Australian “loves the sunshine and glories in it and is very 
liable to regard any precaution against sunburn as womanish and ridiculous”. He 
suggested that sun exposure, not heat, dust, or trauma as previously hypothesized, was 
the primary reason for this difference in incidence. He also put forward the hypothesis 
that it is the ionizing radiation in sunlight that is responsible for causing these tumours.  
There are abundant epidemiological associations between UVR and BCC linking them 
aetiologically. Genetic diseases involving a greater sensitivity to UVR and a concomitant 
risk of early onset NMSC include the autosomal recessive disorder xeroderma 
pigmentosum [77]. People who live in areas of greater UVR exposure have a much 
greater risk of developing skin cancers than those living in areas of lower UVR as can be 
seen in the change of incidence with latitudinal gradients. BCC is commonest on 
regularly exposed skin sites such as the head, neck and face, and there is a correlation 
between BCC and sun-exposure-related conditions including; presence of actinic 
keratoses, solar elastosis of the neck [78], solar lentigines [79] and degree of sun damage 
to the backs of the hands as measured by cutaneous microtopography [80]. Actinic 
keratoses are premalignant lesions occurring on chronically sun exposed sites that rarely 
may progress to SCC if left untreated. Solar elastosis is a degenerative change in the 
dermis on chronic sun exposed sites. It is characterized by thickened skin with yellow 
discolouration and well-defined furrows. Solar lentigines are permanent macular areas of 
brown pigmentation occurring after either acute or chronic sun exposure. There is 
frequently a history of acute sunburn followed by the sudden appearance of large 
numbers of these lesions. Childhood freckling is also associated with all three types of 
skin cancer, however as this phenotypic characteristic is both genetically and 
environmentally determined, it is difficult to determine whether one or both of these 
factors are responsible for the association [78, 81]. Freckles also appear on sun exposed 
sites but differ from lentigines by fading during periods without sun exposure. 
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1.4.1.2. Effects on DNA 
While animal models exist for the capacity of UV radiation to cause SCC and melanoma, 
there are no comparable models for BCC, other than a knockout mouse model for Gorlin 
syndrome. Unfortunately, there is also no practical way that the action spectrum for skin 
cancer can be measured directly in humans. There is however, direct evidence that UVB 
wavelengths produce ‘UV signature’ mutations in certain genes in BCC lesions, 
providing biological evidence to support the epidemiological observations. These are C to 
T or CC to TT mutations at dipyrimidine sites and peak at around 300nm, suggesting that 
this wavelength of UV (in the UVB range) may be effective in causing skin cancers in 
humans [82]; this does not exclude a role for UVA light in causing BCC. The type of 
DNA damage induced by UVA seems to differ from UVB in the proportion of nondimer 
damage induced, such as DNA strand breaks which increase 100-1000 fold in UVA 
compared to UVB irradiated cells [83, 84]. This is likely to be due to the important role 
that reactive oxygen species play in UVA related damage to cells as opposed to the dimer 
induction in UVB damage that follows direct DNA absorption [85]. The latitude gradient 
seen in skin cancer incidence data around the world tends to be higher for SCC incidence 
than melanoma, with the latitudinal gradient of BCC incidence between the two. There is 
a correspondingly higher latitude gradient for UVB radiation than UVA radiation, an 
association suggesting that melanoma and BCC may be more influenced by UVA than is 
SCC [86]. Artificial sources of UV used for tanning primarily use UVA as this has been 
thought to be the safer part of the UV spectrum. These devices have recently been shown 
to be associated with increased risk of melanoma and SCC, but there is equivocal 
evidence regarding the risk of BCC [87-90]. Recent studies in mice have contradicted this 
earlier work with reports of UVA having no role in the initiation of melanoma [91].  
1.4.1.3. Effects on immune system 
UVR is likely to have an effect on the immune system that results in defective immune 
surveillance. Animal studies show that multiple exposures to UVR have systemic effects 
on the immune system with increased tolerance to transplanted UV-induced skin tumours 
[92]. This susceptibility to tumour growth was explained by the action of suppressor T-
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cells which arose in UVR treated animals and prevented immunological rejection of the 
tumour [93, 94]. Localised, low-dose UVB radiation impairs the induction of contact 
hypersensitivity in humans and susceptibility to this immune impairment may be 
associated with skin cancer risk, as persons with a history of NMSC have been shown to 
be more likely to display this UV-associated impairment than normal controls [95]. UVR 
also has an effect on CD4/CD8 T-lymphocyte ratios in a study following high sun 
exposure in the previous 18 months, although this ratio had no predictive ability for 
development of BCC once sun exposure and previous BCC were accounted for [96]. The 
overall increased incidence of BCC and SCC seen in immunosuppressed transplant 
recipients is evidence for a role of the immune system in tumour surveillance and 
development [97]. In a follow up study in Queensland of renal transplant patients with no 
skin cancer prior to transplantation, over a 25 year period, 50% developed both BCCs and 
SCCs with a cumulative incidence of BCCs approximately 25% at 10 years and 54% at 
20 years [98]. Studies showing that transplant recipients develop more BCCs on the trunk 
and arms than non-immunosuppressed patients supports suggestions that immune 
surveillance has a role in determining tumour site [20]. 
1.4.1.4. Pattern of UVR exposure 
It had long been believed that risk of NMSC was solely related to total cumulative dose 
of UV. While the latitudinal gradient of risk would suggest this, the smaller gradient for 
BCC compared with SCC suggests a differing relationship with amount of UV exposure. 
Also, although BCC is commonest on the heavily exposed head and neck it also favours 
sites such as the trunk which are not regarded as continuously exposed. It has emerged 
that BCC has a complex non-linear relationship with sunlight exposure, the 
characteristics of which have only begun to be unravelled over the last two decades. It is 
apparent that the amount, timing and pattern of sun exposure causing BCC is quite 
different from that causing SCC and more similar to that associated with melanoma. 
Patterns of personal sun exposure are usually described with reference to total/cumulative 
lifetime exposure, occupational/continuous exposure, or recreational/intermittent 
exposure. Each of these may be estimated over the whole or part of life and new 
validated questionnaires have evolved to enable this. One such questionnaire links recall 
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of sun exposure to a lifetime residence and work history calendar that subjects complete 
[38, 80]. Creating a link with personal history has proven to be a useful tool, but does not 
necessarily completely prevent differential recall bias.  
The timing of sun exposure appears to be particularly important in BCC and melanoma 
risk. In particular, childhood exposure to UVR seems to be more closely associated with 
adult risk of BCC and melanoma than adult exposure. The link between BCC and 
childhood exposure has been demonstrated with evidence that migration to Australia 
before ten years of age is associated with the same risk of BCC as Australian-born 
persons, and that this risk decreases three-fold with arrival to Australia at ten years or 
older [78]. Also, there is evidence that having had two or more painful sunburns in 
childhood or adolescence increases risk of BCC in later life more significantly than 
sunburns in adulthood [81, 99]. International studies confirm these observations [47, 
100]. Furthermore, there is good evidence that occupational UVA exposure after the age 
of twenty years does not increase risk of BCC [81]. 
The pattern of personal sun exposure is also now known to be an important determinant 
of a person’s risk to different types of skin cancer. Intermittent, recreational sun exposure 
has emerged as the most important pattern of exposure for risk of BCC as compared with 
continuous or occupational exposure, with a complex interaction of UV dose and 
response. This was first suggested in a report on NMSC in Maryland watermen by 
Strickland et al in 1989 [101] and subsequently by Hunter et al [102]. Both studies found 
little evidence for increasing risk of BCC with increasing cumulative UV exposure, 
suggesting a possible plateau in risk at higher total doses. This effect has been repeated in 
a number of studies since these seminal studies [81, 99, 103]. Instead, risk of BCC has 
been positively associated with intermittent sun exposure (especially in the teenage 
years), hours of reported sun exposure on holidays or during water sports, and painful 
sunburn, especially in childhood [81, 99, 103]. It has been speculated that the target 
epithelial cells maybe highly mitotic and may require a relatively low threshold of total 
solar radiation for malignant transformation [103]. BCCs tend to be of the superficial 
subtype on the less exposed trunk and upper limbs [19, 20, 104] and occur at a younger 
average age, suggesting that there also may also be a lower threshold for UV 
carcinogenesis of the superficial subtype. People that tan poorly may have an increased 
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risk of BCC that plateaus with increasing intermittency of sun exposure while people 
who tan well have a constant linearly increasing risk with increasing intermittent 
exposure [81, 103, 105]. This supports a hypothesis of a plateau in the dose-reponse 
curve for BCC in relation to UVR exposure. For those who tan well, the effect of tanning 
and epidermal thickening protects their basal cells so that the effective dose received at 
the basal cell level is on the rising part of the dose-response curve. Thus further exposure 
correlates with increasing risk. For those who tan poorly, their basal cells receive a higher 
effective dose with the same actual hours in the sun, placing them on the hypothesised 
plateau of the dose-response curve.  
Public education ‘skin cancer control’ programs have been operating in Australia for over 
25 years and have focused on the importance of reducing sunlight exposure. A fall in 
incidence of malignant melanoma and NMSC in younger people may be evidence that 
these programs are starting to take effect [1, 106]. Despite these probable gains, the 
prevalence of potentially risky amounts and patterns of sun exposure remains high in 
Australia, with studies showing 10-20% of the population having had multiple blistering 
sunburns, frequent sunbathing/intermittent exposure [99], or skin changes suggesting a 
high cumulative amount of exposure [78]. Armstrong and Kricker [14] performed a 
metanalysis of the studies published that have looked at different types of sun exposure 
and sunburn (at any age) in relation to risk for the three types of skin cancer. Relative 
risks (RR) for BCC with different types and amounts of sun exposure remained in the 
low range, but was highest with sunburn (RR 1.40; 95% CI 1.29-1.51) and intermittent 
sun exposure (RR 1.38; 95% CI 1.24- 1.54). Occupational exposure also had a low-range 
association with risk (RR 1.19; 95% CI 1.07-1.32). Cumulative exposure was not 
associated with any increased risk of BCC in this metaanalysis, supporting other evidence 
of the lack of importance of this factor. Melanoma showed a somewhat higher risk 
association with sun exposure than BCC but still in the low range: for intermittent 
exposure the RR is 1.71 (95% CI 1.54- 1.90) and for sunburn it approaches a doubling of 
risk (RR 1.91; 95% CI 1.69-2.17). SCC was the only type of skin cancer in this 
metanalysis that displayed a strong association with cumulative sun exposure and 
occupational exposure. Together these results suggest that a history of sunburn generally 
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reflects an intermittent pattern of sun exposure, and that intermittent exposure and 
sunburn are risk factors for BCC development. 
1.4.1.5. Population differences in UVR and skin cancer risk 
The difference in incidence of NMSC between white populations (see section 1.3.3.1) 
may intuitively be simply attributed to differences in UV exposure; however the reality is 
likely to be more complex. Models relating BCC risk to increases in UV exposure 
suggest that an increase of 1% of UV exposure increases the risk of BCC by 1.7% [107]. 
Hawaii has a climate similar to that of Australia, but the rates of BCC in white 
populations in Hawaii remain much lower than in genetically similar populations in 
Australia [44]. The differences in incidence seen between these varying populations 
internationally are likely to be due to a complex interplay of different factors including 
differences in UV exposure, genetic heterogeneity, skin types, and behaviour; in other 
words, different combinations of genotype, phenotype and environmental risk factors. 
This inconsistency in incidence underlies the urgency in further evaluating the genetic 
susceptibility to NMSC. 
It has been suggested that continued depletion of stratospheric ozone and climate change 
may be involved in increased international skin cancer rates (see section 1.3.3.3) [108-
110]. However, the increases in incidence are not uniform internationally and cannot be 
entirely explained by the depletion of the ozone layer. For instance, Norway has seen a 
steady increase in skin cancer incidence over the last five decades with no concomitant 
change in measured ozone levels [66]. The observed international increase in BCC 
incidence is likely to be due to a complex interplay of a variety of factors including ozone 
depletion, increased detection rates, change in type of clothing, increased mobility of 
populations between countries and climates, and increase in outdoor recreation and sports 
[111].   
1.4.1.6. Sensitivity to UVR 
Studies have found that the complex of inherited characteristics defining a person’s ‘sun 
sensitivity’ (often measured by the ability to tan) is more important in mediating skin 
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cancer risk than the colour of the person’s skin. Of the three types of skin cancer, the 
weakest evidence for an increase in risk with increasing fairness of the skin is seen for 
BCC and the strongest for melanoma. It is important to note however, that there have 
been difficulties in accurately measuring skin colour in an objective way, and that these 
problems with measurement bias should affect the interpretation of associations found 
through such studies [14]. Kricker et al [78] found that when sun sensitivity and skin 
colour were analysed in a single logistic regression model with hair colour and eye 
colour, only the ability to tan remained a significant predictor of risk for BCC. Most other 
studies that have found an association between skin colour and skin cancer have not 
controlled for the ability to tan [81, 112-114]. The seminal study by Kricker et al [78] 
shows that the relative risk for BCC in persons with no ability to tan is 3.7 (95% CI 1.9-
7.3) times that of persons with the capacity for a deep tan, and that there is a gradient to 
increasing risk with increasing sensitivity; meaning that ‘ability to tan’ is a moderate-
range risk factor, and more significant than that seen for sun exposure history. A gradient 
of risk with sun sensitivity also exists for SCC and melanoma [115, 116]. All of these sun 
sensitivity gradients were steeper than the corresponding gradients in risk with decreasing 
skin colour, supporting a greater importance of the former with respect to skin cancer 
risk. The poor association of risk of NMSC with density of pigmentation is also 
supported by the similarly low rate of skin cancer amongst USA blacks and the lighter-
skinned Chinese people living in the same environment [14]. Many other studies confirm 
that skin that burns easily and tans poorly is a risk factor for BCC [42, 47, 102, 117, 118].  
Early studies on pigmentary traits such as hair colour and eye colour were contradictory 
and suffered from methodological weaknesses relating to ascertainment, use of 
inappropriate controls, and subjective measurements. Blond or red hair and light eye 
colour were reported to increase the risks of skin cancer in several studies [47, 102, 117]; 
subsequently two Australian studies [112, 119] and an Irish study [120] found no 
associations of skin cancer with hair or eye colour. Studies that have controlled for other 
factors such as the ability to tan found that hair colour and eye colour were no longer 
independent risk factors for BCC [78, 81].   
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Evidence that Southern European ancestry is protective for BCC is seen in a study where 
any Southern European grandparent greatly reduces the risk of BCC (OR 0.05, 95% CI 
0.01-0.42) [78], and this is likely to indicate the protection associated with the complex 
combination of genetic, pigmentary and sun sensitivity traits of people of this ethnic 
background. Celtic origin has been reported to be associated with skin cancer in limited 
studies [121, 122] and has been refuted by others [78] who found no evidence of this as a 
risk factor per se.  
1.4.1.7. Personal sun protection 
It is intuitively appealing to assume that personal sun protection measures such as the use 
of hats, clothing and sunscreens should decrease skin cancer risk. Personal sun protection 
is difficult to measure for several reasons; it is difficult to separate sun protection and sun 
sensitivity as those with more sensitive skin are more likely to employ greater sun 
protection measures, and in addition, it would be impossible to ethically support a 
placebo sun protective measure given the strong inferential data suggesting that 
appropriate sunscreen use protects the individual from skin cancer. Several randomised 
controlled trials (RCTs) confirm the ability of sunscreen use to reduce the risk of SCC 
precursors and probably also to reduce the risk of SCC [123-126]. The effect of 
sunscreen use on BCC risk is more contentious: daily sunscreen use has been shown in a  
randomized controlled trial to have no effect on the risk of BCC compared with the 
discretionary use of sunscreen [126]. One observational study indicates a probable effect 
of sun protection measures in adults in reducing risk of BCC in the short term [96]: 
patients were determined to be in either a high or low sun exposure group based on their 
personal protection measures, and this level of sun exposure over 18 months significantly 
predicted the number of new BCCs independently of the number of previous BCCs. 
Other large population-based prospective case-control studies have found that sunscreen 
use is associated with an increased risk of BCC; also that BCC risk is higher on the head 
and neck for those who had worn a hat compared with those who had not [99, 102, 121]. 
That sunscreen use in that study showed a similar within-study pattern of risk to hat use 
suggests that any increased risk found was not due to any specific harmful effect of 
sunscreens (such as chemical mutagenicity or increased exposure to longwave UV 
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radiation). These results should be interpreted with the awareness that protective 
behaviours may be adopted after high risk subjects become aware of their risk status, and 
that the risk of BCC may be associated with sun exposure behaviour prior to this 
awareness. Firm conclusions cannot be made with respect to personal sun protection 
measures. 
The reported associations between melanoma and personal sun protection have also been 
controversial with several studies showing increased risks of melanoma associated with 
sunscreen use and ascribing this to the increased duration of UV exposure permitted by 
the use of sunscreen. A population based case-control study in Sweden reported a slightly 
increased risk of melanoma associatied with sunscreen use [127] and a retrospective 
study on sunscreen use and naevus counts in children concluded that sunscreen use 
increases the risk of melanoma [128]. A well designed RCT found that sunscreen use 
may reduce the incidence of new naevi in children [129]. Following much debate [130] 
[131-133] and criticism over the methodological weaknesses of the studies showing 
associations between sunscreen use and melanoma [132, 134],  the answer is still unclear.  
1.4.2. Phenotypic subtypes  
One research group has looked at BCC risk with respect to measurable phenotypic 
differences within populations of individuals affected by BCC. They describe subgroups 
of patients with BCC that fall into two major phenotypic classifications; the multiple 
presentation phenotype (MPP) characterized by the presence of clusters of 2-10 new, 
primary BCC tumours at any presentation [135]; and the truncal phenotype characterized 
by an initial presentation with a BCC on the less sun exposed trunk as opposed to the 
more frequently affected head and neck region [136]. Initial presentation with a truncal 
tumour has been shown by this group to be associated with the development of 
significantly more BCC lesions (0.13 per year) on this site compared with patients who 
presented initially with head and neck lesions (0.03 per year) . The mean age of 
presentation in patients with initial truncal lesions is younger (59.6 years) than those first 
presenting with head and neck lesions (64.9 years), and these patients are also more likely 
to have multiple BCCs at presentation. Together these results could point towards a 
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predisposition to BCC, and the authors propose that this predisposition is likely to be due 
to a combination of genetic factors [137] and a reduction in immune surveillance [135].  
 
1.4.3. Previous BCC 
One of the strongest known risk factors for developing BCC is a history of one or more 
previous BCC [39, 96, 138-141]. The highest risk period for a second BCC is within one 
year of the previous BCC [141], and the three year cumulative risk is between 33 and 
77% (depending on the number and type of lesions present), at least a 10-fold increase in 
incidence compared with the rate in a comparable general population [142].  
1.4.4. BCC risk and other malignancies 
The association of BCC with the risk of other malignancies remains unclear, with some 
studies showing no association and others showing inconsistent and small increased risks 
of several internal cancers eg lung, thyroid, breast, testicular, cervix, and non-Hodgkin’s 
lymphoma [143-148]. Patients diagnosed with BCC at an earlier age (before 60 years) 
have been shown to be at greater risk of breast, testicular and non-Hodgkin’s lymphoma 
[145]. An increased risk of malignant melanoma has been shown more consistently in 
patients with prior BCC, and varies from 2.2 to 17-fold [144, 146, 149]. Shared risk 
factors such as exposure to the same carcinogens eg UVR, and increased surveillance of 
patients with prior BCC may contribute to this overlap in risk. Overall cancer mortality of 
people with a history of NMSC may also be increased, with reported relative risks of 1.30 
for men (95% CI 1.23- 1.36) and 1.26 for women (95% CI 1.17- 1.35) [150].  
1.4.5. Other risk factors 
Other well established risk factors for BCC include exposure to therapeutic ionizing 
radiation [151-153], and arsenic [154-156] and scars [157, 158]. Smoking has been 
identified as a risk factor for BCC however reports have been inconsistent and no firm 
conclusions can currently be made [88, 100, 159, 160]. Dietary factors such as 
antioxidant vitamin and fat intake may also play a role in risk [161, 162], although large 
prospective studies have refuted this evidence [163, 164].  
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1.4.6. Association with other UVR-associated lesions 
Numbers of melanocytic naevi are unlikely to be associated with individual risk of BCC 
development. Melanocytic naevi are known to be caused by a combination of genetic 
factors and environmental UV exposure, especially in childhood [129, 165] and are not a 
good direct surrogate measure of the sun exposure required for BCC development. One 
study suggested that numbers of larger moles (greater than 5mm in diameter) is 
associated with an increased risk of BCC however the authors note that as subjects 
performed their own mole counts, that there may have been some problems with 
misclassification of solar lentigines as moles [78]. Studies from Australia and 
internationally have noted the poor concordance between patients’ and doctors’ mole 
counts [166, 167] further discounting the relevance of these results. 
Seborrhoeic keratoses are probably related to sun exposure and so it is intuitive that their 
presence may be associated with risk of skin cancer. This question has not yet been 
adequately addressed and despite their frequency, very little is known about the nature or 
causes of these benign cutaneous tumours. What is known is that seborrhoeic keratoses 
may occur on any site of the body except palms and soles; occur more commonly in 
populations with lighter skin than more darkly pigmented populations [168]; seem to 
increase in frequency with age; and are more common on sun exposed areas of the body 
[169]. The incidence of these lesions may have increased in Australian populations over 
the last couple of decades, and seems to be greater in Australia than the UK [170, 171]. 
Together this data gives circumstantial evidence that UVR is involved in the aetiology of 
these lesions, and does not discount the possiblility of genetic predisposition to these 
lesions. 
It is obvious that despite the growth in evidence of important epidemiological 
associations with development of SCC and BCC, studies have not looked at this evidence 
in the context of population-based family studies, and very little is known about the 
probable complex interaction of these epidemiological risk factors with genetic factors.  
1.5. PTCH gene 
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1.5.1. PTCH as a tumour suppressor gene 
Much of the current understanding of the molecular genetics of BCC comes from the 
identification of causative mutations in genes involved in familial cancer syndromes. 
Perhaps the most significant of these to our understanding of BCC is the discovery of the 
molecular basis of naevoid basal cell carcinoma syndrome (NBCCS), also known as 
Gorlin syndrome. In the last decade, disruptions to the hedgehog signalling pathway have 
been inextricably linked to human tumorigenesis, most notably in the pathogenesis of 
BCC. It has long been known that this pathway is pivotal to embryonic development 
[172, 173]. More recently it has been shown that this pathway also has a role in tumour 
suppression, a function that is not surprising considering that many developmental genes 
continue to function in regulation of cell growth and differentiation after embryogenesis. 
Tumour suppressor genes are recessive oncogenes (or anti-oncogenes) whose 
homozygous inactivation is required for their carcinogenic expression. In NBCCS 
individuals are born with an inherited or germline mutation of one allele of the PTCH 
gene. This causes an autosomal dominant syndrome of cancer predisposition, because the 
remaining allele is likely to be lost in a proportion of susceptible cells through somatic 
events. This is explained by the Knudson ‘two-hit hypothesis’ [174] which suggests that 
the first ‘hit’, or mutation, is inherited; the second hit is the loss of the remaining allele 
(or loss of heterozygosity) due to random somatic events causing mitotic nondisjuction, 
deletion, or mitotic recombination. In NBCCS, each cell in the body carries the mutation, 
so that only the one additional hit (eg mutations following UV radiation) is needed. The 
same mutation is seen in sporadic BCCs, where both hits come from the somatic type of 
mutation [175-178].  Individuals with NBCCS get a head start on the mutation of the 
PTCH gene alleles so that BCCs occur earlier than in their non-syndromic counterparts.  
1.5.2. The Hedgehog pathway 
What is known about the Hedgehog pathway in vertebrates has largely been inferred 
from studies in Drosophila melanogaster. The importance of this pathway is displayed by 
its high degree of conservation through evolution [179]. Drosophila hedgehog works in 
concert with other molecules to lay down the basic framework of the embryo, 
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determining anterior-posterior relationships (segment polarity) in developing structures. 
A number of proteins are recognized to be important for the function of this pathway, and 
in most cases a single gene encoding one of these proteins in Drosophila corresponds to a 
family of related homologues in vertebrates.  
The model for hedgehog signaling in vertebrates involves a receptor complex at the cell 
surface made up of two transmembrane proteins PTCH and smoothened (smo) [180, 
181]. While in Drosophila there is one hedgehog protein, in vertebrates there are three 
homologues, named Sonic, Desert and Indian, although Sonic is the most commonly 
expressed. There are also several PTCH homologs in vertebrates, with PTCH1 (PTCH) 
likely to act as the major receptor molecule for all three forms of human hedgehog. 
PTCH2 is a close homolog of PTCH [182] and its normal function is not known, 
although there is evidence for its involvement in a medulloblastoma and also a BCC 
tumour, and thus it may rarely act as a tumour suppressor gene in these tumours [183].  
PTCH is a 12-pass protein that binds the protein hedgehog, whilst smoothened is 
responsible for transducing the hedgehog signal, promoting transcription of downstream 
target genes. In the absence of hedgehog binding, PTCH holds smoothened in an inactive 
state, thus inhibiting signalling to downstream genes. When hedgehog (hh) binds to the 
receptor complex (via PTCH), PTCH inhibition of smoothened is released and the signal 
is transduced.  It is unclear how these two surface molecules interact with each other; 
directly (eg. via a conformational change), or indirectly (eg. via a catalytic mechanism 
[184]).  
Downstream mediation of the hedgehog signal in Drosophila occurs via a zinc finger 
transcription factor, cubitus interruptus (ci). In the absence of a hedgehog signal, this 
molecule forms a tetrameric complex at the microtubules with three proteins; fused, 
suppressor of fused, and costal-2, causing cleavage of ci to generate a smaller fragment 
that enters the nucleus and prevents transcriptional activation. In the presence of a 
hedgehog signal, the tetrameric complex dissociates and inhibits the cleavage of ci 
causing a full length ci to enter the nucleus and activate target genes [185]. Once again 
the vertebrate has three homologues of the Drosophila ci, and these are named Gli1, Gli2 
and Gli3 after their role in human gliomas [186].  
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1.5.3. Target genes 
Studies have uncovered many possible target genes of the hedgehog pathway and these 
are mostly genes involved in cell cycling, cell adhesion, signal transduction and 
regulation of apoptosis [187, 188]. Hedgehog signaling has been shown to oppose cell 
cycle arrest and increase the replicative capacity of cultured epithelial cells [189]. 
Extrapolation from target genes of Drosophila PTCH implicates several possible target 
genes for humans: PTCH itself, signaling-protein members of the Wnt family (wingless 
in Drosophila) and members of the TGFβ family (decapentaplegic in Drosophila) 
encoding the bone morphogenetic proteins (BMPs) [190]. The upregulation of PTCH 
expression is thought to cause the sequestration of hedgehog within the cells that it is 
produced, thus limiting its further movement [191]. The Wnt and TGFβ family proteins 
may be the main mediators of the hedgehog effect by both autocrine effects and paracrine 
effects on surrounding tissues [192]. An expected consequence of Wnt overexpression in 
BCC is increased levels of intracellular β-catenin, a protein that interacts with E-cadherin 
and is important in cell adhesion [193, 194]. The TGFβ superfamily members have 
diverse functions with effects on cell proliferation, expression of extracellular matrix 
proteins, morphogenic movements, apoptosis, and differentiation [195]. BMPs in 
particular play an important role at sites of epithelial-mesenchymal interaction and may 
be important in mediating tumour invasion [196]. There is also some evidence that Gli1 
and Gli2 may mediate the carcinogenic effect. The Gli1 gene has been previously shown 
to act as an oncogene in brain tumours including medulloblastomas [186]. More specific 
to its role in the hedgehog pathway, mouse models overexpressing Gli1 or Gli2 in the 
epidermis develop skin tumours that resemble BCCs [197, 198]. 
1.5.4. Naevoid Basal Cell Carcinoma (Gorlin) Syndrome - NBCCS  
NBCCS was first described in 1960 [199] and is a rare autosomal dominant disorder 
characterized by three ‘major’ features - multiple basal cell carcinomas, dyskeratotic 
palmar and plantar pitting, and odontogenic keratocysts. Many other developmental and 
skeletal anomalies constitute ‘minor’ features and include overgrowth, epidermal scysts, 
calcified falx cerebri, rib anomalies such as bifid ribs, cleft lip and palate, and spina 
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bifida occulta. Other tumours also occur with increased frequency in this disorder and 
these include medulloblastoma, ovarian fibromas, meningioma, and rhabdomyoma [200]. 
The most common and debilitating of all the effects of this syndrome are the BCCs that 
appear much earlier than in the normal population and can number more than 500 in a 
lifetime [201].  
As with other cancer susceptibility genes, a proportion of those carrying the mutation do 
not actually develop the disease, and it is likely that the actual manifestation of tumours 
depends on the constellation of gene and environmental risk factors particular to the 
family and individual. For example, Australian sufferers develop BCCs at an earlier age 
than their English counterparts, which is likely to be due to genetic susceptibility 
interacting with risk due to ultraviolet light exposure in the different environments [201, 
202]. In Australia, nearly 50% of Gorlin syndrome patients will have at least one BCC 
removed prior to the age of 20, a rate 900- fold higher than the Australian population of 
that age. By the age of 40, 95% of Australian Gorlin syndrome sufferers will have had a 
BCC, some 300- fold higher than the rate of the general population [1, 201]. In the UK 
Gorlin sufferers also have a 900- fold increased risk of developing BCC eventually, 
however they do so at an older age, with only 4% having had a BCC removed by the age 
of 20, a 50- fold increase compared with the population [54, 202, 203]. Some 15% of 
Gorlin syndrome sufferers internationally do not manifest basal cell carcinomas at all, 
and this figure is even higher for individuals from darker skinned races. The BCCs in 
NBCCS may appear as early as two years of age, especially on the nape and most often 
proliferate between puberty and 35 years of age [200]. The syndrome’s prevalence is now 
agreed to be around 1 in 60,000 [204].   
1.5.5. Discovery of PTCH mutations as cause of  NBCCS 
An interesting gene-hunting detective story unfolded over the last decade, finally 
culminating in the discovery of the PTCH gene as the gene responsible for NBCCS. 
Tumour suppressor genes are regulators of cell growth and differentiation, and murine 
knockout models support their role in normal development [205] [206, 207]. The clinical 
features and behaviour of neoplasms in NBCCS suggested that the underlying defect may 
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have been a tumour suppressor gene: tumours are multiple and occur relatively early 
compared with sporadic tumours of the same type, and the syndrome also features 
derangements in normal development. If the Gorlin syndrome gene functioned as a 
classical tumour suppressor, then it should be homozygously inactivated in BCCs and the 
other tumour types in this syndrome. Since we know that inactivation of a tumour 
suppressor gene often occurs through mutation of the first allele (the first hit) and loss of 
the second allele (the second hit) then we would expect to see loss of heterozygosity 
(LOH) for polymorphisms surrounding the tumour suppressor gene.  
Linkage analysis placed the gene on chromosome 9q22-31 [176, 208-212]; [213]. As part 
of a collaborative positional candidate search, Hahn et al [213] then found as many genes 
as possible that mapped to that area and searched for submicroscopic rearrangements in 
patients. The PTCH gene was found to lie in the correct region of the chromosome and 
patients were screened for mutations in this gene using single strand conformation 
polymorphism analysis (SSCP) and DNA sequencing. Inactivating mutations within the 
PTCH gene were found in six unrelated NBCCS patients. At almost the same time, 
Johnson et al [214] postulated PTCH as a candidate for NBCCS and found two affected 
individuals with inactivating mutations by SSCP. Furthermore, both of these seminal 
studies also found the PTCH gene to be mutated in sporadic BCCs, implicating this gene 
as a possible aetiologal necessity in the development of non-syndromic BCCs as well. 
There is wide phenotypic variation in NBCCS-affected families, and screening of the 
PTCH coding region also reveals a wide spectrum of mutations in NBCCS patients. The 
majority of the mutations found are predicted to result in premature protein truncation 
[175, 215], but the phenotypic variability does not seem to correlate with the nature or 
location of the mutations in PTCH. Interestingly, even kindreds with identical mutations 
differ markedly in their clinical features, suggesting that other genetic or environmental 
factors may be important modifiers of developmental and neoplastic traits [215].  
1.5.6. PTCH inactivation in sporadic BCC 
Further evidence has since been found for the inactivation of PTCH as a major factor in 
sporadic BCC formation. LOH has been found in over 50% of BCCs suggesting that in 
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many tumours one of the alleles is inactivated by deletion [176]. In some tumours 
without LOH, direct sequencing reveals inactivating mutations in PTCH that have not 
resulted in loss of the allele, suggesting that mutation of PTCH may be a necessary step 
for tumour formation of sporadic BCCs [216]. It is likely that in tumours not showing 
allelic loss, both copies of the gene have undergone point mutation. As with NBCCS 
PTCH mutations, where mutations are found, most lead to premature protein termination, 
and a number of them are C-to-T substitutions typical of ultraviolet B irradiation (UVB) 
involvement. UVB radiation mainly produces DNA lesions between adjacent pyrimidines 
(TT, CT, TC, CC) – the ‘UVB signature’ – and two types of lesions are produced; the 
cyclobutane pyrimidine dimers and the 6-4 photoproducts [217-219]. However, more 
than 50% of the PTCH mutations in sporadic BCCs do not have the UVB signature [216], 
suggesting that environmental factors other than UVB exposure may be important in the 
pathogenesis of BCCs (eg. UVA exposure). Mutations in PTCH have also been detected 
in BCCs associated with Xeroderma Pigmentosum (XP) and in contrast to sporadic 
tumours, XP tumours show a high rate of UVB signature mutations [77].  This is 
consistent with the mechanism of XP whereby sufferers are unable to repair DNA lesions 
such as mutations caused by UVB. 
Despite an absence of an animal model for BCCs, tumours that closely resemble BCCs 
have been demonstrated in PTCH1 +/- knockout mice, and exposure to UVR increases 
the size and number of these tumours and shifts their histological features so that they 
more closely resemble human BCCs [4]. Studies also show that sonic hedgehog signaling 
is a component of T-cell responses to mediate CD4+ T-cell effector function and that 
response varies in individuals, suggesting that PTCH alleles may be involved in the 
effectiveness of immune surveillance [220]. 
1.5.7. PTCH involvement in other tumorigenesis 
A number of key members of the hedgehog signaling pathway are involved in 
tumorigenesis of a range of tumours. These include medulloblastoma, meningioma [221], 
squamous cell carcinomas of the oesophagus [222], transitional cell carcinomas of the 
bladder [223], and the benign skin lesions trichoepitheliomas [224]. Several of these 
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sporadic tumours are not involved in NBCCS therefore suggesting a wider role for PTCH 
mutation in cancer pathogenesis. Other members of the hedgehog pathway have been 
investigated for their role in tumorigenesis. Activating mutations of smoothened have the 
same downstream effects as inactivating mutations of PTCH, and a number of 
independent studies have detected activating mutations of smoothened in 10 to 20% of 
BCCs [225, 226]. Mice overexpressing downstream members of the hedgehog pathway, 
Gli1 or Gli2, develop BCC-like lesions [197, 198]. The Hh gene has also been 
implicated, and overexpression in transgenic human and mouse skin leads to tumours that 
are morphologically indistinguishable from BCCs [227, 228]. The induction of BCC with 
the activation of this pathway alone in the absence of deliberate mutagenesis suggests 
that activation of the hedgehog signaling pathway initiates BCC formation. The exact 
mechanism of dysregulated hh signaling and increased risk of cancer development 
remains to be elucidated. Interestingly, hedgehog pathway target-gene overexpression is 
seen in all BCC subtypes suggesting that this dysregulation is an early rate-limiting step 
in BCC carcinogenesis [177]. 
1.5.8. PTCH pathway in future therapies 
 A better understanding of the molecular processes underlying the pathogenesis of BCCs 
may allow improvements in therapeutic success in its management. Therapies involving 
inhibition of hedgehog signaling might be expected to suppress tumour growth. 
Cyclopamine from the Veratrum lily species is know to inhibit hedgehog signaling and 
reverse the effects of oncogenic smoothened and PTCH mutations [229]. There appears 
to be no adverse effects of exposure of adults to this compound, and it is therefore 
interesting as a basis for a possible therapeutic agent for tumours resulting from 
dysregulation in hedgehog signaling. 
1.5.9. PTCH polymorphisms and BCC 
Some important preliminary work has been performed to investigate PTCH 
polymorphisms in relation to BCC susceptibility. The consequences of polymorphisms of 
exons of PTCH are unknown, and they may have functional implications. There is 
increasing evidence that even silent substitution of nucleotides (effecting no amino acid 
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change) could influence mRNA processes, including affecting splicing accuracy or 
efficiency [230]. This may be the case for the PTCH intronic SNP IVS 15+9 which may 
form part of an intronic enhancer region, as the adjacent sequence conforms to a splicing 
enhancer sequence identified in the growth hormone gene [231, 232]. Haplotypes may 
confer increased risk through encoding of a protein with less efficient function by the 
combination of the individual effects of the SNPs involved; alternatively they may be in 
linkage disequilibrium with other significant variants. 
One research group have found significant associations between certain PTCH 
haplotypes and rate of development of further BCCs/year in English subjects who 
initially developed a head/neck BCC [233]. Subjects were genotyped for two exonic 
SNPs (exon 12: C>T 84 and exon 23: T>C 140) and one intronic SNP (exon 15: IVS 
15+9). They found no association between rate of BCC accrual and these genotypes 
individually, but did find an association with the haplotype of the exon 12/exon 23 
variant, giving a relative risk of increased BCC accrual (BCCs/year for one year 
following presentation) of 2.46 (95% CI 1.27- 3.97). The exon 23 variant causes a proline 
to leucine change (Pro>Leu), and has been linked with breast cancer risk in women using 
the oral contraceptive pill [234], suggesting that there is possibly an as-yet-
uncharacterised functional significance to this SNP. The haplotype association with BCC 
accrual remained significant when controlled for UVR-exposure parameters, skin type, 
gender and age at first presentation. These researchers also found an association between 
the exon 15 variant/exon 23 wild type haplotype and decreased risk of BCC in a case 
control analysis (OR 0.44, p=0.009), with significance unaffected by adult UVR 
exposure. It should be noted that despite a claim to control for UVR-exposure 
parameters, childhood and adolescent exposure were not included in the UVR-exposure 
questionnaire for either study; and as it is evident that UVR exposure at these ages is 
likely to affect later risk of BCC [78] and omission of this may overestimate the effect of 
the genetic association in these analyses. Nevertheless, the importance of further 
investigation into the significance of PTCH polymorphisms with respect to risk of BCC 
is highlighted by these studies. 
52 
The exon 23 Pro>Leu SNP has been investigated further in a pilot study that examined 
the association with populations of differing pigmentary characteristics and risk of 
NMSC [235]. The Pro>Pro genotype was significantly less common in populations with 
characteristically lighter skin colour (eg. Swedes) compared with populations with darker 
skin colour (eg. African-Americans), suggesting a possible association between the 
eumelanin-to-phaeomelanin shift and a shift from the Pro>Pro genotype to Leu-
containing genotypes. There was a non-significant trend for increasing Pro>Pro 
frequency with increasing BCC severity (early-onset or multiple tumours). The authors 
suggest that the failure to replace Pro in phaeomelanin-prevalent populations may be 
associated with an increased population risk for BCC, and an increased individual risk for 
multiple BCC.  
No studies have investigated the involvement of other hedgehog pathway genes or indeed 
any other possible BCC susceptibility genes in the general population outside of the 
context of NBCCS.  
1.6. Familial Cancer Syndromes  
Several other familial cancer syndromes involve a predisposition to the development of 
multiple BCCs. Bazex-Dupre-Christol syndrome was first described in 1966 [236] and is 
a rare X-linked dominant syndrome characterized by congenital generalized 
hypotrichosis, follicular atrophoderma and multiple early-onset BCCs occurring in the 
second or third decade of life that have an aggressive course and are prone to relapse 
[237, 238].  
Rombo syndrome was first described in 1981 and is a rare familial disorder for which 
inheritance is likely to be autosomal dominant [239-241]. This rare familial disorder has 
skin changes that become evident at seven to 10 years of age with cyanotic redness and 
follicular atrophy of the sun exposed skin, and later milia-like papules and telangectasias. 
The skin changes become more pronounced with age and lead to a “worm-eaten” 
appearance of the skin known as atrophoderma vermiculatum. BCCs develop around the 
age of 35, depending on the exposure to other risk factors such as UVR. 
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The recessively inherited diseases; xeroderma pigmentosum (XP), albinism and 
epidermo-dysplasia verruciformis, are also associated with the development of multiple 
BCCs in association with a predisposition to NMSC in general. Patients with XP are 
deficient in the repair of UV-induced DNA lesions and are characterized by their 
predisposition to early-onset NMSC (average age 10) on sun-exposed skin [77, 242]. XP 
cells are deficient in those gene-products required for catalyzing the incision step in 
nucleotide-excision repair of damaged DNA [243, 244]. Albinos also develop BCC at an 
increased rate compared with normally-pigmented persons, although SCCs are more 
common in this group [245]. Epidermo-dyplasia verruciformis is a rare multifactorial 
disorder involving genetic, actinic, and immunologic factors, with a susceptibility to 
NMSC (mostly SCC) associated with the development of multiple pityriasis versicolor-
like lesions as well as flat wart-like lesions [246]. 
There have been several unrelated reports of non-syndromic hereditary BCC [3, 247] 
suggesting the possibility of a genetic predisposition to BCC in addition to the rarer 
familial syndromes described: these include cases exhibiting unilateral distribution 
suggesting mosaicism [248-250]. The PTCH gene is an obvious candidate to contribute 
to non-syndromic susceptibility to BCC, either via a different mutation spectrum or in the 
absence of modifiers that are essential for the full Gorlin phenotype. The reports of 
polymorphisms in this gene associated with number of BCCs per year and their possible 
association with pigmentary factors have given weight to this possibility [231, 233, 235].  
1.7. MC1R 
1.7.1. Melanin and pigmentation 
Cutaneous pigmentation results from the synthesis and distribution of melanin in the skin. 
Melanin is a pigmented heteropolymer produced by melanocytes in the complex process 
of melanogenesis, the regulation of which involves more than 80 genetic loci [251]. 
Melanocytes are specialized dendritic cells that reside at the dermoepidermal junction 
and synthesise and package melanin within membrane bound organelles called 
melanosomes. The melanosomes are distributed to the keratinocytes and the growing hair 
shaft through the dendritic processes of the melanocytes. The keratinocytes then 
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differentiate, mature and migrate to the epithelial surface where the melanin creates light-
absorbing and light-scattering effects depending on its quantity and chemical composition 
[252].  
1.7.2. MC1R receptor 
The MC1R receptor is one of five forms of melanocortin receptors (MC1R - MC5R) that 
have distinctive tissue distribution and physiologic roles. All are activated by the 
melanocortins, a family of structurally-related peptide hormones derived from one 
precursor protein, proopiomelanocortin (POMC). These include corticotropin (ACTH) 
and the α (alpha), β (beta), and γ (gamma) melanocyte stimulating hormones (MSHs) 
[253, 254]. The melanocortin-1 receptor (MC1R) is a G-protein coupled receptor with 7 
transmembrane spanning domains. Although melanocytes have the highest density of 
these receptors, it is expressed in many other cell types in the skin including 
keratinocytes, fibroblasts, endothelial cells and antigen presenting cells [255]. Ligand 
binding activates the enzyme tyrosinase gene expression and activity, melanocyte 
proliferation and melanocyte dendricity [256-258].  
1.7.3. Forms of Melanin  
Melanin exists in two differing forms within human skin, brown-black eumelanin and 
yellow-red pheomelanin. These forms have differing unique biochemical and 
ultrastructural properties within melanosomes. The eumelanosomes are large and 
elliptical with a highly organized matrix, containing high molecular weight, poorly 
soluble melanin. The pheomelanosomes in contrast are small and spherical with an 
unstructured particulate matrix containing low molecular weight, soluble pheomelanin 
[259]. MC1R expression appears to be centrally important to the regulation of 
melanocytes, including induction of photoprotective melanisation in response to UV 
exposure.  
The ratio of eumelanin to pheomelanin as well as total melanin content is higher in 
persons with more darkly pigmented skin compared with those of lighter pigmented skin 
[260]. Pheomelanin levels are generally highest in very red hair, while eumelanin 
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predominates in the hair of most other colours [261 review]. Eumelanin is thought to be 
more photoprotective than phaeomelanin because it is more resistant to degradation by 
UV and more efficient at scavenging reactive oxygen radicals produced by exposure to 
UV [262]. Eumelanosomes also form supranuclear caps that shield the nuclei of cells 
from UV radiation therefore conferring additional photoprotection [263]. Pheomelanin, in 
addition to absorbing a narrower range of wavelengths than eumelanin, is photolabile and 
generates oxidative stress on irradiation, leading to less efficient photoprotection and 
increased photosensitivity [251]. 
1.7.4. MC1R variants 
Following the first report of an association between germline variant MC1R alleles and 
red hair [264], human MC1R variants have been found to occur in more than 50% of 
individuals in white populations [265-267]. There are over 30 variant alleles reported in 
European-derived populations [264, 266-273], with several of these found to be 
associated with red hair and fair skin. There is in fact, such a great deal of MC1R coding 
diversity that it is difficult to identify a wild type. Several groups have looked at a 
combination of gene sequences to deduce a consensus sequence [266, 268, 273], using 
phylogenetic analysis of MC1R gene sequences in geographically diverse populations 
[272]. 
1.7.5. Red Hair Colour variants of MC1R 
The three most common red hair colour variants account for 60% of all cases of red hair- 
Arg151Cys, Arg160Trp, and Asp294His, with individuals carrying two of these alleles 
almost always having red hair [266]. The frequency of these variants differs according to 
the population; studies show the allele frequency of these three types together is 
approximately 20% in Australians [252, 274] and nearly 50% in an Irish cohort [266]. 
These three Red Hair Colour (RHC) alleles give rise to loss-of-function mutations 
although some studies suggest that they may retain some function and that red hair is not 
the null phenotype [275, 276]. The RHC alleles also contribute to fair skin and poor 
tanning response to UV, giving rise to the ‘RHC phenotype’. These phenotypic features 
are explained by increased phaeomelanin in the skin and hair and/or decreased capacity 
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to produce eumelanin, creating a red colour in the hair shaft and reduced skin 
photoprotectivity [264]. There is also evidence that RHC alleles impart a heterozygote 
effect: one study shows that presence of one allele increases the odds of having red hair 
nine- to 16-fold and fair skin five- to seven-fold [266]. The weaker association with skin 
colour in this study may have been due to the limitations imposed by the use of the 
Fitzpatrick classification of skin type used in its determination. 
It is clear that MC1R variant-allele presence is necessary for the RHC phenotype but not 
sufficient. Individuals with identical MC1R variants may nevertheless display different 
hair colour (eg auburn, red or strawberry blonde): even monozygotic twins (sharing the 
same genotype) have been found to differ in their hair colour [266] [268, 277]. Similarly, 
the exact relationship between skin phototype and pheomelanin/eumelanin production in 
the human epidermis is not straightforward [260, 278], although it appears that activation 
of MC1R is involved in switching between eumelanogenesis and pheomelanogenesis 
[279]. Thus other loci must be involved in creating the RHC phenotype, perhaps by 
moderating the expressivity of MC1R variants or masking of the trait. 
1.7.6. MC1R associations with skin cancer 
The involvement of the MC1R locus in pigmentary traits and the cutaneous response to 
UVR makes it an intuitively relevant candidate gene for susceptibility to cutaneous 
malignant melanoma and nonmelanoma skin cancer. MC1R gene variants have been 
shown to be associated with melanoma independent of their association with 
pigmentation phenotype giving two- to four-fold increased risk [274, 280, 281]. The large 
number and low frequency of MC1R alleles make assessment of this gene in the 
pathogenesis of skin cancer difficult, and initial explorations of a possible link with 
NMSC yielded inconsistent results [266] [282]..  
More convincing evidence for associations between MC1R genotype and NMSC has 
since been demonstrated. Box et al [283] demonstrated an association between higher 
NMSC risk individuals and the nine commonly reported MC1R variants, an association 
that persisted after adjusting for pigmentation phenotype. A larger case-control study 
[267] replicated these findings and extended them to include most of the other known 
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MC1R variants. Carriers of any two variant alleles in this study were at increased risk of 
BCC and SCC. Carriers of one variant allele had half the risk, confirming the 
heterozygote effect of this gene. Unfortunately, the MC1R studies involving NMSC to 
date have suffered from a lack of reliable and objective consensus measure of measuring 
constitutive skin colour [284, 285]. These results do however indicate that MC1R variant 
status may be an independent risk factor for the development of BCC: this needs to be 
further explored. Also, other genes and proteins may be involved in modifying the 
expression of MC1R variants. For example, it is possible that PTCH polymorphisms such 
as exon 23 Pro>Leu (see section 1.5.9) or mutations in this gene could interact with 
MC1R variant status to affect NMSC risk.  
1.8. p53 
The gene P53 encodes the protein p53 which has been termed “guardian of the genome”. 
The gene is located on chromosome 17 band p13, and the protein is a 53 kd nuclear 
phosphoprotein [286, 287]. Mutations of this gene occur in a wide variety of tumour 
types and are in fact the most commonly detected genetic abnormality in human cancer 
[288]. The protein is known to be associated with malignant melanoma susceptibility 
through its association with the protein p14ARF and the CDKN2A locus [289]. The p53 
protein functions to sense genotoxic injury and arrest cell division in late G1 of the cell 
cycle, allowing DNA repair to occur before replication. In the case of extensive DNA 
damage, it induces apoptosis in an effort to eliminate defective and potentially malignant 
cells. Mutated p53 can act in one of two ways to contribute to malignancy; as a dominant 
negative oncogene by affecting normal p53 activity [290] or as a tumour suppressor gene 
by creating a nonfunctioning p53 protein in the presence of further mutational events 
[291]. 
A study by Rady et al was the first to identify P53 mutations in BCC, finding 50% of 14 
tumours carrying a P53 mutation, and was the first to give evidence that these are likely 
to be UV induced mutations [292]. Studies following this found mutations from between 
44% and 100% of tumours [8, 84, 291, 293-296], and showed that the UVB portion of the 
spectrum is likely to be more important than UVA in p53 mutations [84]. Mutations in 
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NMSC occur at several hotspots that are much less frequently mutated in internal 
cancers, and most of them contain the dipyrimidine transition mutation that indicates UV 
induced origin [293, 297, 298]. Most of these hotspots are localized in an area of the gene 
that is evolutionarily conserved [299], suggesting that the mutations are likely to have 
functional significance and therefore act as causative mutations. Skin-cancer-specific 
hotspots have been seen to be repaired more slowly by nucleotide excision repair than 
those at surrounding positions on the same strand, supporting a role in tumour induction 
[300] [72]. There are however, likely to be other mechanisms at work in BCC to 
inactivate P53, some tumours without P53 coding sequence mutations have been found 
to harbor aberrant p53 protein stability [293].   
BCC case subjects have been reported as three times more likely to have a P53 mutation 
in normal skin taken from the mirror-image site to the cancer site, suggesting that P53 
mutation is an early occurrence that may predict the risk of BCC development [301]. P53 
point mutations may occur in cells during sun exposure early in life, which then over 
many years acquire other genetic alterations required for BCC [293]. This multiple-
mutation concept is supported by the finding that multiple samples from individual 
tumours have at least one P53 mutation in common, suggesting that the tumour is derived 
form a single cell with a unique P53 mutation as an early event.  
It is also possible that there is a genetic interaction in tumour suppression between PTCH 
and P53, with evidence from PTCH +/- mice that concomitant loss of P53 dramatically 
accelerated tumorigenesis in medulloblastomas [302]. A germ line polymorphism in P53 
has also been noted and its contribution to HPV induced skin cancer remains 
controversial: polymporphisms may lead to increased susceptibility of the p53 protein to 
HPV-mediated degradation [303, 304].  
1.9. HPV 
While the aetiologic role of HPV in anogenital cancer is well established, the 
epidemiological, molecular and functional data required to fulfill the World Health 
Organisation criteria for viral carcinogenesis have yet to be met in NMSC [305]. Fifteen 
epidemiologically defined high risk mucosal HPV types have been found to cause a 
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persistent infection of the cervix as a necessary risk factor for the development of cervical 
cancer [306]. An association between papillomaviruses and NMSC pathogenesis was first 
seen in an animal model whereby SCCs of the skin developed reproducibly following 
experimental infection from virus-induced warts in rabbits [307]. Unlike HPV 
involvement in cervical cancer, HPV may not be necessary for NMSC pathogenesis but 
simply act as a cofactor along with UV radiation exposure. Complicating all deductions 
made with regard to HPV in NMSCs is the fact that HPV is detected with varying 
prevalence in normal skin: the prevalence ranges from 4.7% [308] to 35% [309].  
The earliest evidence for an association between HPV and NMSC in humans originated 
in studies on patients suffering from epidermo-dysplasia verruciformis (EV), a rare 
hereditary disease. The genetic basis of this disorder is not understood, however EV 
patients have increased susceptibility to a group of HPV types (differing from the 
mucosal types) and develop multiple skin warts; multifocal NMSC (mostly SCC) also 
occur on sun exposed skin at a young age [246]. EV HPV types have been detected in 
over 90% of skin cancers in EV patients. It is clear that genetic and immunologic factors 
combine with HPV infection and UVR exposure in EV patients to contribute to their 
NMSC susceptibility. The suggestion of an association between HPV and NMSC is also 
inferred from the susceptibility of renal transplant recipients (RTRs) to both viral warts 
and NMSC (mostly SCCs), suggesting a pathogenic role of HPV in tumour development 
[310] [310] [97]. The long term immunosuppression needed to support a renal transplant 
is associated with an increased risk for certain forms of malignancies including that of the 
skin [311]. HPV has been found in high prevalence and of a similar spectrum in both 
BCCs and SCCs of RTRs prompting some investigators to suggest a differing role of 
HPV in the different tumour types, leading to preferential development of SCCs [312]. 
Most studies of the association between HPV and NMSC are small case series without 
control groups. Early studies employed laboratory methods that caused variability in 
prevalence and spectrum of HPV types found. Despite increasingly sensitive laboratory 
methods, no specific subset of HPV types has been consistently associated with either 
BCC or SCC in immunosuppressed or immunocompetent populations [308, 312-316]. 
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Studies on HPV prevalence in NMSC lesions of immunocompetent subjects from the 
general population report lower figures than those found in RTRs with lower potential for 
mixed HPV infection [308, 312, 315, 317]. With newer laboratory techniques however, 
studies have found HPV infection in over 25% of lesions (see table 1.3).  
 
 
Table 1.3 Studies reporting HPV prevalence in NMSC lesions of immunocompetent people 
NMSC type Iftner et al. 
[308] 
Harwood [312] Shamanin 
[315] 
Biliris [317] 
BCC 27.8% 36.7% 60%# 30.5% 
SCC 59.7% 27.2% 65% 13.0% 
# Note: only 3 BCCs included in this study 
 
Recently there has been one  report of high risk genital type HPV infection of both BCC 
and SCC with significantly greater prevalence seen in malignant lesions compared with 
warts or precancers, supporting an aetiological role of the high risk genital types in skin 
cancer [308]. Patients who were DNA-positive for the high risk types HPV-16, 31, 35 
and 51 were nearly sixty times more likely to have NMSC as compared with unaffected 
controls. This greatly increased risk was calculated after adjusting for age, gender, and 
sun exposure, and despite proving an association only, provokes important questions 
regarding the possible role of specific HPV subtypes in the pathogenesis of skin cancer. 
This evidence is supported by earlier studies that have found mucosal HPV types in skin 
cancers [315, 317-319]. A role for high risk genital types in the aetiology of NMSC 
makes biological sense considering their link already with skin cancer in EV patients and 
to cervical cancer. In addition, three of these types have also been shown to posses 
transforming activity in tissue culture [320, 321].  
Papillomavirus has been detected in the long-living epithelial root sheath and bulb of hair 
follicles in rabbits, [322], which may be relevant to the development of NMSC, as the 
hair follicle plays an important role in this process. The bulge region of the hair follicle is 
considered an immune-privileged site that may contain the reservoir from which HPV 
infection spreads [323]. Recent studies have examined the prevalence of HPV in eyebrow 
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hairs and the association with NMSC, but no firm associations with NMSC have been 
found so far [324] [323, 325].  
E6 and E7 gene products of mucosal HPVs bind to and degrade p53 via the ubiquitin 
pathway and the retinoblastoma protein (pRb) respectively [326]. It was recently 
discovered that certain EV HPV types may bind pRb as efficiently as the mucosal types, 
and that they show transforming properties in human keratinocytes [327].  Other 
cutaneous HPV types from RTRs may mediate p53 carcinogenesis following exposure to 
UVB [328]. Clearly further work is also needed in this area to delineate the involvement 
of HPV and UV light in NMSC carcinogenesis.  
1.10. Other Genetic Influences On BCC Susceptibility And Development 
A number of members the human herpes virus family contribute to human cancer 
pathogenesis: Epstein Barr Virus (EBV) has been implicated in nasopharyngeal 
carcinoma and African Burkitt’s lymphoma [329]; and cytomegalovirus (CMV) has been 
associated with cervical carcinoma [330] and adenocarcinomas of the prostate [331] and 
colon [332]. Because of the ubiquity of CMV and the high seroconversion rates, it has 
been difficult to establish an association between this virus and human cancer, and has 
only been looked at recently with respect to NMSC. A recent study demonstrated a 
frequency of CMV infection in NMSC lesions that suggests a possible role for this herpes 
virus in both SCC and BCC development and this warrants further exploration [333].  
UVR constitutes an oxidative stress on the skin, generating radical oxygen species such 
as hydroxyl and superoxide radicals, hydrogen peroxide and singlet oxygen, that lead to 
protein, lipid, DNA, and gene mutation [334, 335]. It is intuitive to assume that the way 
individuals deal with this oxidative stress may contribute to their susceptibility to 
cutaneous carcinogenesis. The glutathione-S-transferases (GSTs) are involved in the 
protection against this stress as they are critically involved in detoxification of 
electrophilic compounds such as carcinogens and cytotoxic drugs, and they act to protect 
DNA from damage and adduct formation through conjugation [336-338].  GSTs are a 
large family of isoenzymes that comprise five classes: alpha (GST A), mu (GST M), pi 
(GST P), theta (GST T) and zeta (GST Z) [339, 340]. Polymorphic loci have been 
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identified in all GST gene families, but the pathological consequences of these remain 
largely unknown [341].  The polymorphism displayed by these genes makes them 
obvious candidates for cancer susceptibility: reduced ability to remove potential 
carcinogens may result in mutations in key tumour suppressor genes. This has already 
been shown for GST polymorphisms in association with p53 in lung [342] and ovarian 
tumours [343].  
In relation to skin carcinogenesis, interest has focused on polymorphisms in GST T1 and 
GST M1 as both are expressed in skin [341]. It should be noted however that only a 
proportion of the GST enzyme have been studied: it is possible that the genes with the 
greatest effects on skin carcinogenesis have not been investigated. GST polymorphisms 
appear to have a greater influence on outcome within different BCC subgroups rather 
than on susceptibility to BCC overall: variants may affect BCC tumour number and 
accrual. Both GST M1 and GST M3 in combination with skin type I appear to influence 
BCC number [344, 345]. Tumour accrual has been shown to be influenced by male 
gender, number of BCCs at presentation and presence of GST T1 null [345, 346]. GST 
T1 null also appears to be associated with the truncal phenotype compared with patients 
with no truncal lesions [347, 348]. An interesting and poorly understood interaction 
between the GST M1 A and B alleles has been found with GST M1 A/B protective 
against multiple BCC, but not the homozygous state of GST M1 AA or GST M1 BB 
[349]. GST polymorphisms have also been associated with MM [350] and SCC [351] 
susceptibility. 
Cytochrome P450 (CYP) enzymes are also genetically polymorphic and have been 
studied with respect to BCC susceptibility and development. They are also involved in 
detoxification of numerous xenobiotics including carcinogenic components of tobacco 
smoke [352] [341]. Again, associations of polymorphisms of CYP loci have been found 
only with respect to subgroups of patient with BCC rather than overall risk for these 
cancers. Associations are seen with increased numbers of BCCs [344], with truncal 
tumours in association with GST T1 null and with increased no of primary lesions, 
increased accrual [344] and reduced time to next tumour presentation [347]. 
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DNA repair systems are complex and include mismatch repair, photolyases, base 
excision and post-replication repair. The maximum rate of pyrimidine dimer repair in 
normal skin cells is reportedly barely sufficient to cope with the rate at which damage is 
imposed on skin in full sunlight [353]. DNA repair capcity (DRC) was looked at by a 
group who used a plasmid/host-cell reactivation assay in which a UV-damaged 
expression vector plasmid is transfected into peripheral blood T cells from a subject. The 
host cellular repair enzymes repair the photochemical damage in the plamid and it is 
possible to measure the end amount of repair [72]. DRC measured in this way in controls 
shows an age related decline from the age of 20 at a rate of about 0.61% per year, adding 
up to a 25% loss in repair ability over 40 years [72]. This is consistent with the age 
related decline in DNA repair seen in other studies although results have not been 
repeatable [354] [355-357]. This apparent decline in DNA repair activity of normal 
lymphocytes has also been seen in repair of UV [358], x-ray [359], and gamma 
irradiation [360]. Subjects with early onset of BCC (< 44 years) and those with a family 
history of BCC have been shown to have a significantly lower DRC than control subjects 
[72]; DRC has also been linked to MM with a lower DRC seen in those with MM on sun-
exposed areas than unexposed [361].  It has been suggested by the authors of these 
studies that the normal decline in DRC with age may account for the increased risk of 
skin cancer that begins in middle age, and that skin cancer in the young may represent 
precocious ageing.   
Several investigators have noted a weak association of multiple BCCs with the HLA 
immunoregulatory loci. An initial study investigated HLA class II antigens with respect 
to ethnic groups found an association between multiple BCCs and HLA-DR1 in non-Irish 
and non-Ashkenazi patients, however the sample size of this group (14 subjects) may 
have been too small to detect a real difference [362]. Other studies supported this 
association in other populations however they were no longer significant once corrected 
for multiple testing [363, 364] or were contradictory [365-368]. A small significant 
negative association between HLA-DR4 and multiple BCC has been seen in two studies 
[364, 365] however this same HLA type was later shown to be positively associated with 
the development of both multiple BCC and malignant melanoma in the same individual 
64 
[366]. Overall, the role of HLA types in the development of multiple BCCs appears likely 
to be small. 
The Ras gene family has also been implicated in the development of skin cancer however 
appear to have greater links to the aetiology of malignant melanoma [369] and SCC [370, 
371] than BCC. Ras mutations are relatively infrequently seen in BCCs [370, 372, 373], 
however there is evidence that PDGFRα is upregulated in BCC with associated activation 
of the Ras/MAPK pathway [374]. It may be that this pathway is activated in BCCs in an 
analogous way to breast cancer [375] due to a number of factors including 
overexpression of tyrosine kinases.  
1.11. Family and Twin Studies 
The discovery of familial aggregation is a “universal signal for geneticists to begin 
investigation of genetic causes” [376] alongside classical environmental causes that also 
may be shared in families. Systematic study of the patterns of clustering of both common 
and rare cancers has been successful in this aim. In some cases it has led to the 
identification of specific susceptibility genes of strong effect, for example, in the study of 
breast cancer [377, 378] through segregation and linkage analysis. Understanding of 
genetic susceptibility to prostate cancer [379], colon cancer [380], pancreatic cancer 
[381], endometrial cancer [382], and nasopharyngeal cancer [383], have also been 
enriched from this type of research. In the case of melanoma, for example, genetic causes 
of familial aggregation are now understood to include, in a small proportion of cases, rare 
high-penetrance (high lifetime risk) mutations in the genes CDKN2A and CDK4, and 
much more prevalent low-penetrance (mildly elevated lifetime risk) variants in the 
pigment control gene MC1R [384]. 
Twin studies enable the contributions of genetic and environmental factors to the 
aetiology of a disease to be directly examined by comparing the similarity of 
monozygotic and dizygotic twins. Finland has a nationwide Central Population Register 
that includes data on twins, and also a nationwide cancer registry with compulsory 
reporting of all cancers including non-melanoma skin cancers. Case reports of BCC in 
monozygotic twins and in twins of unknown zygosity emerged from this Finnish twin 
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cohort in the 1970s [385]. A more recent study looked at the difference in prevalence 
associated with zygosity by identifying 335 twin pairs of known zygosity in which at 
least one twin had BCC diagnosed between 1953 and 1996 [386]. The co-twin of a twin 
with BCC was found to have an increased risk of BCC (RR 7.0: 95% CI 3.7-1.3), 
suggesting familial aggregation of this cancer. With only 11 concordant pairs for BCC in 
the data from 1976 to 1996, and a total of 16 concordant pairs if the retrospective (1953- 
1975) data was included, there was very little power with which to make conclusions 
regarding the contributions of genetic and environmental effects. The proportion of 
phenotypic variance in susceptibility due to genetic factors was estimated at 8%, however 
the 95% confidence limits were 0-56%. 
There have been very few other studies of familial clustering of BCC outside the context 
of Gorlin syndrome. One Australian study [3] described 1108 consecutive cases of 
histologically confirmed nonmelanoma skin cancers in a single Melbourne clinic over an 
18 month period in the early 1990s. Among these patients, 12 families were identified in 
which more than one member had a nonmelanoma skin cancer and in which the known 
inherited predisposition syndromes were excluded. Because of potentially biased 
ascertainment of cases with a positive family history of skin cancer to the clinic it is not 
possible to conclude whether or not this proportion of family history positive cases is 
greater than would have been expected by chance. However the patterns of family history 
seen are instructive. In 11 of these families skin cancer had occurred in more than one 
generation, and in nine multiple skin cancers had developed in two or more generations. 
Most of the affected members developed BCCs only; there were some with both BCCs 
and SCCs, and a few with only SCCs. This suggests that familial forms of NMSC 
predisposition may exist, that they may genetic and cancer type-specific. The vertical 
patterns of ‘inheritance’ seen indicate that they may be an autosomal dominant trait. 
Case reports also support the existence of familial aggregation of BCC with case reports 
of multiple superficial BCC in twins [387] or in two generations, including instances of 
male-to-male transmission [247, 388]. There have also been three reports of unilateral 
manifestations of superficial BCC [250], in which familial cancer syndromes were 
excluded by examination and in one case also by radiography. The phenomenon of 
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lateralisation is difficult to explain without the assumption that non-syndromic hereditary 
multiple BCC can occur as a distinct Mendelian trait, with the apparent mosaicism likely 
to have occurred as an early postzygotic mutational event. Thus, a separate phenotype of 
hereditary non-syndromic mulitiple BCC may exist, characterized by the presence of 
multiple superficial BCC and by the absence of other anomalies (as per the MPP 
described in section 1.4.2). One author [250] suggests that this possibly polygenic trait 
has a clinical appearance that differs from those observed in Gorlin, Bazex-Dupre-
Christol and Rombo syndromes because the BCCs are stereotypically of a superficial 
type and preponderantly involve the trunk. There is already preliminary evidence that 
BCC has differential genetic susceptibility to SCC and MM, as suggested by the different 
HLA associations for these tumours [366, 389]. 
In summary, there is preliminary evidence for specific familial aggregation of BCC, but 
no knowledge of its causes. Based on the sum of research on other common cancers, it 
would be expected that a small proportion of such aggregation might be due to rare, high-
penetrance alleles such as PTCH, and the majority due to common, low- to medium-
penetrance factors such as pigmentation genotypes (e.g. MC1R), and sharing of the major 
environmental risk factor, sun exposure. However, it is clear that much further research is 
needed to understand the genetic epidemiology of this common and burdensome cancer. 
1.12. Aims and scope of this thesis 
Although much work has been done on rare genodermatoses involving BCC, very little is 
known about genetic susceptibility to BCC outside these settings. A small Australian 
study looking at familial clustering of NMSC that noted apparent differences in 
susceptibility to BCC versus SCC between NMSC pedigrees, suggesting differing genetic 
influences [3]. However, there have been no larger-scale studies of this phenomenon. 
Gorlin syndrome is one of the rare familial syndromes that has received research 
attention, and involves autosomal dominant inheritance of marked susceptibility to BCC 
and a range of developmental defects. Mutations in the cell growth regulatory gene 
patched (PTCH), when present in the germline are responsible for this disorder. They 
have also been found in a high percentage of sporadic tumours, suggesting a critical 
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involvement of this pathway in BCC tumour development generally. Furthermore, mice 
with Gorlin syndrome-like knockouts of one copy of PTCH develop BCCs if exposed to 
UVR, mimicking the human situation [4]. No studies have yet investigated whether 
germline mutations or less highly penetrant variants of this gene might account for part of 
non-syndromic BCC susceptibility in the general population. 
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Chapter 2: Methods 
 
2.1. Patients and recruitment 
2.1.1. Ascertainment 
 
The subjects of this analysis are part of a larger study of familial aggregation of non melanoma 
skin cancer, which involves cases of early-onset of both BCC and SCC occurring in the greater 
Sydney metropolitan area, and their relatives. This geographical area is defined by the borders 
of Wollongong to the South, Gosford to the North, and the Blue Mountains to the West. These 
cases were identified through the database of the Dermatopathology Division of the Skin & 
Cancer Foundation Australia (SCFA). This academically affiliated service receives pathology 
from a significant proportion of dermatologists practising in New South Wales (NSW), as well 
as from those working at the SCFA’s two large Sydney clinics in Darlinghurst and Westmead. 
Patients are referred to these dermatologists from their general practitioners for assessment and 
treatment of skin conditions including skin cancer, and to make use of the dermatopathology 
service of the SCFA. Referrals to these services are unlikely to have been biased towards 
people with a family history of NMSC. Neither BCC nor SCC are registrable in Australia, but 
their combined incidence has been estimated by population-based surveys to be 2200 per 100 
000 in 1997 in Australia [390]. This figure is likely to also represent the incidence in Sydney 
because NSW has melanoma rates (a surrogate for sun-related skin cancer) that are close to the 
national average, and greater Sydney includes more than two thirds of the State’s population. 
The incidence of melanoma in NSW in the year 2001 was 42.4 and 31.6 per 100,000 for males 
and females respectively, age standardised to the 2001 world population. The national average 
was 53.7 and 38.0 per 100,000 for males and females respectively in the year 2000, age 
standardised to the 2001 world population (from the Australian Bureau of Statistics, 
www.abs.gov.au). Preliminary searches of the SCFA database for BCC and SCC showed that it 
had captured 8200 individuals histologically-verified as having NMSC from 1994- 1999, of 
whom 80% were residents of the Sydney metropolitan area. This equates to 200 per 100,000 
cases per year in Sydney (ie 8200/4,000,000 x 100,000), which is 10% of the total estimated 
incidence. The SCFA database can thus be considered a quasi-population-based register of 
biopsy proven NMSC in the Sydney metropolitan area. 
2.1.2. Recruitment 
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Eligible subjects (probands) were those of either sex, with histologically verified primary 
cutaneous BCC, diagnosed at forty years of age or younger during the 12 month period from 
January to December 2000, or SCC diagnosed at fifty years or younger, during the 24 month 
period from January 1999 to December 2000. These age thresholds were selected so that the 
youngest 7-8% of the total number of BCC and SCC-affected individuals per year were 
captured, and the longer period of SCC eligibility was required because SCC is significantly 
less common than BCC in these age groups [1]. Only the BCC arm of the study will be 
reported here. 
A letter was sent to the referring doctors of 257 BCC cases asking permission to contact their 
patients regarding this project. Once consent was given, and information pack was sent from 
SCFA to the patient, containing information on the research project, consent forms to 
participate in the study and a form to release this consent from SCFA to the research team. . If 
there was no response to this information, SCFA attempted to contact the subjects by telephone 
for a response. For subjects that were unable to be contacted by these methods, a ‘Yes-No’ 
response form was sent out asking them to simply tick a box and return the form, to let us 
know that they were actively refusing participation. If there was still no response a second Yes-
No form was sent. For all correspondence that was ‘returned to sender’ by the postal service, 
the referring doctor was asked for updated contact details. For all subjects whose current 
address or telephone numbers were unable to be discovered by these methods, ‘Marketing Pro’ 
software was used to attempt to obtain current details. If new details were discovered by any of 
these means, the process began again with a new information pack sent to the new address 
and/or a telephone call from SCFA to the new telephone number to follow up on information 
packs sent. The team only contacted the subjects once their consent was returned, which 
included 56 BCC affected individuals, and 48 SCC affected individuals.  
Twenty-three of 201 eligible subjects were denied consent by their treating doctor. Of  the 
remaining 178 early-onset BCC cases approached, 56 consented, 50 actively or passively 
refused, 13 were not contactable after exhausting the methods detailed above, and for 59 it was 
unclear whether or not the patient had received the information or not. Thus the actual 
percentage of eligible contactable subjects consented is between: 56/165 (34%) and 56/106 
(53%), depending on how many of the not-contactable subjects were actually passive refusals. 
2.2. Interviews and histological confirmation of cancers 
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Each family stucture was determined by interviewing probands about their first and second 
degree relatives. Each first degree relative was then approached, and if they consented to 
participate in the study, they were interviewed about their cancer history. Cancer history 
information on deceased first degree family members was also obtained where possible 
through proxy interviews with a consented family member. Attempts were made to verify all 
reports of cancer with histopathological records if possible or alternatively through medical 
records. This was done through contacting the treating doctor or relevant pathology service 
for BCCs and SCCs, and through the cancer registry for registrable cancers. If the registry 
could not verify the reported cancer then the treating doctor was contacted for these records. 
The earliest reported cancer of each type was the priority for verification. Where multiple 
reports were received, they were all followed up until at least one confirmation of NMSC was 
received. Where more than one NMSC was confirmed, the earliest dates of BCC and SCC 
diagnoses were used for subsequent analysis. The information was coded according to the 
level of confirmation (self-report alone/ clinical diagnosis alone/ histological confirmation). 
In situ SCC was accepted as equivalent to invasive SCC because recent data indicate that the 
prospective risk of further SCC is similar in these two conditions. Relatives were only 
labelled ‘unaffected’ if they never had any potential NMSC lesions treated, and if they had no 
NMSC or premalignant lesions present on examination. The oldest unaffected sibling for each 
proband (if available) was designated as an intra-family control. 
In all subsequent analyses, the word ‘relatives’ refers to the consented first-degree relatives of 
probands in this study.  
2.3. Phenotyping 
2.3.1. Skin examination 
All probands and their sibling controls were invited to attend skin examinations at SCFA in 
Westmead or Darlinghurst, at Westmead hospital, or at outer metropolitan or rural hospitals 
for a few subjects who could not attend a city venue. The same measurement equipment was 
used at each site, and the same lights were used to enable standardized illumination. The 
candidate, a medical graduate, was trained to assess premalignant and malignant lesions and 
the markers of sun damage on subjects, according to a standard protocol as, described below. 
Height and weight were recorded. Subjects were asked to identify the hair colour that was 
closest to their natural colour at age 18, using synthetic hair swatches (Clairol, USA) designed 
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for wig-making. Colours used in this study included: High-Lift golden blonde HL-G, Sable 
Brown 48D, Dusk Blonde 93D-N, Nightfall Brown 95D-N, Sunberry 72R, Reddest Fire Red 
206RR, Golden Apricot 41G, Black Azure 52D. Skin colour was recorded using a reflectance 
spectrophotometer, as described in 2.3.3.  
All subjects were tested for features of Gorlin Syndrome, including mandibular keratocysts 
(through the questionnaire) and examination of the palms for pitting. Each of these features 
would be expected to be seen in over 80% of patients with Gorlin syndrome [200]. 
Markers of sun exposure and damage were then assessed on a semi-quantitative scale and 
included:  ephelides (freckles), solar lentigines, actinic keratoses, actinic damage/elastosis, 
seborrhoeic keratoses, and presence of any new skin cancers noted. If a lesion was suspicious 
of malignancy, the subject was referred to their local GP or dermatologist. Results were 
recorded on a patient data sheet and entered into a password-protected database in secure 
facilities. Data for analysis were deidentified. 
All subjects undergoing skin examination also filled out a questionnaire (see section 7.1 for 
clinical protocol) regarding their skin type, hair colour, eye colour, childhood and adult 
freckling, and history of dental cysts. 
The candidate undertook an informal audit of examining technique with an experienced 
dermatologist after the examinations were complete. Her technique was considered adequate 
for all variables except seborrhoeic keratoses, where fainter lesions were missed. Absolute 
values for this variable should be regarded as underestimates and were not interpreted, 
whereas categorisation of individuals with respect to number of these lesions was regarded as 
suitable for analysis. 
2.3.2. Skin examination recoding variables 
All skin phenotype variables, from examination and questionnaire, were subjected to an initial 
analysis to determine their distribution and informativeness. The number of categories was 
reduced by recoding in many cases in order to maximise the number of individuals in each 
recoded category. All recoded variables are described here. 
Only one subject (1.1%) reported having black hair when asked to name their hair colour at 
age 21, and this subject chose a brown hair swatch when asked to select a representative hair 
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swatch colour visually: the category of ‘black’ was therefore combined with the category 
‘dark brown’ for the analysis.  
Few people (3.4% or 3/88) reported that they ‘go brown without any sunburn’ when asked 
“which statement best describes what would happen if your skin were exposed to bright 
sunlight for the first time in summer for one hour in the middle of the day without any 
protection?” (see section 7.1). Therefore the answers for the ‘no sunburn/tanning’ were 
combined with the ‘mild sunburn’ category for analysis. 
No subject out of 88 reported that they ‘never burn’ as a response to the question “in general, 
how does your skin react to the sun?” and therefore this phototype category was removed 
from the analysis. 
Examination for presence of actinic keratoses (AKs) revealed that most subjects did not have 
many of these lesions on the regions of the body included (see section 4.2.4). The categories 
of ‘sparse’ and ‘moderate’ were therefore collapsed to the single category of ‘present’ or 
‘absent’ for presence of any AK on the regions head/neck, chest, dorsum arms and dorsum 
hands examined. A large proportion of subjects had a high amount of solar elastosis, skewing 
the results. Therefore the score for each body region (Head/neck/anterior chest, periorbital, 
lips, dorsa forearms, and dorsa hands) were added up with a score of 0 for ‘absent’, 1 for 
‘mild’ and 2 for ‘severe’. This was added up across all categories and each subject was given 
a score of ‘low’for a total body score between 0 and 9, and a score of ‘high’ for a total body 
score of 10.  
Semi-quantitative counts of solar lentigines were skewed across the 88 subjects examined 
with a disproportionate number falling into a low or high count category (see table 7.8 for raw 
scores). Therefore the median count category for each body region was determined and 
subjects re-categorised into ‘low’ or ‘high’ solar lentigines groups. For the face this meant 
that raw scores of 0 – 2 were recoded as ‘low’ with the remainder of scores 3 – 10 recoded as 
‘high’. Similarly, the raw scores for solar lentigines on the forehead were recoded 0 – 1 ‘low’ 
and 2 – 10 ‘high’. For the upper limb raw scores, 0 – 4 became ‘low’ and 5 – 9 became ‘high’. 
For the upper back and shoulders, 0 – 6 became ‘low’ and 7 – 9 became ‘high’.  
Reporting of freckling in childhood and adulthood was skewed to include a greater proportion 
in the category ‘very few’ than the other positive freckling categories (see table 7.9 for raw 
scores). ‘Very few’ was therefore renamed ‘some’, and the ‘few’, ‘some’, and ‘many’ 
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categories were collapsed into the single category of ‘many’. As with the analysis of semi-
quantitative examination results for solar lentigines, subjects’ ephiledes (freckling) scores 
were skewed or biphasic (see table 7.9) and so the median (if skewed) or the score between 
the two peaks (if biphasic) for each region was taken, and subjects reclassified into high and 
low numbers of freckles based on this median division. For ephilides on the face, raw scores 
of 0 – 3 were recoded as ‘low’ and 4 – 10 as ‘high’. For raw scores of ephilides on the 
forehead, 0 – 3 were re-classified as ‘low’ and 4 – 10 as ‘high’. For the upper limbs, raw 
scores of 0 – 7 were scored as ‘low’ and 8 – 10 as ‘high’. For the upper back and shoulders, 0 
– 6 raw scores were recoded as ‘low’ and 7 – 10 as ‘high’. 
Examination results for numbers of seborrhoeic keratoses were skewed with many subjects 
scoring ‘nil’ on this variable for several of the body regions (see table 7.10). The results were 
reclassified into an absent/present dichotomy for each region examined to allow any real 
associations to be seen. The score for all the body regions examined (head/neck, upper limbs, 
chest, abdomen, back, lower limbs) were then summed to give a total body score, and this was 
also divided into ‘low’ (score of 0 – 1) and ‘high’ (score of 2 – 8) categories based on the 
median score. 
2.3.3. Skin colour assessment 
The apparent colour of a person’s skin is due to the aggregate of reflected light, the 
wavelengths of which depend on four biochromes: melanin, carotenoids, oxyhaemoglobin and 
reduced haemoglobin. Melanin and the carotenoids are brown and yellow respectively, and 
are found in the epidermis, the uppermost layer of the skin. Oxyhaemoglobin is bright red and 
found in the arterioles and capillaries of the upper dermis of the skin, just deep to the 
epidermis. Reduced haemoglobin is bluish-red and is found in the venous plexus of the 
dermis, just deep to the arterioles and capillaries [21]. 
Skin colour of each subject examined was assessed with a BYK Gardner spectrophotometer; a 
portable instrument that measures reflected colour and the colour difference using the 
Commission International de l’Eclairage (CIE; 1976) L*a*b* standard colour system. The L* 
value (luminance) represents the relative lightness ranging from total black to total white; the 
a* value represents the balance between red and green; and the b* value the balance between 
yellow and blue. This instrument uses the same wavelengths of light (400 to 700nm at 20nm 
intervals) to measure skin reflectance as the Minolta 508, a spectrophotometer with 
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measurement of skin colour that correlates highly (r = 0.68) with melanin density seen 
histologically on biopsied skin from the site measured [391]. The Minolta does not separate 
the reflected light into the L, a and b axes, giving a single reading of reflected light for each 
20nm interval of reflected light. Based on best correlation with melanin density over the 
spectrum of light used, researchers using the Minolta generally use the difference between the 
reflectance measurements at 400nm and 420nm of incident light as a single parameter. 
The Minolta and BYK Gardner instruments are regarded as equivalent in commercial colour 
measurement applications. However, there are no published data on correlates between 420-
400nm reflectance and L*a*b* measurements, or between L*a*b* measurements and 
melanisation. In this thesis, the raw L*a*b* measurements were used without further 
manipulation in order that all available information on skin colour should be used. 
The spectrophotometer was recalibrated prior to each skin examination session to ensure 
comparable readings between subjects, and the mean of 6 consecutive readings was recorded. 
The measurements were taken on the medial axillary wall (constitutional skin colour) and 
upper outer arm (sun exposed skin colour) of each subject examined. The mean L*a*b* 
values was recorded on the subject’s data sheet. 
2.4. DNA extraction 
Blood (20 ml EDTA) was collected from the probands, sibling controls and parents of 
probands by standard venipuncture. DNA was extracted from whole blood as described in 
appendix 7.2. The total concentration of the DNA was checked by spectrophotometry at 260 
nm and 320 nm (Genequant Pro; Amersham Pharmacia Biotech, England). The DNA quality 
was estimated by running the DNA samples on a 1% agarose gel, stained with ethidium 
bromide (final concentration of 0.5µg/ml). Gels were photographed under UV light (NovaLine 
Gel Documentation System; Sweden).  
2.5. Genotyping of PTCH 
2.5.1. Exon and primer selection 
The exons chosen for amplification and analysis were exons 2, 3, 5 to 18, and 20 to 23. Exon 
23 was split into 23a and 23b to allow for easier amplification and dHPLC (exon numbering 
of the PTCH exons is as described by Johnson et al [214]. The priorities for exon choice were 
based on those for which PTCH mutations have been documented in Gorlin subjects. The 
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genbank accession number for the PTCH gene is U59464. Exons 1 and 4 were excluded 
because no mutations have been seen in these exons in previous studies, and exon 19 was 
excluded due to repeated difficulties with PCR amplification. Primer pairs used are according 
to Hahn et al (exons 6, 7, 8, 9, 10, 11, 15, 17 and 18) [213], Fujii et al (exon 2) [392] and Xie 
et al (exons 12, 13, 14, and 21) [221]. Primer pairs for exons 3, 5, 16, 20, 22, 23a, and 23b 
were provided by BJ Wainwright (personal communication). Primer sequences for all exons 
amplified are listed in table 2.1 and have been used extensively for dHPLC analysis of Gorlin 
syndrome patients and somatic mutations in non-familial BCC in the laboratory of Prof BJ 
Wainwright, University of Queensland; Brisbane, Australia. 
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Table 2.1 Primer sequences to amplify PTCH exons 
Exon Primer sequence 
2 F 5’-ACTCCTCCCTTCTGCTTCGT-3’ 
 R 5’-GCGCTGGCGAATATCTCTAT-3’ 
3 F 5’-CTATTGTGTATCCTATGGCAGGTAGTCAGATAACAGAT-3’ 
 R 5’-ATTAGTAGGTGGACGCGGCGGGCCT-3’ 
5 F 5’-GCAAAAATTTCTC AGGAACACC-3’ 
 R 5’-GGAACAAACAATGATAAGCAA 
6 F 5’-CCTACAAGGTGGATGCAGTG-3’ 
 R 5’-TTTGCTCTCCACCCTTCTGA-3’ 
7 F 5’-GTGACCTGCCTACTAATTCCC-3’ 
 R 5’- GGCTAGCGAGGATAACGGTTTA- 3’ 
8 F 5’- GAGGCAGTGGAAACTGCTTC -3’ 
 R 5’- TTGCATAACCAGCGAGTCTG-3’ 
9 F 5’-GTGCTGTCGAGGCTTGTG-3’ 
 R 5’-AGAAGCAGGAGCAGTCATGG-3’ 
10 F 5’-TTCGGCTTTTGTTCTGTGC-3’ 
 R 5’-CCGGTGGCATTTGTCAAC-3’ 
11 F 5’-CTGTTAGGTGCTGGTGGCA-3’ 
 R 5’-CTTAGGAACAGAGGAAGCTG-3’  
12 F 5’- GACCATGTCCAGTGCAGCTC-3’ 
 R 5’- CGTTCAGGATCACCACAGCC-3’ 
13 F 5’- AGTCCTCTGATTGGGCGGAG-3’ 
 R 5’- CCATTCTGCACCCAATCAAAAG-3’ 
14 F 5’-AAAATGGCAGAATGAAAGCACC-3’ 
 R 5’-CTGATGAACTCCAAAGGTTCTG-3’ 
15 F 5’-GACAGCTTCTCTTTGTCCAG-3’ 
 R 5’-ACGCAAAAGACCGAAAGGACGA-3’ 
16 F 5’-CGCTAGGACCAGGGTCCTTCTGGCTGCGAGTTATA-3’ 
 R 5’-TCAGTGCCCAGCAGCTGGA-3’ 
17 F 5’-AACCCCATTCTCAAAGGCCTCTGTTC-3’ 
 R 5’-CACCTCTGTAAGTTCCCAGACCT-3’ 
18 F 5’-AACTGTGATGCTCTTCTACCCTGG-3’ 
 R 5’-AAACTTCCCGGCTGCAGAAAGA-3’ 
20 F 5’- CATTTAGGACAGAGCTGAGCA-3’ 
 R 5’- GGCCCAATCACAATGATTTC-3’ 
21 F 5’-TGTTCCCGTTTCCTCTTG-3’ 
 R 5’-GCACAGGAAACACAGCATTC-3’ 
22 F 5’-AGTGTGGCCAGCAGGTAAAT-3’ 
 R 5’-CTCCAGGCCCACTACCAC-3’ 
23a F 5’-AAACCCAAGGAGGGAAGTGT-3’ 
 R 5’-CCGAGGGTTGTGAGAACG-3’ 
23b F 5’-GCATTCTGGCCCTAGCAATA-3’ 
 R 5’- TCTTTGCCTGGCTCTAGGTC-3’ 
Forward (F) and reverse (R) primer sequences of exons 2 to 4 and 5 to 23b of the PTCH gene. The primer pairs 
of exons 15, 17 and 18 correspond to primer pairs 14, 16 and 17 respectively as described by Hahn et al. [213] 
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2.5.2. PCR protocol for amplification of PTCH exons 
PCR reactions were performed in a total volume of 52.8µl. The reaction contained 5µl of PCR 
buffer (1.5 mM MgCl2; 10mM Tris-HCl, pH 8.5; 50mM KCl), 1 µl DMSO, 1µl dNTP 10mM 
(Fisher Biotec, Australia), 1µl of each primer 50µM (forward and reverse), 0.3µ of AmpliTaq 
Gold 5U/µl (Roche Applied Biosystems, USA), 3µl DNA 25ng/µl, and 40.5 µl dH2O (table 
2.2). The same PCR protocol suited the amplification of exons 2, 5- 20, 22, and 23a (and 
19?). For exons 3 and 21, 2.5 mM MgCl2 was used, and for exon 23b, 2.0 MgCl2 was used. 
Each reaction contained a negative control that contained all the stock ingredients with water, 
to ensure that the reagents were not contaminated. A positive control was not available. All 
PCR reactions were done using sterile techniques, working in a laminar flow hood.  
The annealing temperature for exon 2, 3, 5, 7, 8, 9, 10, 12, 13, 15, 17, 18, and 20 was 55ºC, 
for exons 6, 11, and 14 it was 57ºC, for exons 16, 21, 22, and 23a it was 59ºC and for exon 
23b it was 60ºC. The thermocycling parameters included an initial denaturing step at 95º for 
30 minutes, followed by 95º for 45 seconds, the specific annealing temperature for 50 
seconds, 72º for 50 seconds for 35 cycles, and a final elongation cycle of 72º for 7 minutes 
(Palm-Cycler version 2.2; Corbett Research, Australia). The PCR tubes were stored at -20ºC 
until required for denaturing High Performance Liquid Chromatography (dHPLC) or 
sequence analysis.  
 
Table 2.2 PCR Cocktail (52.8 µl total) 
Reagent (conc) Volume (µl) Final concentration 
dH2O 40.5 - 
PCR Buffer (MgCl2, Tris-HCl, KCl) 5.0 MgCl2: 1.5mM; Tris-HCl: 10mM (pH 8.5); KCl: 50mM 
DMSO 1.0 - 
dNTP’s (10 mM)  1.0 0.19 mM 
PTCH F primer (50 µM) 1.0 0.95 µM  
PTCH R primer (50 µM) 1.0 0.95 µM 
AmpliTaq Gold (5U/µl) 0.3 1.5 U 
DNA (25 ng/µl) 3.0 75 ng 
Total 49.8 + 3.0 µl  
 
 
2.5.3. Agarose gel electrophoresis 
All PCR products were checked for purity and correct sizing on a 1.5% agarose gel (1.5g 
agarose in 100 ml 0.5x TBE), stained with ethidium bromide (final concentration of 0.5 
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µg/ml). For all samples, 3 µl of each PCR product was mixed with 2 µl of loading dye and 
pipetted into successive wells of the gel, running them next to 2µl of low DNA mass ladder 
(4µl/appl; Invitrogen Life Technologies, Australia) and the negative control. The gels were 
electrophoresed at 80V for approximately 30 minutes at room temperature and subsequently 
photographed under UV light (NovaLine Gel documentation system; Sweden). It was always 
ascertained that the negative control did not show any bands on the gel. If the negative control 
did show a band in a particular experiment, the resultant samples were discarded, the reagents 
replaced, and the reaction repeated until the negative control did not show a band on the gel.  
2.6. dHPLC analysis of the PTCH gene 
The PCR products were denatured at 95ºC for 5 minutes, followed by slow renaturing at -1ºC 
per minute, from 94º to 60ºC (Palm-Cycler version 2.2; Corbett Research, Australia) and 
subsequently stored at -20ºC until dHPLC analysis. Denatured PCR products (5-20µl) were 
analyzed for heteroduplexes by dHPLC (WAVE® DNA Fragment Analysis System; 
Transgenomic Inc, Omaha, Nebraska, USA) at the dHPLC Fragment Analysis Facility, 
Westmead Millennium Institute, Sydney, Australia. The PCR product was eluted from a 
temperature-equilibrated DNASep® analytical column (Transgenomic Inc, Omaha, Nebraska, 
USA) using a gradient of 0.1 M triethylammonium acetate buffer (TEAA) (A) and 0.1 M 
TEAA/25% acetonitrile (B), pH 7.0, at a constant flow rate of 0.9 ml/min. The gradient was 
predicted by the WAVEMakerTM software (Transgenomic) (table 2.4). Eluted DNA fragments 
were detected with ultraviolet absorption at wavelength 260 nm. Temperatures used for 
dHPLC were based on temperatures used by the University of Queensland, Brisbane (kindly 
provided by Wainwright BJ; personal communication) and predictions determined by the 
WAVEMakerTM software (table 2.4). The sequence of the wild type PTCH amplicon used for 
predictions is Genbank sequence U59464 (see section 7.3).  
For the eight exons most likely to harbour mutations based on previous research (exons 2, 3, 
6, 8, 14, 15, 17 and 18), two temperatures were used to screen each exon, in an attempt to 
detect all variations in the majority of the exon. These eight exons have been found to have 
the highest mutation rate of all the coding regions of the PTCH gene, and mutations in these 
exons account for approximately 60% of the total mutations cited in the literature. 
Unfortunately, exons 6 and 8 were able to be screened at one temperature only, due to 
procedural difficulties and time constraints. Thus mutation in the exons screened at two 
temperatures accounted for approximately 50% of the total mutations cited in the literature. 
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The two temperatures were used to screen 19 of the 58 probands, including all of those 
probands for whom there was histopathological confirmation of a family history of BCC at 
the time that laboratory work was practicable. This included 17 probands from the BCC arm 
of the study and 2 from the SCC arm. See table 2.3 for a summary of family cancer 
prevalence in the 19 probands chosen to have extra screening for higher risk exons. For the 
remainder of the 39 probands for these seven exons and the remaining exons screened, one 
dHPLC temperature only was used. The melting profiles for the temperatures used as 
predicted by the WAVEMaker TM software can be found in appendix 7.4; one example is 
given in figure 2.1.  
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Table 2.3 Family history of BCC, SCC, and MM (proband and first degree relatives) for high risk subjects 
included for two temperatures of  dHPLC screening 
aDNA unavailable at time of laboratory work for screening at two dHPLC temperatures 
# Underlined age indicates that the subject is deceased 
*Indicates proband age of diagnosis 
Proband ID Total number 
of family 
members 
recruited 
Number 
of BCC-
affected 
family 
members 
Age of onset of BCC# Number of 
SCC-
affected 
family 
members 
Age of 
onset of 
SCC 
Number 
of 
NMSC-
affected 
family 
members 
Number 
of MM-
affected 
family 
members 
Age of 
onset 
of MM 
BCC probands 
8755 5 2 31, 34* 1 55 3   
8761 4 2 34*, 62 1 65 2   
8763 8 2 36*, 43,  2 41, 71 4 1 42 
8768 4 2 20*, 48 0 - 2   
8770 5 3 39*, 69, 70 1 75 3 2 33, 78 
8773 6 2 39*, 52 0 - 2   
8781 3 2 35*, 51 1 51 2   
8797 9 2 35*, 53 2 53, 42 3   
8800 10 4 26, 38*, 43, 69 1 70 4   
8815 5 2 19*, 58 0 - 2   
8816 9 6 39*, 44, 50, 50, 53, 76 2 53, 76 6 2 38, 49 
8840 6 6 23, 23, 25, 28*, 49, 54 2 42, 46 6 3 23, 
37, 47 
8846 4 3 26*, 55, 56 0 - 3   
8857 4 2 35*, 63 0 - 2   
9022 9 6 35*, 36, 44, 54, 58, 74 0 - 6   
9125 6 3 25, 37, 38* 2 43, 67 4   
9194 4 2 33*, 62 1 64 2   
9242a 7 2 30*, 50 0 - 2   
SCC probands        
8701 7 6 29*, 30, 39, 54, 69, 75 3 40*, 51, 
84 
6 1 69 
8001 6 3 37, 37, 53 1 41* 4   
8196a 7 3 34,43, 45 3 34, 41*, 
53 
4   
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Table 2.4 Amplicon size and DHPLC conditions for PTCH fragments 
Exon Size (bp) dHPLC gradient dHPLC temp (ºC) 
2 294 54-63%B in 4.5 min 59.9
  54-63%B in 4.5 min 62.5
3 313 55-64%B in 4.5 min 56.5
  55-64%B in 4.5 min 58
5 248 52-60% in 4.5 min 57 
6 335 57-66% in 3.5 min 59.2 
7 294 54-63% in 4.5 min 57 
8 256 53-62%B in 4.5 min 61.8
9 281 54-63%B in 4.5 min  60.8 
10 242 54-63%B in 3.5 min 60.2 
11 253 53-62%B in 4.5 min 58.3 
12 211 53-62%B in 3.5 min 62.6 
13 222 51-60%B in 4.5 min 59.2 
14 540 59-68%B in 4.5 min 61.5
  56-65%B in 4.5 min 63.8
15 425 57-66%B in 4.5 min 58
  57-66%B in 4.5 min 60.5
16 219 51-60%B in 4.5 min 59.3 
17 268 53-62%B in 4.5 min 59.8
  51-60%B in 4.5 min 64.5
18 410 57-66%B in 4.5 min 61.2
  57-66%B in 4.5 min 62.8
20 267 54-63%B in 4.0 min 61.3 
21 186 49-58%B in 4.5 min 61.7 
22 371 56-65%B in 4.5 min 62.8 
23a 331 55-64%B in 4.5 min 63.9 
23b 407 57-66%B in 4.5 min 63.1 
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Figure 2.1  Predicted dHPLC melting curve for PTCH exon 15, wild type. 
Helical fraction (%) of the DNA (Y-axis) versus base position in the amplicon (X-axis). The helical fraction 
ranges from 0% (completely denatured DNA; single stranded DNA) to 100% (double stranded DNA). dHPLC 
can detect mutations in partially denatured DNA, optimally 30-80% helical fraction (Leary J, Manager dHPLC 
Fragment Analysis Facility, Westmead Millennium Institute; Personal Communication).  
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2.7. DNA sequencing of PTCH exons 
Samples with detectable dHPLC variants were sequenced, together with a sample of the 
same exon that displayed a normal dHPLC melting curve, for comparison. The PCR 
products were purified using a QIAquick PCR Purification Kit (Qiagen; Australia. Cat. 
No. 28106), following the manufacturer’s instruction manual (see appendix 7.5). The 
quantity of the purified PCR product was estimated using gel electrophoresis (see above), 
loading 2 µl of each sample mixed with 2 µl of loading dye, comparing it to 2 µl of low 
DNA mass ladder. 
Sequencing was carried out in both the forward and reverse direction or, in some cases, 
only in forward direction. Each sequencing reaction comprised template DNA, 3.2 pmol 
of the respective primer and 1µl of DMSO. Water was added to make up to a total 
volume of 12 µl.  For all exons except exon 15, 10ng of template DNA was included, and 
for exon 15, 20ng of template DNA was included due to its larger size (see appendix 7.3 
for exon sizes).  
Sequencing was carried out in the DNA Sequencing Facility at the Westmead 
Millennium Institute, Sydney, Australia. The facility uses an ABI PRISM 3100 Genetic 
Analyser (Applied Biosystems; Australia); using POP-6 polymer with a 50 cm capillary 
array. 
2.8. PTCH gene SNP identification numbers 
Table 2.5 SNPs seen in probands that have previously been identified in SNP databases with their 
identification numbers  
Exon SNP  SNP identification number
2 C>T 116 rs1805153 
6 IVS6-55T>C rs2297087 
8 IVS8+23G>A rs2066840 
11 IVS11-50G>C rs574688 
12 T>C 63 rs16909910 
12 C>T 84 rs2066836 
15 IVS15+9 G>C rs2066829 
23a 140 T>C rs357564 
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2.9. Estimating Australian population cumulative risk (prevalence of a prior 
diagnosis) of NMSC 
2.9.1. Estimating cumulative risk from incidence 
NMSC are not notifiable to cancer registries in most of Australia, so verification of self-
reported past diagnoses is not as feasible as it is for other cancers. Cumulative risk 
(prevalence of a prior diagnosis) of SCC and BCC was estimated from the most recent 
Australian general population incidence data available [1]. Five-year incidence data was 
obtained for men and women separately from survey data collected in 1995. Although 
lifetime prevalence of skin cancer was surveyed in this study, only the previous 12 
months of skin cancer incidence data had been validated, and therefore only this data was 
suitable for analysis. Although the numbers of non-melanoma skin cancers were provided 
for five year age groups beyond 69 years (ie. 70-74, 75-79, 80-84, 85+), the number of 
people at risk for these age groups was only provided as a single group (70+).  Therefore, 
incidence and prevalence was able to be estimated only for individuals up to 70 years of 
age. 
Estimating prevalence and cumulative risk from incidence data has been discussed by 
other researchers [393] [394]. Most approaches require registry data which are not 
available in this instance.  These models allow for the effects of competing risks. 
Statistician collaborators, Dr Karen Byth and Ms Peta Forder constructed estimates by 
making simplifying assumptions, and adapting existing epidemiological methods to 
incidence and cumulative risk estimation for BCC and SCC. The general population 
cumulative risk was estimated via a suitable model for the incidence. This novel approach 
is described below. All references to “prevalence” after this point mean prevalence of a 
prior diagnosis of skin cancer (ie cumulative risk). 
Assume for the moment that the incidence of the particular cancer of interest at age i is 
independent of year (period) and of year of birth (cohort). Let the incidence of this cancer 
at age i be denoted by iλ  and note that iλ <<1.  Suppose that there are iN  individuals of 
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age i.  Assume that the probability distribution of the number of individuals who develop 
the cancer of interest at age i can be approximated by a Poisson distribution with 
parameter i iN λ . Inspection of the observed incidences for ages <70 years in the Staples 
et al (1998) data suggested a log-linear model for iλ  of the form 
( )0 1ln( )i iageλ β β= + ×  
so that  
( )0 1 iage
i e
β βλ + ×= . 
Assume further that any immigration or emigration processes operating on the general 
population occur independently of the cancer incidence process. Since we are interested 
in non-melanoma skin cancers, also assume that the death process operating on the 
general population is independent of the cancer incidence process.  These assumptions 
and their implications are discussed in detail later. 
Let iP  denote the probability that an individual has a first cancer of the prescribed type 
diagnosed at age i.  Using conditional probability arguments, this is the product of the 
probabilities that no cancer of that type was diagnosed at any earlier age multiplied by the 
probability of this cancer diagnosis at age i. Therefore, 
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The ‘prevalence’ of first cancer by age i is then : 
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Substituting ( )0 1 iagei eβ βλ + ×=  into the above equation and denoting 1 1 as ( )iage iβ β×  gives 
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The prevalence at age i ( ˆPrevi ) can therefore be estimated by ‘plugging in’ the ML 
estimates 0βˆ  and )(ˆ1 iβ .  The delta method (Armitage et al, 2002), which is a first order 
approximation based on a Taylor series expansion, can then be used to provide an 
estimate of the variance of ˆPrevi . 
If 0
0
ˆPrev
ˆ
iD β
∂= ∂  and 1 1
ˆPrev
ˆ
iD β
∂= ∂  then the delta method gives 
[ ] 0 0 1
0 1 1
0 0 1 1
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Under the log-linear model, 
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The 95% confidence bounds for prevalence at each age i can be estimated as 
( )ˆ ˆ ˆPrev 1.96 var(Prev )i i± × . 
2.9.2. Comparison of the observed and expected prevalences within a sample 
Finally, we must estimate the expected number of cancers amongst the proband relatives 
under the null hypothesis H0 that the relatives are a random sample of particular ages and 
genders from the general population. Consider a single individual and suppose that the 
prevalence in the general population for that individual’s age and gender is π .   
0, if the individual has no cancer
Let X=
1, if the individual has cancer.   
⎧⎨⎩  
Then, under H0, X has a Bernoulli distribution with parameter π .  In particular, under H0,  
E(X) ,  
and
var(X) (1 ).
π
π π
=
= −
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Suppose that π  is estimated by πˆ , calculated from a random sample of the general 
population.  (In our study, πˆ = ˆPrev , the prevalence estimate for the individual based on 
the random 1995 National Survey).  Using a variance decomposition result based on the 
conditional variance of X (see, for example, Lindgren, 1976), we know that 
[ ] [ ]
[ ]
ˆ ˆvar(X) E var(X| = ) var(E X| = )
ˆ ˆ ˆ=E (1 ) var( )
ˆ ˆ ˆPrev(1-Prev) var(Prev) 
π π
π π π
= Π + Π
− +
≈ +
 
For a sample of individuals, the observed number of cancers is simply 
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The expected number of cancers (E) under H0 can therefore be estimated by  
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which is the sum of the estimated gender and age-specific prevalences for each individual 
in the sample. 
Furthermore, 
( )
{ }
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ˆ ˆ ˆPrev (1-Prev ) var(Prev )
V
n n
i i i
i i
n
i i i
i
= =
=
⎛ ⎞ =⎜ ⎟⎝ ⎠
≈ +
=
∑ ∑
∑  
It is therefore possible to estimate an approximate 95% confidence interval for the 
expected number of cancers in the sample under H0 by calculating 
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This allowed the observed prevalences of NMSC from the proband relatives to be 
compared with the 95% confidence intervals of the estimated Australian population 
prevalence. 
The difference between observed and expected prevalences for each cancer was deemed 
to be significant if the observed prevalence fell outside of the 95% confidence intervals of 
the expected prevalence for that cancer. 
 
2.10. Estimating expected prevalence of malignant melanoma 
Malignant Melanoma is notifiable and as such we have cancer registry records of the 
incidence and prevalence of this disease in the Australian general population. Cancer 
registry prevalence of MM was calculated from cancer registry data from 1996, to enable 
it to be comparable to the data used in the calculations for BCC and SCC expected 
prevalences. Statistician collaborators determined 95% confidence limits for the 1996 
Australian registry incidence data using world standardised population data from that 
year [395]. The number of expected MMs with 95% confidence intervals was then 
estimated from this data for each gender and relative type. For MM, calculations could be 
made on all live subjects, as the registry included data on all agre groups by five years to 
80 – 84 years. This allowed the observed prevalences of MM from the proband relatives 
to be compared with the 95% confidence intervals of the estimated Australian population 
prevalence of MM. 
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Chapter 3: Incidence of skin cancer in families of BCC 
probands 
3.1. Introduction 
Despite being the most common of all cancers, almost nothing is known about the 
patterns and causes of familial aggregation of basal cell carcinoma in the population. 
Studies of susceptibility to this disease to date have either focussed on the specific, rare 
familial syndrome NBCCS (see section 1.5.4), in which features other than BCC must be 
present, or have assessed risk factors without making use of the information that family 
history can provide (section 1.4). 
Systematic study of the patterns of clustering of other common tumour types has given 
completely new insights into their causes. They have led to successful mapping of new 
susceptibility loci and the development of genetic models incorporating rare high-
penetrance gene mutations and common medium- and low-penetrance genetic variants. 
This complex genetic aetiology, coupled with the influence of the environment has 
furthermore led to the recognition that risks caused by even classic susceptibility gene 
mutations are highly dependent on an individual’s and a family’s overall risk profile 
(section 1.11). There is no reason why BCC ought not to be subject to the same 
complexities. 
One major BCC susceptibility gene, PTCH, is well known to cause familial BCC 
susceptibility in the context of Gorlin syndrome; its alleles are probably very rare, but 
confer risks of up to 900- fold, depending on the baseline incidence in the population (see 
section 1.5.4). It is not known to what extent familial BCC susceptibility occurs other 
than in association with Gorlin syndrome, and if it does, whether it could be accounted 
for in part by high-penetrance mutations in PTCH or other genes. No genome-wide 
linkage studies have been performed on familial clusters of non-Gorlin-associated BCC; 
indeed no such cohorts have been reported. 
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One critically important low-medium genetic risk factor for both BCC and SCC has been 
identified: the red hair-associated variant alleles of the pigmentation control gene MC1R 
(see section 1.7). In Australian populations these variants have a frequency of around 
20% and relative risks of two to four, and are likely to contribute strongly to familial 
aggregation of BCC and SCC in European-derived populations. Finally, high-risk 
patterns of sun exposure are a ubiquitous risk factor for all forms of skin cancer, with 
frequency in the 15-25% range and relative risks of 1.2 -1.9, i.e. in the low range (see 
section 1.4.1.4).  
The high prevalence of susceptible skin phototypes ie MC1R variants, and of high-risk 
sun exposures in Australia suggests that a large proportion of cases of BCC and SCC in 
the population will be due to these two risk factors alone. They are both commonly 
shared in families and are risk factors for SCC and melanoma, so it would be predicted 
that these two skin cancers would also co-aggregate strongly with BCC in families. 
The present study sought to test this hypothesis by focussing on a cohort of individuals 
that had developed BCC much earlier than average, and therefore might be enriched for 
BCC risk factors; examining the incidence of skin cancer among their relatives, and 
conducting a preliminary study of the factors associated with BCC by comparing these 
cases with unaffected siblings. The incidence of BCC and SCC was confirmed separately 
in relatives of probands, and this may establish whether there is a differential risk in 
relatives of people with early-onset BCC with respect to these two forms of NMSC. A 
greater risk of BCC than SCC in relatives may suggest the influence of BCC-specific risk 
factors on this group. In this chapter the patterns of aggregation and incidence of skin 
cancers are described in a series of 56 individuals who developed BCC under the age of 
40, and in their close relatives. 
3.2. Results 
3.2.1. Subject selection and characteristics 
3.2.1.1.Probands 
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The primary subjects ascertained for the study were individuals diagnosed with 
histologically-confirmed BCC at the Skin and Cancer Foundation in the year 2000, who 
were under the age of 40 at the time of diagnosis (see section 2.1.2). After obtaining 
treating doctors’ consent, subjects were approached first by mail and then by telephone 
with information about the study and an invitation to participate. 56 of the 201 eligible 
subjects consented to the study. 23 of 201 were refused contact by their treating doctor, 
50 actively or passively refused, 13 were not contactable after multiple attempts, and for 
59 it was unclear whether or not the patient had received the information or not. The 
percentage of eligible, contactable subjects consented is between 56/165 (34%) and 
56/103 (53%) depending on how many ‘not contactable’ subjects actually received the 
invitation. 
The probands were 18 men and 38 women aged 22 to 44 years (at recruitment) who 
together had a median age of 40 years. Both the female and the male probands had a 
median age of 40 years at recruitment.  
3.2.1.2.Family members 
The family structures for the 56 families were determined by interviewing probands 
about their first degree relatives; permission was sought to contact all of these individuals 
which included 260 parents and siblings. Of these 260 eligible first-degree relatives, 17 
were denied contact by probands including 12 siblings and five parents. For two of these 
relatives the reason given by probands was that it was due to mental or medical illness, 
for six it was due to intra-family discord, for four it was because it was felt that they 
would not be interested in participating, and for five no reason was given. Interviewers 
contacted all of those relatives for whom permission was granted for contact by the 
proband. Overall, 82% (212/260) of the eligible first-degree relatives consented to 
participate in the study. Excluding those for whom no proband consent for contact was 
given, there was an 87% (243/260) overall participation rate. This included 86% (89/103) 
of the available parents and 88% (123/140) of the siblings. Two probands were adopted 
and had no knowledge of their biological relatives; this meant that approximately four 
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(212/54) first-degree relatives were recruited for participation per proband where 
biological relatives were available to approach.  
Overall, 212 first-degree relatives of probands participated in the study, of which 50% 
(107/212) were men and 50% (105/212) were women. Of the 123 recruited siblings of 
probands, 53% (65/123) were men and 47% (58/123) were women. Included in this 
group were two half-siblings (sharing one biological parent), and one who was deceased. 
Of the 89 parents recruited, 47% (42/123) were men and 53% (47/89) were women, 
including 17 who were deceased. Consent and cancer histories for deceased relatives 
were obtained by proxy interview with another recruited family member.  
3.2.2. Skin cancer prevalence 
Each subject was asked whether they had been diagnosed with any form of cancer, and 
all self-reports were followed up with an attempt at histopathological verification (see 
section 2.2). In the case of NMSC reports, the treating doctor was approached, and if this 
contact was unsuccessful then the local pathology service was contacted. Where multiple 
reports were received, they were all followed up until at least one confirmation of NMSC 
was received. Where more than one NMSC was confirmed, the earliest dates of BCC and 
SCC diagnoses were used for subsequent analysis. 
Table 3.1 describes for each proband the total number of subjects that were recruited in 
each family; the number of them who have had histologically confirmed BCC, SCC, and 
melanoma (MM), and the age of onset for each affected family member.  
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Table 3.1 Number of family members with BCC, SCC, and MM (proband and first degree relatives) for 
each proband 
 
Proband 
ID 
Total 
number 
of family 
members 
affected 
Number 
of BCC-
affected 
family 
members 
Age of 
onset of 
BCC# 
Number 
of SCC-
affected 
family 
members 
Age of 
onset of 
SCC 
Number 
of 
NMSC-
affected 
family 
members 
Number 
of MM-
affected 
family 
members 
Age of 
onset of 
MM 
8755 5 2 31, 34* 1 55 3   
8756 2 1 38* 0 - 1   
8759 4 1 37* 2 38, 60 3   
8761 4 2 34*, 62 1 65 2   
8762 6 1 31* 0 - 1   
8763 8 2 36*, 43  2 41, 71 4 1 42 
8764 6 1 36* 0 - 1   
8766 4 1 39* 0 - 1   
8767 4 1 40* 0 - 1   
8768 4 2 20*, 48 0 - 2   
8769 5 1 27* 0 - 1   
8770 5 3 39*, 69, 
70 
1 75 3 2 33, 78 
8771 5 1 36* 1 71 2   
8772 3 1 37* 0 - 1   
8773 6 2 39*, 52 0 - 2   
8774 3 1 22* 0 - 1   
8775 7 1 39* 1 81 2   
8776 5 1 29* 0 - 1   
8778 2 1 37* 0 - 1   
8779 5 1 33* 0 - 1   
8781 3 2 35*, 51 1 51 2   
8794 6 1 39* 0 - 1   
8797 9 2 35*, 53 2 53, 42 3   
8800 10 4 26, 38*, 
43, 69 
1 70 4   
8810 4 1 32* 0 - 1   
8815 5 2 19*, 58 0 - 2   
8816 9 6 39*, 44, 
50, 50, 
53, 76 
2 53, 76 6 2 38, 49 
8818 7 2 37*, 44 0 - 2   
8825 3 2 34*, 73 1 67 3 1 60 
8826 2 1 35* 0 - 1   
8832 2 1 35* 0 - 1   
8840 6 6 23, 23, 
25, 28*, 
49, 54 
2 42, 46 6 3 23, 37, 
47 
8846 4 3 26*, 55, 
56 
0 - 3   
8857 4 2 35*, 63 0 - 2   
8928 4 1 27* 0 - 1   
9022 9 6 35*, 36, 0 - 6   
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44, 54, 
58, 74 
9094 5 1 39* 1 65 2   
9125^ 6 3 25, 37, 
38* 
2 43, 67 4   
9167 4 1 32* 0 - 1   
9168 5 1 38* 0 - 1   
9194 4 2 33*, 62 1 64 2   
9207 2 1 36* 0 - 1   
9208 1 1 38* 0 - 1   
9240 3 1 33* 0 - 1   
9241 7 1 28* 0 - 1   
9242 7 2 30*, 50 0 - 2   
9273 1 1 31* 0 - 1   
9274 4 3 34*, 38, 
59 
1 59 4 1 59 
9275 5 3 30*, 45, 
45 
0 - 3   
9334 1 1 36* 0 - 1   
9445 5 5 38*, 50, 
51, 68, 
75 
1 78 5 1 53 
9446 9 1 35* 1 83 2   
9459 5 1 37* 1 70 2   
9465 6 1 31* 0 - 1   
9491 4 3 30, 31*, 
52 
0 - 3   
9527 4 1 39* 0 - 1   
 
*indicates the age of onset for the proband, the person first entering the study and the person screened for 
mutations in the PTCH gene 
# Underlined age indicates that the subject is deceased 
^ Gorlin syndrome reported in family 
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Table 3.2 Number of skin cancers in first degree relatives of early-onset BCC probands 
Number 
Cancers in 
1st Degree 
Relatives 
BCC 
Frequency* 
SCC 
Frequency 
NMSC 
Frequency 
MM 
Frequency 
1 13 14 14 4 
2 6 6 9 2 
3 1 - 3 1 
4 1 - 1 - 
5 3 - 3 - 
*Indicates number of families out of 56 with the specified number of that cancer among first degree 
relatives 
 
 
Table 3.3 Number of BCCs in families affected by BCC alone (ie without any members affected by MM 
or SCC) 
Number cancers in 1st 
degree relatives 
Frequency of families with 
BCC alone (no MM or 
SCC history)* 
2 6 
3 3 
6 1 
*Indicates number of families with the specified number of BCC among first degree relatives with no 
members affected by MM or SCC 
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The 56 probands had developed BCC at a median age of 36. None of them had developed 
either SCC or MM. 
Overall, 28% (60/212) of the first-degree relatives had been affected by NMSC, including 
20% (25/123) of the siblings and 40% (36/89) of the parents. Taking the pool of relatives 
as a whole, the earliest confirmed age of onset of NMSC for each affected individual 
ranged from 23.0 to 83.0 years, with a median age of 53.0 years. As is expected from 
ascertainment bias in family studies, ages of onset for siblings (median 42.0, range 23.0 – 
54.0) were earlier than for parents (median 62.0, range 46.0 – 84.0) because, as a 
generation, the siblings have lived through fewer years at risk. The median age of 
diagnosis for mothers (58.5 years) was non-significantly earlier than for fathers (65.0 
years)(Χ2 = 56, p=0.229), and the median age of diagnosis for brothers (41.0 years) was 
earlier than for sisters (43.0 years) (X2 = 20, p=0.220). 
More than half the probands (30/56, 54%) had at least one first-degree relative with 
NMSC, more than one quarter (16/56, 29%) had two or more, and in three cases (3/56, 
5%) five relatives were affected by NMSC. These affected relatives included 23 siblings 
and 24 parents affected by BCC, and five siblings and 22 parents affected with SCC. 
Three siblings and ten parents had been affected by both cancer types. 
Overall, 22% (47/212) of the first-degree relatives had been affected by BCC, including 
19% (23/123) of the siblings and 27% (24/89) of the parents. When considering the pool 
of relatives as a whole, the earliest confirmed age of onset of BCC for each affected 
individual ranged from 23.0 to 76.0 years, with a median age of 51.0 years. The earliest 
confirmed age of onset of BCC among the siblings ranged from 23.0 to 54.0 years, with a 
median age of 43.0. The earliest confirmed age of onset of BCC among the parents 
ranged from 48.0 to 76.0 years with a median age of 58.5 years. The median age of 
diagnosis for mothers (57.0 years) was earlier than for fathers (62.0 years) (X2 = 6, 
p=0.199), whereas the median age of diagnosis for brothers (50.0 years) was earlier than 
for sisters (57.0 years) (X2 = 12, p=0.213). 
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Nearly one half of the probands (24/56, 43%) had at least one first-degree relative with 
BCC, one fifth (11/56, 20%) had two or more, and in three cases (3/56, 5%) five relatives 
were affected by BCC.  
Overall, 13% (27/212) of first-degree relatives had been confirmed to be affected by 
SCC, including 4% (5/123) of the siblings and 25% (22/89) of the parents. When 
considering the pool of relatives as a whole, the earliest confirmed age of onset of SCC 
for each affected individual ranged from 38.0 to 83.0 years, with a median age of 64.5 
years. The earliest confirmed age of onset of SCC among the siblings ranged from 38.0 to 
53.0 years, with a median age of 42.0 years. The earliest confirmed age of onset of SCC 
among the parents ranged from 42.0 to 83.0 years with a median age of 67.0 years. The 
median age of diagnosis of SCC for fathers (66.0 years) was slightly earlier than for 
mothers (67.0 years), and the median age for brothers (41.0 years) was slightly earlier 
than for sisters (42.5 years). 
More than one third of the probands (20/56, 36%) had at least one first-degree relative 
with SCC, and in six cases (6/56, 11%) two relatives were affected by SCC. There were 
no cases where more than two relatives within a family were affected by SCC. In first-
degree relatives of probands, there were nearly twice as many BCC-affected relatives as 
SCC-affected ones, with a BCC-affected: SCC-affected ratio of 1.7:1. 
Overall, 5% (11/56) of first-degree relatives had been confirmed to be affected by MM, 
including 4% (5/123) of the siblings and 7% (6/89) of the parents. When considering the 
pool of relatives as a whole, the earliest confirmed age of onset of MM for each affected 
individual ranged form 23.0 to 78.0 years, with a median age of 47.0 years. The earliest 
confirmed age of onset of MM among the siblings ranged from 23.0 to 53.0 years with a 
median age of 38.0 years. The earliest confirmed age of onset of MM among the parents 
ranged from 37.0 to 78.0 years, with a median age of 53.0 years.  
More than one tenth (7/56, 12.5%) of the probands had at least one first-degree relative 
with MM; in two cases (2/56, 4%) two relatives were affected by MM and for one case 
(1/56, 2%) there were three relatives affected by MM. 
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It can be hypothesised that increased susceptibility to BCC primarily reflects a general 
increase in risk of skin cancer, as might be related to high sun exposure or a sun-
vulnerable skin type. This hypothesis predicts that BCC, SCC and possibly melanoma 
would co-aggregate in families. The incidence of NMSC in the cohort of relatives is 
formally compared with incidence data from the general population in the next section. 
However a survey of the patterns of aggregation gives evidence both for and against this 
hypothesis. Among 30 probands with a positive family history of NMSC in first-degree 
relatives, 20 had at least one relative affected by SCC; so the majority of family clusters 
included both BCC and SCC. However, of the other ten probands there were four who 
had at least two first-degree relatives affected by BCC and none affected by SCC, one 
being part of a six-case cluster of BCC (see table 3.3). This amounts to nearly one fifth of 
families affected by BCC alone, and suggests that a subset of the probands shares a 
specific susceptibility to BCC, rather than to NMSC generally, with their relatives. 
One proband (ID 9125) out of 56 (2%) reported a personal history of clinically diagnosed 
Gorlin syndrome. Two of her three siblings had histologically confirmed BCC, with both 
of these affected siblings having had an early-onset of their tumours; her sister at 37 years 
and her brother at 25 years of age. Two of her first-degree relatives also had a history of 
SCC with her father having been affected at 67 years of age and her sister at 43 years of 
age (see appendix 7.7 family ID 29125 for pedigree). Clinically, her mother did not have 
Gorlin syndrome and her father was deceased at the time of her diagnosis. From a review 
of his records a diagnosis could not be made conclusively. Mutation analysis of the 
PTCH gene in several family members at the Queensland Institute of Medical Research 
had revealed no PTCH mutation in this family (participant’s medical record). 
3.3. Comparison of NMSC prevalence in relatives with that in the Australian 
population 
As described in section 2.9.1, the term “prevalence” used here refers to prevalence of a 
prior diagnosis of NMSC. In order to address whether the prevalence of previous NMSC 
in this cohort of relatives differed from that expected for this group, it was necessary to 
make use of data from the most recent Australian survey of the population incidence of 
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NMSC (note that the word ‘relatives’ refers to consented first-degree relatives of 
probands as per section 2.2). This survey of 60,000 individuals Australia-wide was 
judged appropriate for this purpose, even though the cohort of the present study was 
concentrated in the Sydney basin. The incidence of melanoma (a surrogate for all sun-
related skin cancer) in NSW is close to the national (see section 2.1.1 for exact data). 
This presumably reflects two facts: that a large proportion of the Australian population 
resides in NSW, and that greater Sydney lies about mid-way on the gradient of 
population incidence of melanoma in Australia. The overall Australia-wide NMSC 
incidence is noted to be most similar to the central (including NSW) zone than the 
northern or southern zones, and therefore can be assumed to be a fairly good estimate of 
the incidence of these cancers for the Sydney metropolitan area. We hypothesised that 
NMSC incidence in Sydney would therefore also be similar to the national average. 
Incidence data from state-based cancer registries are available for melanoma but not for 
NMSC, as these cancers were not registrable in NSW at the time of writing. 
Raw data were obtained from the authors of the Australia-wide survey, and used by 
statistician collaborators Dr Karen Byth and Ms Peta Forder to re-estimate age-specific 
incidence rates of BCC and SCC, together with their 95% confidence limits (see methods 
section 2.9.1). This was necessary because the original publication only included 
confidence limits for the observed crude incidence rates in each age/sex group, but not 
for the curve the authors had fitted to their data. First, a curve was fitted to the raw data 
from this survey by maximum likelihood estimation using a Poisson regression routine in 
the statistical package STATA. The estimated regression parameters and their associated 
variances are presented in Table 3.4. 
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Table 3.4 Maximum likelihood parameters and associated variances for incidence of BCC and SCC in 
data from Staples et al [1] using a Poisson regression routine 
Cancer Group 
0βˆ  1ˆβ  Var( 0βˆ ) Var( 1ˆβ ) Cov( 0βˆ , 1ˆβ )
SCC Male -11.5525 0.113261 0.468784 0.000129 -0.00768 
 Female -11.8153 0.1082343 0.722557 0.000203 -0.011942 
BCC Male -9.112422 0.0865304 0.122610 0.000037 -0.00208 
 Female -8.058947 0.0608958 0.109614 0.000037 -0.001963 
 
The incidence rates for BCC and SCC are shown in Figure 3.1, from Staples et al. (1) 
together with the curve newly fitted to the data. 
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Figure 3.1 Fitted curves for incidence rates for BCC and SCC in men and women in Australia in 1996 
(re-analysis of data provided from Staples et al [1]) 
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Cumulative risk (prevalence of a prior diagnosis) of BCC and SCC in Australia was then 
calculated for men and women of various ages, together with their associated 95% 
confidence limits, from the fitted data. These results are summarized in tables 3.5 and 3.6 
and shown graphically in Figure 3.2. 
 
 
Table 3.5 Estimated prevalence (with 95% CI) of SCC and BCC in Australian men in 1996 (re-analysis 
of data provided from Staples et al [1]) 
Age Estimated Prevalence (cases per 100,000 people) 
SCC (95% CI) BCC (95% CI) 
15 41 (0,87) 364 (154,575) 
20 78 (0,160) 627 (293,961) 
25 144 (8,280) 1030 (529,1531) 
30 260 (40,480) 1648 (927,2368) 
35 464 (118,810) 2592 (1589,3594) 
40 821 (293,1350) 4028 (2680,5375) 
45 1448 (665,2232) 6196 (4448,7944) 
50 2542 (1423,3662) 9431 (7259,11603) 
55 4438 (2908,5967) 14160 (11593,16728) 
60 7677 (5678,9675) 20844 (17961,23727) 
65 13074 (10446,15703) 29703 (26577,32829) 
70 21622 (17700, 25546) 39931 (36771, 43091) 
 
 104
 
 
Figure 3.2 Estimated prevalence (with 95% CI) of SCC (A) and BCC (B)  in Australian men and women 
in 1996 (re-analysis of data provided from Staples et al [1]) 
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B. 
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Table 3.6 Estimated prevalence (with 95% CI) for SCC and BCC in Australian women in 1996 (re-
analysis of data provided from Staples et al [1]) 
Age Estimated Prevalence (cases per 100,000 people) 
SCC (95% CI) BCC (95% CI) 
15 30 (0,72) 827 (377,1278) 
20 56 (0,129) 1297 (642,1951) 
25 101 (0,220) 1930 (1037,2822) 
30 179 (0,366) 2782 (1618,3945) 
35 311 (23,600) 3924 (2462,5386) 
40 539 (107,970) 5449 (3673,7226) 
45 928 (302,1555) 7476 (5386,9565) 
50 1594 (714,2474) 10145 (7767,12523) 
55 2726 (1537,3915) 13621 (10995,16247) 
60 4638 (3078,6198) 18071 (15216,20925) 
65 7825 (5706,9944) 23619 (20458,26781) 
70 13012 (9632,16393) 30252 (26562,33942) 
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3.3.1. Comparison of observed and expected prevalence of NMSC in first 
degree relatives  
The population data from Staples et al. were only age-stratified to the age of 70 yr, so 
analysis of the cohort of relatives in the present study was restricted to data from the 
siblings and parents of the BCC proband cases who were alive and aged less than 70 
years. Of the 123 siblings for whom data was obtained, one deceased subject was 
removed from analysis, leaving 122 sibling individuals (63 men, 59 women).  Of the 89 
parents for whom data was available, 17 subjects were deceased and 29 subjects were 
removed because they were aged 70 years or older.  Thus, the parental group for analysis 
included only 43 subjects (18 men, 25 women). The subjects whose data was removed 
because they were deceased are identified in table 3.1 by underlining of the age of onset 
of their cancers. 
For each group, the observed prevalence of a prior diagnosis of BCC and SCC was 
calculated. The method outlined above was then used to calculate the expected number of 
BCC and SCC in that group of relatives, taking into account their current age, and their 
95% CIs, under the null hypothesis that the subjects had the same prevalence distribution 
as the general population. The observed and expected prevalences are presented in table 
3.7 below. 
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Table 3.7 Observed and expected prevalence of skin cancers in siblings and parents  
of proband subjects by gender 
Group Gender Cancer 
Type 
Observed 
prevalence
Expected prevalence 
(95% C.I.) 
Relative 
Risk 
 
Siblings Men SCC 1 0.70 (0.00, 2.32) 1.43 
  BCC 15 2.87 (0.00, 6.05) 5.23* 
 Women SCC 3 0.55 (0.00, 1.99) 5.45* 
  BCC 8 4.05 (0.27, 7.82) 1.98* 
Parents Men SCC 7 1.69 (0.00, 4.09) 4.14* 
  BCC 5 4.16 (0.70, 7.63) 1.20 
 Women SCC 1 1.18 (0.00, 3.24) 0.85 
  BCC 9 4.22 (0.61, 7.84) 2.13* 
*indicates result was significant at 0.05 level (non-overlapping 95% confidence limits of expected and 
observed prevalences, as per section 2.9.2) 
Significantly more BCC cases were observed among the siblings, both brothers and 
sisters (relative risks 5.23 and 1.98 respectively), and in the mothers of probands (RR 
2.13), than expected. Significantly more SCC cases were observed among the sisters (RR 
5.45) and fathers (RR 4.14) of probands than expected. 
The degree of familial aggregation of NMSC therefore differed by sex, relative and 
cancer type. In brothers, only BCC risk was elevated, whereas sisters had increased risks 
of both BCC and SCC. Among mothers only BCC risk was elevated, and among fathers 
only SCC risk was increased. Taken together, these data show that being a first-degree 
relative of a case of early-onset BCC was associated with marked increases in risk of 
NMSC, both BCC and SCC.  
3.3.2. Comparison of observed and expected MM in first degree relatives 
The expected number of malignant melanomas for the group of first degree relatives was 
calculated directly from the 1996 Australian Cancer Registry data (see methods section 
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2.10). Of the 123 siblings for whom data was obtained, one deceased subject was 
removed from analysis, leaving 122 sibling individuals (63 men, 59 women). Of the 89 
parents for whom data was available, 17 subjects were deceased, leaving 72 subjects 
(eight men, nine women) for the analysis. A comparison of the observed and expected 
numbers of this cancer is seen in table 3.8. 
Table 3.8 Relative risk of MM in first degree relatives of early-onset BCC probands 
Group Gender Observed 
Prevalence
Expected Prevalence 
(95% C.I.) 
Relative 
Risk 
Siblings Men 3 0.289 (0, 1.339) 10.3* 
 Women 1 0.323 (0, 1.433) 3.1 
Parents Men 3 0.987 (0, 2.901) 3.0* 
 Women 2 0.74 (0, 2.437) 2.7 
*indicates result was significant at 0.05 level (non-overlapping 95% confidence limits of expected and 
observed prevalences, as per section 2.10) 
All relatives had an increased risk of MM compared with the general population, and this 
was significant for male relatives. Brothers of the early-onset probands had a significant 
ten-fold increased risk of MM compared with the Australian population, and fathers had a 
three-fold increased risk. 
3.4. Other cancer diagnoses 
No proband reported a personal history of any cancer other than BCC. It can be seen in 
Table 3.9 that 17 first-degree relatives reported cancer diagnoses other than skin cancer, 
most of which could be histologically verified. Seventeen first degree relatives exhibited 
a variety of cancer diagnoses including colorectal (six relatives), breast (three), renal cell 
(two), laryngeal SCC (two), ovarian (one), prostate (one) and squamous cell lung (one) 
cancers, and malignant fibrous histiocytoma (one). The six relatives with colorectal 
carcinoma had an average age of onset of 66 years, which is close to the population 
average. Three first-degree relatives had breast carcinoma, two with invasive ductal 
histological types and the other not specified, and an average age of onset of 52 years. 
None of these data suggest abnormal aggregation of non-skin cancers in these families. 
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Table 3.9 All cancer diagnoses (excluding skin cancers) in first degree relatives of probands 
Family ID Relationship to 
Proband 
Gender Cancer diagnosis Age of 
Onset 
28775 Sibling Female Breast (invasive 
ductal) 
47 
28770 Parent Male Laryngeal SCC  77 
29779 Parent Female Ovarian 45 
28781 Parent Male Colorectal 65 
28797 Parent Female Colorectal 65 
28816 Parent Male Renal Cell 
Carcinoma 
68 
28818 Parent Female Breasta 49 
28825 Parent Male Colorectal 69 
28857 Parent Male Laryngeal SCC 55 
29094 Parent Male Colorectal 58 
29168 Parent Female Colorectal 73 
29168 Parent Male Squamous Cell 
Lung 
69 
29240 Parent Male Malignant fibrous 
histiocytoma 
(sarcoma) 
62 
29275 Parent Female Breast (invasive 
ductal) 
60 
28767 Parent Male Renal Cell 
Carcinoma 
61 
28762 Parent Female Colorectal 67 
28762 Parent Male Prostate 70 
aClinical information only for this patient (not histologically verified) 
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3.5. Pedigrees of affected families 
Of the 56 probands included in this study, three had histopathologically-verified 
clustering of 6 cases of BCC among first-degree relatives. As is implied by the analysis in 
section 3.3, and shown in Figure 3.3, most families with more than one NMSC exhibited 
a combination of both types of skin cancer. However some families’ cancer histories 
included only BCC (e.g. see pedigree for family ID 29022). 
 
Figure 3.3. Pedigrees for families 28840, 28816, and 29022 
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Legend forFigure 3.3: 
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3.6. Discussion 
As with other malignancies, the causes of BCC are likely to be due to a complex 
interplay of environmental and genetic factors. A better understanding of the way that 
BCC aggregates in families may help us to start to unravel these aetiological factors. In 
this chapter we see an examination of familial aggregation for BCC and SCC, a study that 
has no parallel in the literature to date.  
The participation rate of eligible subjects for this study was 34%, however the effective 
participation rate of 53% may be a better assessment of participation: there were a 
relatively large number of non-contactable subjects due to the young age and mobility of 
the population sample compounded by the fact that the SCFA database contact 
information on these subjects was three years old. The population from which the 
subjects were ascertained needed to be from this database to allow comparison with the 
information gathered for the SCC arm of the study (see section 2.1.2). Despite this, there 
may be some ascertainment bias in that consenting subjects may be those in whom there 
is a family history of cancer, giving an overestimate of the cancer prevalence in relatives 
of early-onset BCC subjects. A family history of melanoma, the skin cancer of highest 
mortality, may be thought to produce a larger ascertainment bias than other types of skin 
cancer, due to the nature of the prognosis and likelihood of discussion among family 
members. If all eligible subjects who did not participate were to have no family history of 
BCC 
SCC
proband 
36
Malignant Melanoma
Other Cancer 
  Age first affected; m: multiple cancers 
Control sibling 
 
xxxx 
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cancer, then our overestimates would be between 1.9-fold and 2.9-fold at worst (based on 
the inverse of the participation rates calculated above).  
The participation rate of eligible relatives of this study was very high at over 85% in both 
parents and siblings. There was a female preponderance of proband subjects with a F:M 
ratio of  2.1:1. As this does not affect the sex distribution of their relatives, and as the sex 
ratio of relatives was equal, the bias towards female sex in probands should not affect the 
interpretation of cancer prevalence in relatives.  
From examination of histopathologically-verified prevalence of NMSC in these 56 
families of people with early-onset BCC, it is evident that familial aggregation of NMSCs 
is occurring. Over half of the families studied display aggregation of either BCC or SCC 
with two thirds of these including a history of both types of NMSC. Significantly, the 
other one-third of these families include family members with a history of BCC but not 
SCC, and in nearly half of these, clusters of three first-degree relatives or more affected 
relatives exist. There are also three families in whom two or more first-degree relatives 
were affected by melanoma. Together these results indicate that families of people with 
early-onset BCC may be at increased risk for skin cancer in general, and also for BCC in 
particular.  
Here for the first time, relative risks of BCC, SCC, and MM for first-degree relatives of 
early-onset BCC cases have been determined. The computed relative risks confirm 
suspicions that arise when looking at the aggregation seen in the pedigrees in these 
families: first-degree relatives of people with early-onset BCC have an increased risk of 
NMSC. The expected prevalence of NMSCs in the subjects was calculated from data on 
the Australian population, and a significantly increased risk of BCC, SCC and melanoma 
occurred for first-degree relatives, with differential risks for different relative, sex and 
cancer type. Sisters and mothers of probands had a two-fold increased risk of BCC, and 
brothers had a 5-fold increased risk of BCC compared with that estimated for the general 
population. Sisters and fathers of people with early-onset BCC had over four times the 
prevalence of SCC than expected. For melanoma, the increased risk was significant for 
male relatives only, with a 10-fold increased risk for brothers of people with early-onset 
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BCC and three-fold for fathers. In general, the relative risks of cancers were greater in 
siblings than parents, which is not surprising given the larger baseline risk of parents due 
to their more advanced age. 
These estimates should be interpreted with the understanding that they are based on some 
strong underlying assumptions. Cumulative risk of NMSC was estimated from validated 
Australian population annual incidence data (see section 2.9.1). This annual incidence 
data was used despite unvalidated lifetime data being available from this survey, as only 
validated data was deemed suitable for such an analysis. It was assumed that the period- 
and cohort-specific incidence rates for a given age and gender were constant.  This 
assumption may not be correct especially given the recorded increase in incidence seen in 
Australia and internationally over the last few decades (see section 1.3). The national 
survey from which the incidence figures were obtained for the estimation of prevalence 
suggest that SCC age-specific incidence rates have increased between 1985 and 1995, 
while BCC rates have fallen for those aged under 50 years and have risen in those aged 
older than 50 years during this same 10-year period [1]. Thus it is possible that estimates 
of expected prevalence for SCC are in fact overestimates, such that the risk ratio based on 
observed prevalences could be slightly underestimated. Thus the SCC relative risks 
calculated are likely to be conservative estimates. If BCC incidence has actually declined 
by 10% in people under 50 years of age from 1985 to 1995 as suggested by the latest 
national survey, then the BCC relative risk in siblings may be a slight overestimate. 
Changes of this magnitude in the younger age group, even if real, cannot fully account 
for the two- to five-fold excess of observed to expected BCCs seen in siblings and 
mothers of the probands. 
Empirical evidence supporting the Poisson model assumptions is illustrated in the close 
agreement between the observed and fitted incidence rates provided in figure 3.1.  Death 
from NMSC is known to be extremely rare in Australia [396]. Although the occurrence 
of malignant melanoma is known to be associated with the presence of NMSC, death 
from malignant melanoma as an overall cause of death in Australia is also rare. 
Therefore, it is reasonable to approximate the incidence processes for SCC and BCC as 
acting independently of the overall death process on the Australian population.  If 
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probands’ relatives are more prone to death from malignant melanoma which in turn is 
associated with increased rates of NMSC, then those relatives with NMSC who died of 
melanoma have not been counted amongst the observed cases.  This is because only those 
relatives who were alive contributed to this observed total. There is, therefore, a 
conservative effect on risk assessment due to any association between NMSC incidence 
and melanoma death in the probands’ relatives. 
It has been observed that the risk of NMSC is lower for immigrants (arriving after the age 
of 10 years) than native-born Australians [78].  Consequently, the SCC and BCC 
incidence processes do not act independently of the immigration process, as assumed in 
our mathematical derivation of estimated prevalences.  It is not clear whether the 
emigration process acts independently of the SCC and BCC incidence processes.  
Unfortunately, using the available data, it is impossible to quantify these effects and those 
of other related variables, such as ethnicity and lifetime latitude of residence.   
The mean age of diagnosis of BCC in the Australian population has been estimated at 63 
for men and 59 for women, and for SCC it is 66 years for men and 64 years for women 
[1]. Although these figures cannot be directly compared with those from the subjects of 
this study due to differences in ascertainment and measurement; it is evident that mean 
ages of onset in the family members of this study were younger for the siblings (as 
expected due to ascertainment bias), and of a similar magnitude for parents. 
Since the majority of families with aggregation of skin cancer have a combination of 
SCC and BCC, and it is likely that general risks for skin cancer are increased in relatives 
of people with early-onset BCC. These general risk factors are likely to include 
environmental, genetic, and phenotypic risks that are common to UVR-related skin 
cancers in general. Environmental risk factors that may to be common to all three types 
of skin cancer include sun exposure levels, sun protection measures employed, HPV or 
other viral infection, and increased surveillance in family members. Inherited, genetic 
characteristics that may cause increased risk to all three types of skin cancer may include 
those which relate to pigmentary traits such as MC1R, HPV susceptibility eg through 
polymorphism p53Arg, and probably multiple as-yet unidentified genetic susceptibilities. 
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Phenotypic risk factors for all three types of skin cancer include sun sensitivity, 
pigmentary characteristics, signs of sun exposure such as actinic keratoses, and 
phenotypic results of a combination of higher risk skin pigmentation and sun exposure 
such as freckling. 
Given that nearly one fifth of families in this study had aggregation of BCC to the 
exclusion of SCC or MM, BCC-specific risk factors are also likely to be at work. BCC-
specific factors probably include environmental risks such as the pattern of sun exposure, 
with childhood and intermittent exposure affecting BCC risk to a greater degree than 
SCC risk [47, 78, 81]. Toxins such as arsenic are also specific risk factors for BCC. 
Genetic factors such as PTCH polymorphisms or mutations within the germlines of these 
families could also affect risk of BCC. This tumour-suppressor gene causes increased risk 
of BCC to those with the rare genodermatosis Gorlin syndrome, but beyond some 
preliminary haplotyping studies, has not been examined as a potential contributor to BCC 
susceptibility in the general population (considered in chapter 5). Presence of Gorlin 
Syndrome would also cause an increased risk of BCC differentially compared with SCC, 
and one proband reported a prior clinical diagnois of this syndrome. 
Further information about the origins of skin cancer risk may be obtained through 
phenotypic examination of probands and their unaffected siblings who can act as intra-
family controls. Environmental risk factors are assumed to be similar for siblings within a 
family, meaning that observed phenotypic differences are likely to be attributable to 
genetic causes. Questionnaires to ascertain exposure to environmental risk factors would 
be useful and could be employed in future studies. These issues will be explored further 
in the next chapter. 
Sources of error in comparing this study’s subject prevalence with population prevalence 
include the differences in latitude of the people involved, and differences in sibling 
numbers of the people measured. However, as discussed in section 2.1.1, the Sydney 
basin is likely to have a similar incidence of skin cancer to the general population.  
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Chapter 4: Case-control analysis: phenotypic risk 
factors for early-onset BCC 
4.1. Introduction 
The subjects of this study are 56 people who have developed BCC under 40 yr, i.e. earlier 
than 93% of Australians who are affected by this type of skin cancer. It was hypothesised 
that they would exhibit increased risk factors for BCC. In the previous chapter their 
relatives were shown to have increased prevalence of not only BCC, but also SCC and 
melanoma. Importantly, in a proportion of these families there were multiple cases 
affected by BCC in the absence of SCC, in one family this included six first-degree 
affected relatives. Exploration of underlying causative factors therefore needs to address 
both susceptibility to skin cancer in general and also susceptibility factors that might be 
unique to BCC. 
Particular skin phenotypes are known to be associated with skin cancer risk. The complex 
of inherited characteristics defining a person’s ‘sun sensitivity’ has a moderate 
association with BCC. Pigmentary characteristics such as skin colour and tanning ability 
are key features of this complex and may play a causative role, with eye colour and hair 
colour surrogate markers (see section 1.4). Genetic variation in MC1R is largely 
responsible for these individual differences in pigmentary characteristics, in combination 
with other as yet unknown genes, and acts as an independent risk factor for BCC (see 
section 1.7). 
Risk of BCC is increased by sun exposure, with acute intermittent exposure rather than 
cumulative total dose the more important pattern of exposure for determining risk of this 
tumour (see section 1.4). Signs of high total cumulative sun exposure such as presence of 
pterygium on the sclera of the eye, and solar elastosis or actinic keratoses on the 
chronically sun exposed regions of the body have been associated with SCC, and to a 
lesser extent BCC. However it is difficult to disentangle these phenotypes from varying 
individual susceptibility to sun-related skin damage: they are not uncontaminated markers 
of solar radiation dose. Some commonly occurring skin lesions that are the result of 
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combinations of pigmentary traits and sun exposure include solar lentigines and 
freckling. More poorly understood are the presence of seborrhoeic keratoses; these 
benign lesions may be associated with sun exposure and are very prevalent in Australian 
populations. They do not have any known associations with skin cancer. In this chapter, 
the causes of BCC in the probands are explored by comparing their skin phenotype with 
that of their unaffected siblings. Siblings are similar genetically and are even more likely 
to have shared a common early environment. Differences seen between affected-
unaffected sibling pairs can therefore not be confounded by population admixture and, if 
not due to chance, are more likely to have a genetic than an environmental basis. 
Several skin characteristics were measured, using both self-reports and physical 
examination by a trained examiner under standardised conditions (see section 2.3). 
Pigmentary characteristics of the skin were measured along with sun sensitivity factors, 
characteristics relating to previous sun exposure, and characteristics due to a combination 
of sun sensitivity and sun exposure. All tests of association described in this chapter were 
carried out using logistic regression, either unconditionally or conditioning on family 
membership (i.e. taking into account their membership of a proband-sibling pair). 
Differences in skin colour, skin phototype, signs of sun sensitivity and sun exposure were 
seen between the sibling pairs, indicating identifiable phenotypic risk factors for early-
onset BCC. 
The following chapter (section 5) describes analysis of genetic factors that may explain 
the clustering of skin cancer within these families.  
4.2. Results 
4.2.1. General characteristics 
A nested case-control analysis was performed by selecting the oldest NMSC-unaffected 
sibling as a control for each proband where available. Examinations were performed on 
88 subjects, including assessments of pigmentary characteristics and semi-quantitative 
analysis of various sun exposure-related lesions on their skin. Of these 88 subjects, 73% 
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(64/88) were part of proband-sibling case-control pairs, with the 27% (24/88) remaining 
subjects undergoing examination unpaired. 
Table 4.1. Age, Height, Weight paired t-tests 
Measurement Mean Case-Control SD Sig (2-tailed) 
Age (years) -1.8 6.0 .101 
Height (cm) -1.3 9.3 .449 
Weight (kg) -2.9 14.7 .266 
 
There were no significant differences between probands and siblings with respect to age, 
height, or weight (see table 4.1). The siblings chosen as a control for the probands were 
selected to be the oldest NMSC-unaffected sibling. The average age of the siblings was 
1.8 years older than the probands, or one year and 10 months (SD 6.0 years). The sibling 
controls were also on average slightly taller than their proband pair by 1.3 cm (SD: 9.3 
cm) and heavier by 2.9 kg (SD: 14.7 kg).  
All subjects were investigated for evidence of Gorlin syndrome, through history of 
mandibular keratocysts and presence of palmar pitting (see section 2.3.1). These features 
are both pathognomonic of Gorlin syndrome, and presence of both features occurred in 
one patient only (proband ID 9125) who had previously been clinically diagnosed with 
this syndrome.  
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4.2.2. Pigmentary factors 
4.2.2.1.Hair Colour 
Table 4.2 Case control comparison of hair colour by self report and by identification of a swatch of hair 
colour (from subjects’ answers to questionnaire) 
 
Subjects most commonly reported a light or mouse brown hair colour with dark brown 
the next most common hair colour, then blonde/fair, then red. Only one subject reported 
having black hair (see table 4.2 and appendix table 7.2). Dark brown was the second most 
common hair colour reported with 31/88 (35.2%) in this category. There were 17/88 
(19.3%) who reported blonde/fair hair with 6/88 (6.8%) reporting red hair and 1/88 
(1.1%) reporting black hair. Black and brown hair results were aggregated for the 
analysis (see table 4.2). 
Subjects were asked to self-identify their hair colour in two ways: by answering the 
question “Which colour best describes your natural hair colour at age 21- red, fair/blonde, 
light/mouse brown, grey, dark brown, or black?”, and by matching their recalled hair 
colour at age 21 by a standard  wigmaker’s hair swatch (see section 2.3.1). Hair colour 
observed at time of examination is not a relevant variable in studies of human 
pigmentation because of age-related and cosmetic changes. Identification of hair swatch 
Variable  n (%) Unconditional 
Logistic 
Regression 
Odds 
Ratio  
(95% 
CI) 
p-
value 
Conditional 
Logistic 
Regression 
Odds 
Ratio  
(95% 
CI) 
p-
value 
Hair colour 
self report 
88(100.0) As continuous 
variable  
1.112 (.803-
1.543) 
.521 As 
continuous 
variable  
1.094 (.675-
1.773) 
.715 
32(36.3) Brown/black 1 - - Brown/black 1 - - 
33(37.5) Light brown  1.789 (.646-
4.957) 
.263 Light brown 2.916 (.611-
13.925) 
.180 
17(19.3) Fair 1.111 (.337-
3.659) 
.862 Fair .821 (.116-
5.800) 
.843 
6(6.8) Red 1.556 (.248-
9.750) 
.637 Red 1.708 (.087-
33.488) 
.725 
Identification 
of hair colour 
by swatch 
88(100.0) As continuous 
variable  
1.147 (.616-
2.137) 
.665 As 
continuous 
variable  
1.000 (.464-
2.155) 
1.000 
36(40.9) brown/black 1 - - brown/black 1 - - 
39(44.3) blonde/fair 1.429 (.558-
3.655) 
.457 blonde/fair 1.000 (.277-
3.608) 
1.000 
13(14.) red 1.143 (.312-
4.189) 
.840 red 1.000 (.191-
5.241) 
1.000 
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is a more objective measure because it removes the subjectivity of naming the colour and 
is therefore probably a more objective measure of the subjects’ true hair colour.  
The subjects showed reasonably high correlation between these two self-reported 
measures, with Spearman’s rank correlation of 0.71 (significant correlation at the 0.01 
level), indicating 71% agreement between the measures (see appendix table 7.2). All 
subjects who self-reported red hair also identified their hair as red visually by hair 
swatch. Only one person reported having black hair, and this individual identified their 
hair colour as brown by selection of hair swatch. Nearly all (94.1%, 16/17) self-reported 
blondes also identified this colour by hair swatch, with one (5.9%) selecting a red hair 
swatch. Most (87.1%, 27/31) self-reported brunettes identified a brown swatch, with 
three (9.7%) selecting a fair/blonde swatch and one (3.2%) a red hair swatch. A ‘light or 
mouse brown’ self-report was less specific, with most selecting a fair/blonde swatch 
(20/33 or 60.6%), and the remainder either a brown swatch (8/33, 24.2%) or red (5/33, 
15.2%) swatch. If the ‘light or mouse brown’ named category is combined with the ‘dark 
brown’ named category to allow an analysis of agreement with the self-report by swatch, 
the agreement between the two measures is 0.43 (Kronbach’s Kappa). If instead, the 
‘light or mouse brown’ named category is combined with the ‘fair/blonde’ named 
category for a comparison with the swatch self-reports, agreement improves to a measure 
of 0.65 (Kronbach’s Kappa). 
No consistent or significant trend between hair colour and history of BCC was seen in the 
subjects examined, whether determined by self report or identification of hair swatch 
colour (see table 4.1). Subjects with self-reported lighter pigmented hair than dark 
brown/black were more likely to have had BCC; however the odds did not increase 
consistently with increasing fairness. When the groups were compared as matched pairs, 
the odds of BCC were still raised for light-brown (OR= 2.92, 95% CI 0.61 -13.93) or red-
heads by self report (OR = 1.71, 95% CI 0.09 – 33.49), but was the relationship was 
completely lost for the more reliable measure of hair colour by hair swatch. Overall, there 
is little evidence for an association of hair colour and BCC risk in this group.   
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4.2.2.2.Eye Colour 
Table 4.3 Case control comparison of eye colour (from subjects’ answers to questionnaire) 
Variable  n (%) Unconditional 
Logistic 
Regression 
Odds 
Ratio  
(95% 
CI) 
p-value Conditional 
Logistic 
Regression 
Odds 
Ratio  
(95% 
CI) 
p-
value 
Eye 
colour 
88(100) As continuous 
variable 
1.700 (.759-
2.404) 
.306 As 
continuous 
variable 
1.155 (.547-
2.433) 
.706 
 17(19.3) brown/black 1 - - brown/black 1 - - 
 34(38.6) green/hazel .887 (.273- 
2.884) 
.842 green/hazel .825 (.211- 
3.225) 
.782 
 37(42.0) blue 1.655 (.500- 
5.470) 
.409 blue 1.337 (.298- 
6.001) 
.704 
 
Blue (37/88 or 42.0%) or green eyes (34/88 or 38.6%) were more commonly reported by 
subjects with only 19.3% (17/88) reporting brown/black eyes (see table 4.3).  
No significant relationship between eye colour and history of BCC was evident, with 
slightly increased odds of BCC in subjects with lighter eye colour, a relationship that was 
weakened by comparing matched proband-sibling pairs (OR = 1.16, 95% CI 0.55- 2.43), 
reducing the likelihood of a real association. There was also no trend for consistently 
increasing risk with decreasing eye pigmentation, as the odds of BCC were decreased for 
green/hazel eyes  (OR = 0.83, 95% CI 0.21- 3.23) and increased for blue eyes (OR = 
1.33, 95% CI 0.30- 6.00). Together, these results provide no evidence for an association 
between eye colour and BCC risk in these subjects.  
4.2.2.3.Skin Colour 
The commonest reported skin colour among all subjects was fair (47/88 or 53.4%) with 
39.8% (35/88) reporting very fair skin, and only 6.8% subjects overall (6/88) reporting 
olive or brown skin colour (see table 4.4).  
The odds of BCC was higher for people reporting a lighter skin colour, and this 
relationship strengthened in the case-control analysis (OR = 2.04, 95% CI 0.67- 6.29) but 
remained non-significant. There was a trend for increasing risk of BCC with 
progressively increased fairness of skin, with ORs of 1.47 (95% CI 0.27- 8.10) for fair 
skin and 2.18 (95% CI 0.38- 12.58) for very fair skin compared with the whole unpaired 
group of control siblings. Given that there were so few subjects reporting olive/brown 
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skin, odds ratios were unable to be determined for categories of increasing fairness of the 
skin for case-control pairs. 
People with BCC had very slightly lighter overall constitutive skin colour as measured by 
luminance (see 2.3.3 for detailed explanation of skin colour parameters as determined by 
reflectance spectrophotometry), which also strengthened with case-control matching but 
did not reach significance (OR = 1.20, 95% CI 0.93- 1.55; see table 4.6). Inner arm 
(constitutive, non-sun exposed) skin colour was slightly less red on a red-green 
reflectance scale in probands compared with the group of siblings (OR = 0.91, 95% CI 
0.76- 1.08), with cases on average having nearly one unit lower readings on reflectance 
spectrophotometry on this variable. This association became significant when case-
control pairs were matched (OR = 0.59, 95% CI 0.36 – 0.98, with paired t-test 2-tailed 
significance =0.019), suggesting that constitutive red-green reflectance of the skin is 
associated with a lower risk of BCC compared with those whose skin is made up of less 
of this pigment. People with BCC also had less yellow in their skin pigment as measured 
by the yellow-blue reflectance parameter, and although this relationship strengthened 
with matching of probands with their siblings in the analysis (OR = 0.83, 95% CI 0.64- 
1.07), it remained small and not significant.  
None of the outer arm (a sun-exposed skin area) measurements of skin colour were 
significantly different between cases and controls. There was very little difference in 
exposed skin colour, with essentially no difference between exposed skin in overall 
fairness (OR = 1.08, 95% CI 0.94- 1.24), and little difference seen before case-control 
pairing in red-green reflectance or yellow-blue reflectance. In an analysis with case-
control pairing, there was a trend for a small association with outer arm red-green 
reflectance (OR = 0.83, 95% CI 0.62- 1.11) and yellow-blue reflectance (OR = 0.85, 95% 
CI 0.69- 1.07) with BCC, with an increasing degree of either measure decreasing the 
odds of BCC slightly. 
The measures L (‘luminance’), a (‘red-green reflectance’) and b (‘yellow-blue 
reflectance’) are independent dimensions of colour, but skin types are likely to be 
expressed as recurring combinations of these measures, due to the effect of a small 
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number of skin structures contributing to colour in a limited number of ways (see section 
2.3.3 for a discussion on the main contributors to skin colour). Correlations between the 
measures were examined using linear regression; Spearman’s correlation coefficient for 
the outer arm measure L was R2=0.81, i.e. 81% of the variance in the measure L is 
explained by the outer arm measures a and b. Inner arm measure L had a Spearman’s 
correlation coefficient of R2=0.72, suggesting that 72% of the variance in inner arm L is 
explained by the inner arm a and b measures. When the a and b measures for the outer 
arm and the inner arm are combined in a linear regression analysis, inner arm red-green 
reflectance was the only independent predictor of BCC risk.  
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Table 4.5 Case control comparison of self- reported skin pigmentation (from subjects’ answers to questionnaire) 
Variable n (%) Unconditional Logistic 
Regression 
Odds 
Ratio  
(95% CI) p-value Conditional Logistic 
Regression 
Odds 
Ratio 
(95% 
CI) 
p-
value 
 
 
Self reported skin 
pigmentation 
88(100) As continuous variable 1.479 (.714-
3.058) 
.292 As continuous variable 2.044 (.665-
6.289) 
.212 
 6(6.8) Olive/Brown 1 - - Olive/Brown 1 - - 
 47(53.4) Fair 1.474 (.268- 
8.091) 
.655 Fair 2085.670 ? .899 
 35(39.8) Very Fair 2.182 (.378- 
12.583) 
.383 Very Fair 3649.923 ? .892 
Table 4.6 Case control comparison of spectrophotometric measurements of outer and inner arm skin colour 
Variable Paired t test Mean 
difference 
case - 
control 
(95% CI) Sig (2-
tailed) 
Unconditional 
Logistic 
Regression 
Odds Ratio  (95% CI) p-value Conditional 
Logistic 
Regression 
Odds 
Ratio 
(95% 
CI) 
p-
value 
 
 
Observed 
exposed skin 
colour 
Outer arm 
luminance  
1.02452 (-.97464-
3.02367) 
.304 Continuous 
variable 
1.019 (.955-
1.088) 
.563 Continuous 
variable 
1.076 (.935-
1.238) 
.309 
 Outer arm red-
green 
reflectance  
-.66129 (-1.66190-
.33932) 
.187 Continuous 
variable 
.963 (.842-
1.101) 
.582 Continuous 
variable 
.828 (.621-
1.105) 
.200 
 Outer arm 
yellow-blue 
reflectance  
-.89097 (-2.13435-
.35242) 
.154 Continuous 
variable 
.975 (.886-
1.073) 
.607 Continuous 
variable 
.854 (.685-
1.065) 
.162 
Observed 
constitutive 
skin colour  
Inner arm 
luminance  
1.06194 (-.34603-
2.46990) 
.134 Continuous 
variable 
1.041 (.947-
1.144) 
.404 Continuous 
variable 
1.197 (.925-
1.548) 
.171 
 Inner arm red-
green 
reflectance  
-.99484 (-1.81555--
.17413) 
.019* Continuous 
variable 
.906 (.757-
1.083) 
.278 Continuous 
variable 
.591 (.356-
.980) 
.041* 
 Inner arm 
yellow-blue 
reflectance  
-.88742 (-2.04297-
.26813) 
.127 Continuous 
variable 
.952 (.855-
1.060) 
.372 Continuous 
variable 
.826 (.639-
1.068) 
.145 
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4.2.3. Propensity to burn, ability to tan, and phototype 
Overall, only nine (10.2%, 9/88) subjects reported severe sunburn with blistering 
following a single exposure to bright sunlight for one hour for the first time in summer. 
Most subjects reported mild or no sunburn (29.5%, 26/88) or painful (60.2%, 53/88) 
sunburn (see section 2.3.2 for recoding of variable information and appendix table 7.3 for 
raw data).  
There was a trend for progressively increased risk of BCC for people with increasing 
propensity to burn, and this effect was magnified by analysis by case-control pairs. A 
painful burn increased risk of BCC slightly (OR = 1.21, 95% CI 0.47 – 3.15) and a severe 
burn increased the risk more than two-fold (OR = 2.57, 95% CI 0.44 – 14.82). Analysis 
by case-control pairs increased this relationship, with a greater than three-fold risk of 
BCC for a painful burn after their first summer exposure to sunlight (OR = 3.50, 95% CI 
0.73- 16.85), and a seven-fold risk if reporting severe sunburn with blistering (OR = 7.00, 
95% CI 0.70- 70.74); this trend did not quite reach significance (p for trend = 0.08).  
However, only 6.8% (6/88) of persons reported a response of deep tanning following 
repeated exposure to the sun (‘ability to tan’), with 18.2% (16/88) of people at the other 
end of the spectrum, reporting no tanning/freckling only. The remainder fell nearly 
equally into the groups of ‘moderately tanned’ (38.6% or 34/88) or ‘mildly/occasionally 
tanned’ (36.4% or 32/88) (see appendix table 7.3).  
There was an effect of increased risk of BCC in people with reduced ability to tan 
although significance was not achieved: there was a small increased risk of OR 1.61 
(95% CI 0.28- 9.23) for moderate tanning, OR 1.46 (95% CI 0.25- 8.40) for mild tanning 
and a larger effect of OR 3.00 (95% CI 0.42- 21.30) for no tan or freckling only (p for 
trend = 0.33). This effect was increased by case-control analysis, with the odds of BCC 
2.15 (95% CI 0.19- 24.93) for moderate tanning, 1.74 (95% CI 0.13- 22.75) for mild 
tanning, and six-fold increased odds of BCC (OR = 5.97; 95% CI 0.33- 107.26) for those 
reporting no tan or freckling only (p for trend = 0.25). These results are consistent with a 
protective effect of the ability to tan on risk of BCC. 
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Only 9.1% (8/88) reported ‘always burning/never tanning’, with the remainder reporting 
‘usually burning/sometimes tanning’ (52.3%, 46/88), or ‘sometimes burning/usually 
tanning’ (38.6%, 34/88) (see appendix table 7.4).  
The trend for risk of BCC with lower skin phototype was present but small (OR = 1.72, 
95% CI 0.84 – 3.56) but became larger and statistically significant (p for trend = 0.045) 
in the case-control analysis, with a more than three-fold increased risk of BCC with 
decreasing phototype (OR = 3.56; 95% CI 1.03 – 12.35); the risk of BCC was greater 
than four-fold for phototype II (usually burn/sometimes tan; OR = 4.24; 95% CI 0.91 – 
19.81), and nearly ten-fold for people with phototype I as compared with phototype III 
(always burn/never tan; OR = 9.79; 95% CI 0.668 – 143.42), although remained non-
significant.  
In summary, effects of these measures were only weakly discernible in these data due to 
limited power of the study, and the intrinsic limitation of a sibling-control design in 
which many risk factors will be shared by cases and controls. However the directions of 
the trend data are all consistent with effects observed in population-based studies of BCC. 
The trend was for increased risk of BCC with increased propensity to burn, decreased 
ability to tan, and lower skin phototype, with this latter variable the only one to reach 
significance (p = 0.045.) 
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Table 4.7 Case- control comparison of skin reactions to single, repeated, and general exposure to the sun (from subjects’ answers to questionnaire) 
Variable  n (%) Unconditional 
Logistic 
Regression 
Odds Ratio  (95% CI) p-value Conditional 
Logistic 
Regression 
Odds Ratio  (95% CI) p-value 
Single 
exposure to 
sun 
(propensity 
to burn) 
88(100.0) As continuous 
variable  
1.429 (.688-2.967) .338 As continuous 
variable  
2.747 (.876-8.621) .083 
 26(29.5) mild/no sunburn 1 - - mild/no sunburn 1 - - 
 53(60.2) painful 
sunburn/peeling 
1.210 (.465-3.147) .696 painful 
sunburn/peeling 
3.500 (.727- 
16.848) 
.118 
 9(10.2) severe 
sunburn/blistering 
2.567 (.444-14.822) .292 severe 
sunburn/blistering 
7.000 (.693- 
70.743) 
.099 
 
Repeated 
exposure to 
sun (ability to 
tan) 
88(100.0) As continuous 
variable 
1.288 (.770- 2.155) .334 As continuous 
variable 
1.518 (.749- 3.077) .247 
 6(6.8) deeply tanned 1 - - deeply tanned 1 - - 
 34(38.6) moderately 
tanned 
1.615 (.283- 9.235) 
 
.590 
 
moderately tanned 2.148 (.185- 
24.933) 
.541 
 
 32(36.4) mildly tanned 1.462 (.254- 8.401) .671 mildly tanned 1.742 (.133- 
22.746) 
 
.672 
 
 16(18.2) no tan/freckle 
only 
3.000 (.423- 21.297) .272 no tan/freckle only 5.973 (.333- 
107.257) 
.225 
 
General 
reaction to 
sun 
(phototype) 
88(100) As continuous 
variable 
1.727 (.839-3.559) .138 As continuous 
variable 
3.559 (1.029-
12.346) 
.045* 
 88(100) As continuous 
variable recoded 
1.934 (.799-4.695) .144 As continuous 
variable recoded 
4.500 (.972-20.827) .054 
 34(38.6) sometimes 
burn/usually tan 
(phototype III) 
1 - - sometimes 
burn/usually tan 
(phototype III) 
1 - - 
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 46(52.3) usually 
burn/sometimes 
tan 
(phototype II) 
1.837 (.737- 4.577) .192 usually 
burn/sometimes 
tan  
(phototype II) 
4.243 (.909-19.811) .066 
 8(9.1) always 
burn/never tan 
(phototype I) 
2.667 (.470-15.136) .268 always burn/never 
tan (phototype I) 
9.787 (.668-
143.415) 
.096 
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4.2.4. Sun exposure 
Table 4.8 Case-control comparison of presence of actinic keratoses, solar elastosis and pterygium (as measured by 
skin examination) 
Variable n (%) Unconditional 
Logistic 
Regression 
Odds 
Ratio 
(95% 
CI) 
p-
value 
Conditional 
Logistic 
Regression 
Odds 
Ratio 
(95% 
CI) 
p-
value 
 
 
Presence of  
actinic 
keratoses  
44 
(50.0)/ 
44 (50.0) 
Presence/ Absence 3.000 (1.216-
7.399) 
.017* Presence/ 
Absence 
3.667 (1.023-
13.143) 
.046* 
Total solar 
elastosis 
27 
(30.7)/ 
60 (68.2) 
Low/high 
categories 
1.016 (.396- 
2.604) 
.974 Low/high 
categories 
1.222 (.723-
2.064) 
.454 
Presence of 
pterygium 
56 
(63.6)/ 
31 (35.2) 
Presence/ 
Absence 
.917 (.368- 
2.285) 
.852 Presence/ 
Absence 
.750 (.260-
2.162) 
.594 
 
Half of the subjects had at least one actinic keratosis at examination (see table 4.8 and appendix 
table 7.6). One subject was not examined for total solar elastosis or pterygium and so the analysis 
for these two factors included 87 subjects only. A large proportion of subjects had a high amount of 
solar elastosis (see section 2.4.2 and appendix table 7.7), and nearly two-thirds of subjects had the 
sun-exposure-related lesion ‘pterygium’ visible on the sclera of their eye at examination. 
The presence of any actinic keratoses were significantly associated with history of BCC with an OR 
of 3.00 (95% CI 1.22- 7.40; p = 0.017) for this variable, an association that was increased 
marginally in the case-control analysis (OR = 3.67; 95% CI 1.02- 13.14; p = 0.046). The other signs 
of sun exposure showed smaller associations and required case-control analysis to become evident; 
total solar elastosis was associated with a slightly increased risk of BCC in the case-control analysis 
(OR = 1.22, 95% CI 0.72- 2.06); and risk of BCC was paradoxically slightly reduced in people with 
a pterygium when cases were analysed with respect to their matched siblings (OR = 0.75; 95% CI 
0.26- 2.16).  
In summary, the large amount of sun-exposure-related skin changes in this group made any potential 
associations with BCC risk difficult to determine. The direction of the trend data for actinic 
keratoses and solar elastosis was consistent with population-based studies on BCC risk, with actinic 
keratoses presence significantly associated with BCC risk (p = 0.017).  
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4.2.5. Skin characteristics that are influenced by sun exposure 
Solar lentigines and freckling are pigmentary lesions with complex aetiology (see 1.4.1.1). 
Lentigines have their strongest associations with prior sunburn and occur in sites of previous 
burning, freckles are influenced by sun exposure more broadly. Freckling is strongly geneticly 
determined whereas the genetics of solar lentigo formation, if any, are not understood. 
 
4.2.5.1.Solar lentigines 
Table 4.9 Case-control comparison of numbers of solar lentigines on the face, forehead, upper limbs, and back and 
shoulders (as measured by skin  examination) 
Variable n (%) Unconditional 
Logistic 
Regression 
Odds 
Ratio 
(95% 
CI) 
p-
value 
Conditional 
Logistic 
Regression 
Odds 
Ratio 
(95% 
CI) 
p-
value 
Solar lentigines 
face 
88 (100) Continuous 
variable 
1.088 (.856-
1.382) 
.491 Continuous 
variable 
1.146 ( .873- 
1.503) 
.326 
 43 
(48.9)/ 
45 
(51.1) 
low/high 
categories 
1.185 (.500-
2.811) 
.700 low/high 
categories 
1.667 (.606-
4.586) 
.323 
Solar lentigines 
forehead 
88 (100) Continuous 
variable 
.949 (.757-
1.190) 
.653 Continuous 
variable 
1.010 ( .771- 
1.322) 
.945 
 47 
(53.4)/ 
41 
(46.6) 
low/high 
categories 
.729 (.306-
1.732) 
.474 low/high 
categories 
1.167 (.392-
3.471) 
.782 
Solar lentigines 
dorsal upper limbs 
88 (100) Continuous 
variable 
1.254 (1.026-
1.532) 
.027* Continuous 
variable 
1.424 ( 1.075- 
1.886) 
.014* 
 46 
(52.3)/ 
42 
(47.7) 
low/high 
categories 
2.583 (1.052-
6.346) 
.038* low/high 
categories 
3.250 (1.060-
9.967) 
.039* 
Solar lentigines 
upper 
back/shoulders 
88 (100) Continuous 
variable 
1.074 (.878-
1.313) 
.487 Continuous 
variable 
1.384 ( .958-  
2.000) 
.084 
 43 
(48.9)/ 
45 
(51.1) 
low/high 
categories 
1.440 (.605-
3.426) 
.410 low/high 
categories 
2.000 (.602-
6.642) 
.258 
 
Table 4.9 shows a trend for increased risk of BCC for people who have had a high number of solar 
lentigines (see section 2.3.2 for recoding and appendix table 7.8 for raw data). Having a high 
number of solar lentigines on the upper arms increased risk of BCC significantly (OR = 2.58; 95% 
CI 1.05- 6.35), and this association was strengthened to a 3-fold risk of BCC in the case-control 
analysis (OR = 3.25, 95% CI 1.06- 9.97). There was a smaller, non-significant risk with high 
numbers of solar lentigines on the face (OR = 1.19, 95% CI 0.50- 2.81) and this increased 
marginally in the case-control analysis (OR = 1.67, 95% CI 0.61- 4.59). Solar lentigines on the 
forehead had essentially no effect on risk, with an odds ratio approaching unity. High numbers of 
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solar lentigines on the upper back and shoulders was associated with a small increased BCC risk, 
and this increased to a two-fold risk (OR = 2.00; 95% CI 0.60 – 6.64) in the paired case-control 
analysis. 
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4.2.5.2.Freckling 
Table 4.10 Case-control comparison of freckling (from questionnaire answers and from skin examination) 
Variable n (%) Unconditional 
Logistic 
Regression 
Odds 
Ratio 
(95% 
CI) 
p-
value 
Conditional 
Logistic 
Regression 
Odds 
Ratio 
(95% 
CI) 
p-
value 
 
 
Reported freckling 
in childhood 
88 
(100.0) 
As continuous 
variable 
1.455 (.757-
2.798) 
.261 As continuous 
variable 
1.752 (.749- 
4.097) 
.196 
 8 (9.1) None 1 - - None 1 - - 
 31 (35.2) Some 1.385 (.291-
6.581) 
.682 Some .250 (.016- 
3.997) 
.327 
 49 (55.6) Many 2.062 (.456-
9.328) 
.347 Many 1.500 (.251- 
8.977) 
.657 
Reported freckling 
in adulthood 
88 
(100.0) 
As continuous 
variable 
1.177 (.632-
2.191) 
.607 As continuous 
variable 
1.472 (1.472- 
3.038) 
.296 
 15 (17.0) None 1 - - None 1 - - 
 43 (48.9) Some 1.633 (.496-
5.383) 
.420 Some 3.000 (.555- 
16.208) 
.202 
 30 (34.0) Many 1.511 (.430-
5.313) 
.520 Many 3.000 (.555- 
16.208) 
.202 
Clinical freckling 
face 
88 
(100.0) 
Continuous 
variable 
.975 (.802-
1.186) 
.803 Continuous 
variable 
1.012 ( .746- 
1.374) 
.938 
 60 
(68.2)/  
28 (31.8) 
low/high 
categories 
1.000 (.420-
2.379) 
1.000 low/high 
categories 
1.333 (.298-
5.957) 
.706 
Clinical freckling 
forehead 
88 
(100.0) 
Continuous 
variable 
1.099 (.906-
1.334) 
.338 Continuous 
variable 
1.249 ( .932- 
1.674) 
.137 
 66 
(75.0)/ 
22 (25.0) 
low/high 
categories 
.975 (.407-
2.337) 
.956 low/high 
categories 
1.750 (.512-
5.978) 
.372 
Clinical freckling 
dorsal upper limbs
  
88 
(100.0) 
Continuous 
variable 
1.160 (.909-
1.480) 
.233 Continuous 
variable 
1.903 ( 1.068- 
3.391) 
.029* 
 78 
(88.6)/ 
10 (11.4) 
low/high 
categories 
1.815 (.749-
4.396) 
.187 low/high 
categories 
4.000 (.849-
18.836) 
.080 
Clinical freckling 
upper 
back/shoulders 
88 
(100.0) 
Continuous 
variable 
1.112 (.884-
1.398) 
.365 Continuous 
variable 
1.221 ( .883- 
1.688) 
.228 
 43 
(48.9)/ 
45 (51.1) 
low/high 
categories 
1.105 (.460-
2.654) 
.823 low/high 
categories 
1.400 (.444-
4.411) 
.566 
 
Reported freckling in childhood was not consistently associated with BCC risk, as seen in table 4.10 
(see section 2.3.2 for recoding of variables and appendix table 7.9 for raw scores). Reporting of 
some freckles in childhood was associated with a small increased risk of BCC (OR = 1.39, 95% CI 
0.29- 6.58); many freckles were associated with a higher risk (OR = 2.06, 95% CI 0.46- 9.32); 
neither association was significant. The validity of these predictions are questioned when 
considering the marked decrease in predicted risk resulting from the case-control analysis (some 
freckles; OR = 0.25, 95% CI 0.02- 4.00, many freckles; OR = 1.50, 95% CI 0.25- 8.98).   
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Freckling in adulthood showed a more consistent but still non-significant association with more 
evidence for a trend, with a slightly elevated risk that increased to 3-fold in the case-control analysis 
(OR = 3.00; 95% CI 0.55- 16.21 for both).  
As with examination of solar lentigines, the dorsal upper limbs were the only region of the body 
examined to show a significant association of freckling with BCC risk. Here, there was a four-fold 
risk (OR = 4.00, 95% CI 0.85- 18.84) of BCC with high numbers of freckles seen on the upper 
limbs, with a p value approaching significance at 0.08. The p value drops to significance at the 0.05 
level when all categories on the semi-quantitative scale are included in the analysis, giving a 2-fold 
risk of BCC associated with upper arm freckling (OR = 1.90, 95% CI 1.07- 3.39, p = 0.029). 
Observed freckling on the face and forehead both had no effect on BCC risk without the case-
control analysis, but was associated with slightly increased odds of BCC with the case-control 
analysis (face freckling; OR = 1.33; 95% CI 0.30- 5.96; forehead freckling; OR = 1.75; 95% CI 
0.51- 5.96). Upper back and shoulder freckling also showed a small non-significant association with 
BCC risk with odds of 1.40 (95% CI 0.44- 4.41) with case-control matching. 
In summary, the trends seen in this case-control data reflect those seen in population studies on 
BCC. Risk of BCC was increased by the presence of sun-exposure-related lesions including solar 
lentigines and freckling. The most significant associations were seen for both variables on the 
chronically sun-exposed region of the arm (p = 0.014 and p = 0.029 respectively). The amounts of 
solar lentigines were more consistently associated with BCC risk than freckling, which may reflect 
their relatively simple relationship to sun-exposure. The measures of freckling included both self-
reported variables and clinically measured ones. The self-reported measure of childhood freckling 
showed the most inconsistent associations with risk of BCC, which may reflect the difficulties 
associated with reliance on subjects’ memory of the variable.  
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4.2.6. Seborrhoeic keratoses 
Table 4.11 Case-control comparison of numbers of seborrhoeic keratoses (from skin examination) 
Variable n (%) Unconditional 
Logistic 
Regression 
Odds 
Ratio 
(95% 
CI) 
p-
value 
Conditional 
Logistic 
Regression 
Odds 
Ratio 
(95% 
CI) 
p-
value 
 
 
Seborrhoeic 
Keratoses head 
and neck 
88 (100.0) Continuous 
variable 
.456 (.148-
1.402) 
.170 Continuous 
variable 
.429 ( .111- 
1.657) 
.220 
 15 (17.0)/ 
73 (83.0) 
Present/Absent 
categories 
.456 (.148-
1.402) 
.170 Present/Absent 
categories 
.429 (.111-
1.657) 
.220 
Seborrhoeic 
Keratoses upper 
limbs 
88 (100.0) Continuous 
variable 
1.283 (.530-
3.108) 
.581 Continuous 
variable 
1.000 ( .351-  
2.851) 
1.000 
 29 (33.0)/ 
59 (67.0) 
Present/Absent 
categories 
1.214 (.480-
3.069) 
.682 Present/Absent 
categories 
1.000 (.351-
2.851) 
1.000 
Seborrhoeic 
Keratoses chest 
88 (100.0) Continuous 
variable 
.500 (.188-
1.332) 
.166 Continuous 
variable 
.286 ( .059-  
1.375) 
.118 
 22 (25.0)/ 
66 (75.0) 
Present/Absent 
categories 
.500 (.188-
1.332) 
.166 Present/Absent 
categories 
.286 (.059-
1.375) 
.118 
Seborrhoeic 
Keratoses 
abdomen 
88 (100.0) Continuous 
variable 
.919 (.412-
2.051) 
.837 Continuous 
variable 
.667 ( .188-  
2.362) 
.530 
 25 (28.4)/ 
63 (71.6) 
Present/Absent 
categories 
.683 (.266-
1.756) 
.429 Present/Absent 
categories 
.500 (.125-
1.999) 
.327 
Seborrhoeic 
Keratoses back 
88 (100.0) Continuous 
variable 
.778 (.350-
1.730) 
.538 Continuous 
variable 
.625 ( .204-  
1.910) 
.410 
 34 (38.6)/ 
54(61.4) 
Present/Absent 
categories 
.776 (.321-
1.874) 
.572 Present/Absent 
categories 
.714 (.227-
2.251) 
.566 
Seborrhoeic 
Keratoses lower 
limbs 
88 (100.0) Continuous 
variable 
.841 (.373-
1.896) 
.676 Continuous 
variable 
.857 ( .288-  
2.550) 
.782 
 30 (34.1)/ 
58 (65.9) 
Present/Absent 
categories 
.688 (.279-
1.697) 
.417 Present/Absent 
categories 
.857 (.288-
2.550) 
.782 
Seborrhoeic 
keratoses total 
body (sum) 
88 (100.0) Continuous 
variable 
.884 (.680-
1.150) 
.358 Continuous 
variable 
.717 (.461-
1.117) 
.141 
 40 (45.5)/  
48 (54.5) 
Low/high 
categories 
.551 (.228-
1.335) 
.187 Low/high 
categories 
.500 (.171-
1.463) 
.206 
 
Overall, scores for seborrhoeic keratoses were low and found to be absent for many subjects on 
different regions of their bodies (see section 2.3.2 for recoding and appendix table 7.10 for raw 
scores). There were no significant associations between BCC and seborrhoeic keratoses. The overall 
summed score of total body seborrhoeic keratoses for proband-sibling pairs gave an odds ratio of 
0.72 (95% CI 0.46 – 1.12) when assessed as a continuous variable, and 0.50 (95% CI 0.17 – 1.46) 
when divided into high and low categories; these results did not quite reach significance. In addition, 
odds ratios of association between seborrhoeic keratoses in the various body sites were less than 1.0, 
suggesting that presence of seborrhoeic keratoses may be associated with a reduced risk of BCC. 
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The decreased risk of BCC for presence of seborrhoeic keratoses on the chest approached 
significance for the case-control paired analysis, with an OR of 0.27 (95% CI 0.06- 1.38, p = 0.118).  
In summary, the data trend is for lower BCC risk with increased seborrhoeic keratoses. Little 
literature exists on the risks associated with these benign lesions (see section 1.4.6) although these 
trends contradict the suggested relationship of seborrhoiec keratoses to sun exposure. 
4.3. Effect of date of examination on measurements 
Sun exposure-related variables and skin pigmentary measurements are likely to be affected by the 
time of year that examination took place, due to variation in the amount of UVR exposure according 
to season. The dates of examination for all probands and siblings were compared (see figure 4.1 and 
4.2). It is evident that the date of examination was not significantly different between the proband 
and control groups for both the unconditional and conditional logistic regression analyses and it is 
therefore unlikely that measurements were systematically biased by this variable.  
The number of subjects from the whole group of 88 probands and siblings is sufficient to allow 
analysis by month of examination (see figures 4.1 and appendix table 7.11). As seen in figure 4.1, 
there is no significant difference between the month of examination in the proband compared with 
the sibling groups (Fisher’s Exact Test p= 0.860).  
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Figure 4.1 Proband and sibling groups’ date of skin examination by month  
 
Case-control pairs were also compared by month of skin examination in a scatterplot that shows no 
correlation between the two measures (see figure 4.2), meaning that there is no systematic difference 
between the two groups on this variable. 
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Figure 4.2 Date of skin examination by month for case-control pairs 
 
 
The 66 subjects in the case-control sample were best compared for significance by the season of 
examination, as there were too few subjects to allow enough power for a comparison by month (see 
appendix table 7.12). There was also no significant difference between the season of examination of 
the probands compared with their matched sibling pairs (McNemar Test p = 0.267). 
Among all of the variables measured in the skin examinations, the ‘L* a* b*’ spectrophotometric 
measurements of the skin (see section 2.3.3) are the parameters most likely to have been affected by 
the date of examination. Other sun exposure variables measured reflect the cumulative effects of sun 
exposure as well as acute effects, while pigment of skin in general, and the outer aspect of the arm in 
particular, is affected more acutely by changes in melanin density and distribution due to recent 
UVR exposure. Outer arm measures of luminance (L) were smaller than on the inner arm, reflecting 
the constitutive lightness of pigment overall on the less exposed skin. Outer arm red-green 
reflectance (a) and yellow-blue reflectance (b) was greater than inner arm, reflecting greater 
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amounts of pigment on the exposed area compared with the less exposed area. L can be seen as a 
measure of whiteness of the skin and an overall average increase in this measure was seen among all 
subjects on the outer arm in winter as compared with summer, when UVR exposure is assumed to 
be reduced. Inner arm (constitutive) L varied slightly also, but predictably not as much as the outer 
arm measure. Overall, outer arm a in subjects showed an increase over the warmest season, with 
inner arm a decreasing slightly over this same period. Outer and inner arm b both increased in the 
warmest months (see figure 4.3). In figure 4.3, the variance of results for spring are larger than 
results for the other seasons due to the smaller number of subjects examined in this season (n = 4 
examined in spring). 
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Figure 4.3 Outer and inner arm luminance (A), red-green reflectance (B) and yellow-blue reflectance (C) as 
measured by spectrophotometry, by season of examination 
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B.  
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C. 
 
 
4.4. Discussion 
Probands and their unaffected siblings were examined for phenotypic differences in skin, eye, and 
hair pigmentation; as well as differences in sensitivity to the sun and signs of the amount of previous 
sun exposure. Of the pigmentary variables, only constitutive red-green reflectance was significantly 
associated with BCC risk, and this occurred in the direction opposite to that expected, in that red-
green reflectance of the skin associated with a decreased risk of early-onset BCC. Of the sun 
sensitivity factors, decreasing skin phototype was significantly associated with an increasing risk of 
BCC. A marker of cumulative sun exposure - presence of actinic keratoses - was associated with 
significantly increased risk of BCC. Signs reflecting the combination of pigmentary characteristics 
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and sun exposure - in the form of arm freckling and solar lentigines - also gave subjects a 
significantly increased risk of this tumour.  
There were no significant differences detected in height or weight of the two groups, and no 
systematic differences in the date of examination that may have skewed results that depend on 
effects of recent ambient UVR. The tendency towards older age in the sibling group is not surprising 
given that the oldest unaffected sibling was selected where available. Since the age difference was 
only 1.8 years on average, the difference did not reach significance. An older sibling was chosen as 
the control to ensure that the sibling would have attained at least the same age as the probands, as 
age is such a strong predictor of skin cancer.   This ensured that the sibling pair was as discordant as 
possible with respect to skin cancer phenotype.  
This group of subjects was fairly ‘sun sensitive’ in that most (96.6%) reported some burning in 
response to their first exposure to summer sun, and very few (6.8%) reported an ability to build up a 
‘deep tan’. In addition, nearly a fifth of the subjects overall (18.2%) reported a total inability to tan. 
There was a trend for an association of the propensity to burn with risk of BCC, with non-significant 
odds ratios reaching the moderate to high range (highest OR for affected-unaffected pairs 7.0) for 
people with a high propensity to burn. It is likely that with a larger sample size a significant 
association of BCC risk with propensity to burn may be seen. The ability to tan displayed a 
relationship with BCC risk that could be interpreted as due to a complex interplay of pigmentary 
factors and sun exposure behaviours. Despite no significant associations, the risk of BCC showed a 
tendency toward an association with moderate tanning ability and also with the total inability to tan; 
the risk was still positive in those with a mild ability to tan but lower than for the other two 
categories. The literature shows that ability to tan interacts with exposure so that if a person tans 
well, there is a linearly increased risk with intermittent exposure; whereas for those that tan poorly, 
risk plateaus with increasing intermittent exposure [81, 103]. Measurement of patterns and amount 
of sun exposure by interview would be necessary to help disentangle these effects but were beyond 
the scope of the present study. 
It is unsurprising that there were no probands or siblings of the darker skinned skin phototypes IV, 
V or VI. Most people self categorised themselves as skin phototype II (usually burn/sometimes tan) 
or III (sometimes burn/usually tan). For the more sensitive measure of analysis by case-control 
pairs, a significant relationship was seen for risk of BCC with decreasing phototype, with an overall 
OR of 3.6. When broken down to assess the contributors to the risk in this figure, phototype II was 
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associated with a more than 4-fold risk, and phototype I a nearly 10-fold risk compared with people 
of phototype III. When looked at separately, these categories did not quite reach significance 
although given the significance of the relationship when looked at together, this relationship is likely 
to hold up with greater sample numbers. There is extensive evidence in the literature that skin that 
burns easily and tans poorly (ie skin of lower phototype) is at increased skin cancer risk, and this 
finding is replicated in the present study [42, 102, 117]. 
Actinic keratoses can be viewed as a surrogate measure of cumulative exposure and are 
premalignant lesions. Between 1:100 and 1:1000 will develop into an SCC and for this reason they 
are always treated or removed. Half of the subjects had at least one of these premalignant lesions, 
and there was a significant association of the presence of any actinic keratosis with a 3-fold 
increased risk of BCC, reflecting previous findings [78]. Solar elastosis was so common among the 
subjects that there was little power to detect an association: more specific measures of this variable, 
if developed, may be of more value. Presence of a pterygium was also common among the subjects 
with nearly two-thirds of them displaying this surrogate marker cumulative of sun exposure. 
Paradoxically, the presence of a pterygium was associated with a decreased risk for BCC, although 
the effect was small and not significant. 
Both childhood and adult freckling have been associated with BCC and SCC risk and this effect is 
replicated here [78]. Pigmentary characteristics and sun exposure combine to cause freckling 
(ephelides) and solar lentigines (larger freckles that don’t disappear in winter). All subjects had 
evidence of some of these lesions. Most subjects (91.9%) reported having freckles in childhood. 
Although 17% of subjects reported a lack of freckles in adulthood (on the face), most had some 
freckles present at the time of examination. Risk of BCC was moderately increased for people with 
increased numbers of both freckles and solar lentigines on their arms. The arms are a commonly sun 
exposed area and accessible to the clinician as a quick and easy addition to the assessment of a 
person’s risk of skin cancer. For these lesions elsewhere on the body risks of BCC were mostly also 
elevated, with the highest risks (although still in the low range of OR 2.0 or less) seen in the most 
sensitive case-control analysis analysis ie people with a low versus a high number of the lesion. 
These trends of increased risk of BCC with freckling and solar lentigines on other parts of the body 
require confirmation in a larger study of early-onset BCC. 
More than half the subjects had no evidence of seborrhoeic keratoses on each body site examined. 
These poorly-studied benign lesions are also known as ‘senile warts’ and have been associated with 
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sun exposure, but not with skin cancer to date (see section 1.4). No significant associations with 
BCC risk were found, and there was a consistent and paradoxical reduced risk of BCC with presence 
of seborrhoeic keratoses: risk was halved with higher overall body numbers of these lesions. 
Similarly, lesions on the chest, abdomen, head and neck, back and lower limbs were all associated 
with small but not significantly decreased risks. The arms were the only body site where risk of 
BCC was not reduced, although it showed no evidence of giving an increased risk. Numbers of 
seborrhoeic keratoses found in this study were far lower than those seen in a comparable Australian 
population [169] (see section 2.3.1). Fainter lesions that would be assessed as seborrhoeic keratoses 
by an experienced examiner may have been missed in the proband and sibling examinations. If 
undercounting of these lesions occurred, it is likely that they would have occurred across all body 
areas and for all subjects examined, and therefore does not account for the paradoxical reduced risk 
of BCC seen. The possibility that any genetic predisposition leading to BCCs in these subjects also 
suppresses the development of seborrhoeic keratoses needs further exploration. The trends of 
decreased risk of BCC with these lesions require confirmation in a larger study of early-onset BCC. 
Hair colour and eye colour reflected the general fairness of skin pigmentation with few subjects 
reporting dark hair or brown eyes. It was evident by the two measures employed to estimate 
constitutive hair pigmentation that reporting by naming of hair colour is subjective and probably 
unreliable. Self-reported hair colour by naming differed from self-report by identification of hair 
swatch, with the term ‘light or mouse brown’ associated with the most variation in selection of 
swatch; more of these individuals selected a fair/blonde hair swatch than a brown one. Neither eye 
colour nor hair colour emerged as convincing predictors of BCC risk: green eye colour was 
associated with a small non-significantly decreased risk and blue with a small non-significantly 
increased risk compare with darker eyes. Thus there was no clear trend of an effect with for this 
variable on the risk of BCC. Similarly, hair colour associations were inconsistent although mostly 
tended towards increased risk of BCC with fairer hair. The most reliable measure to detect a 
difference in risk with hair colour - if one was indeed present - was from the hair swatch selection 
by case-control pairs. No effect of hair colour was seen in this study. This is not a surprising finding 
given the variability in predictive value of these traits in the literature [47, 112]. They may act as 
surrogate markers for pigmentary characteristics or sun sensitivity, but seem to be relatively 
unreliable ones. 
 148
Overall, these early-onset BCC probands and their siblings were relatively fair-skinned, with 93.2% 
describing themselves as fair- or very fair-skinned, and the remainder olive/brown. Significant 
differences in skin pigmentation were detected between the two groups as measured by 
spectrophotometer, suggesting that constitutive red-green reflectance of the skin decreases the risk 
of BCC (OR 0.6). Constitutive luminance was associated with a slightly (but non-significantly) 
increased risk of BCC, however much of the variance of this measure was explained by the 
measures of yellow-blue reflectance and red-green reflectance. Constitutive yellow-blue reflectance 
tended towards a decreased risk of BCC but was also not significant. Red-green reflectance was the 
only independent predictor of BCC risk.  
The red-yellow pigment phaeomelanin prevalent in lighter skinned persons probably causes 
decreased skin photoprotectivity [251, 264] compared with the darker, more photoprotective 
eumelanin [262]. Although lighter, easy-burning skin is likely to have more phaeomelanin and less 
eumelanin than darker skin, the exact relationship between skin phototype and 
pheomelanin:eumelanin production in the epidermis is not straightforward or directly predictable 
[260, 278]. MC1R variants are thought to contribute to individual differences in pigmentation, and 
in particular, to eumelanogenesis and pheomelanogenesis; MC1R variants also contribute to risk of 
BCC, independently of their effect on pigmentation [283]. Individuals with the same MC1R variants 
may display differences in hair pigmentation; for example, auburn or strawberry blonde [266]. Thus 
other loci are likely to be involved in the creation of pigmentary characteristics. It has been 
hypothesised that MC1R variants may be involved in the switching between eumalanogenesis and 
pheomelanogenesis [279].  
Skin colour has shown less association with risk of BCC in the literature than sun sensitivity has; 
however the lack of access to or use of objective measurement techniques for skin colour may have 
contributed to this. Skin colour is not only dependent on melanin pigmentation, but is also 
influenced by the presence of superficial capillaries (increases redness), collagen content (increases 
yellowness), body hair, thickness, and moisture [397]. The BYK Gardner spectrophotometry 
readings are not calibrated to melanin content of the skin or a suitable surrogate such as MC1R 
variant status, and this analysis is urgently necessary to allow better interpretation of 
spectrophotometric measures. Nevertheless, it is evident from the changes in pigmentation on the 
outer arm seen over the seasons (see figure 4.3) that yellow-blue reflectance and red-green 
reflectance are greater on the outer than the inner arm, suggesting a relationship with sun exposure 
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that is likely to be related to melanin in the skin. Yellow-blue reflectance and red-green reflectance 
also increase slightly in the hotter months (summer) compared with the cooler months (winter), 
suggesting that these two variables do increase concomitantly with the tanning response; of the 
possible contributors to skin colour, melanin pigmentation is the only one that is likely to change 
skin colour acutely in this way. Constitutive skin colour also changes with the season although not 
as markedly as the outer arm, with a small increase of yellow-blue reflectance and decrease of red-
green reflectance with summer as compared with winter.  
Constitutive red-green reflectance was associated with a significantly decreased risk of BCC in our 
subjects. It was seen in these data that outer arm a* (red-green) values increased in the summer, so it 
is a reasonable inference that high a* values are positively correlated with skin melanisation. The 
simplest interpretation of these data is that high constitutive pigmentation, as seen in the inner arm 
measurements, is associated with reduced risk of early-onset BCC. However further studies are 
required to establish the relationship of the L*a*b* parameters with biological parameters such as 
skin melanin content and changes due to tanning. 
We used the BYK Gardner spectrophotometer to measure skin pigmentation (see section 2.3.3), 
whereas the few other studies that have used full-spectrum spectrophotometry for objective 
measurement of skin colour have used other insturments such as the Minolta 508 spectrophotometer, 
and recorded the measurements differently. Using the Minolta, one group found that risk of BCC in 
men and women had a small positive association with spectrophotometric readings [398]. These two 
instruments use the same wavelengths of incident light to measure reflected light which may be 
recorded in different ways: using the L*a*b* system or through a measure at each wavelength in 
20nm increments across all or part of the spectrum measured (400nm to 700nm). Both machines 
were tested on the upper arm of three human subjects and the L*a*b* readings were found to be 
almost identical (see appendix 4.23). Researchers using the Minolta have chosen to use the 
difference between readings at 400nm and 420nm for measurements of skin pigmentation; some of 
the information on the spectrum of reflected light is lost by the use of only two wavelengths of light. 
We have chosen to use the L*a*b* measure as it may capture more information about the reflected 
light across wavelengths of relevance to the perception of the human eye, and therefore probably 
provides more information about the skin’s colour than a difference between two wavelengths. This 
difference in recording affects the ability to compare the results of research using both instruments. 
A study has shown that presence of hair may overestimate pigmentation readings, although this was 
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seen using a different measure of reflected light, and on a different part of the body: it is difficult to 
know how this would apply to our results [399]. It may be worthwhile to test this on the outer arm in 
future to determine whether subjects should be shaved at the test site. 
MC1R variant analysis was not carried out in this project and will be essential to elucidate the 
relationships between the L*a*b reflectance measures and risk. A first step would be analysis of 
associations between the MC1R red hair-associated (RHC) variants and L*a*b* measures in a large 
cohort of controls, examined at different times of the year, in both sun-exposed and non-sun-
exposed sites. 
Together these results suggest that skin colour, sun sensitivity, and sun exposure are associated with 
an increased risk of BCC.  
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Chapter 5: Analysis of patched for germline mutations in 
clusters of BCC cases 
 
5.1. Introduction 
BCC, SCC and MM all showed significant increases among the first-degree relatives of cases of 
early-onset BCC, as shown in chapter three. Sun sensitivity, skin pigmentary characteristics, and 
evidence of sun exposure all showed associations with BCC when the cases were compared with 
unaffected sibling controls. These data are most consistent with the increase in BCC risk to these 
probands being largely due to causes that increase the risk of all forms of skin cancer. 
Nevertheless, some striking family clusters of only BCC, to the exclusion of SCC and MM, were 
observed. The hypothesis therefore remained that at least some proportion of the observed clusters 
of BCC cases, or at least some part of their aggregation, was due to a genetic factor or factors 
specific to BCC risk. 
Inactivating germline mutations of PTCH cause Gorlin Syndrome, a rare and usually familial 
genodermatosis comprising early-onset BCC and developmental abnormalities (section 1.5.4). 
Mutation of this gene is associated with a 900-fold increased risk of BCC in Australia. Recently, a 
common single nucleotide polymorphism (SNP) in PTCH exon 23 (Pro>Leu) has been associated 
with degree of skin pigmentation [235], and combinations of polymorphisms (ie certain haplotypes) 
in this gene have been associated with rate of BCC accrual [233]. 
The melanocortin-1 receptor (MC1R) is involved in individual variation in the type of melanin 
synthesized and the way it is distributed in the skin, and variations in this receptor contribute to 
individual differences in pigmentary characteristics. MC1R variants are very common in light 
skinned populations including Australians of European origin, and red hair-associated variant alleles 
of this gene have been associated with a two- to four-fold risk of BCC [267, 283]. No other germline 
mutations have been consistently associated with BCC risk, although p53(Arg72) has been linked 
with NMSC risk. This chapter addresses the question of whether mutations in PTCH are 
contributing significantly to the higher risk of BCC in these individuals. Probands from 56 families 
with early-onset BCC were included for genetic analysis. In addition, two probands from a related 
cohort of early-onset SCC cases was analysed; these had three or more BCC-affected first degree 
family members (see section 2.6 and table 2.3). 
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 DNA from peripheral blood from all 58 probands was screened for mutations of the PTCH gene 
using PCR, dHPLC and direct sequencing. Twenty of the 23 exons of the PTCH gene were 
amplified by PCR and screened in this way. Two dHPLC temperatures were used to screen the 
subjects with the highest probability of carrying a PTCH mutation, for the eight exons that most 
commonly bear PTCH mutations in Gorlin syndrome (see section 2.6). The remaining subjects were 
screened at a single dHPLC temperature for all 20 exons. 
No mutations were found in the exons screened for these 58 subjects with personal or family history 
of high risk BCC. The SNPs observed were present at frequencies similar to those in the literature. 
Where population frequency data for a SNPs were lacking, they were determined in a comparable 
Australian cohort without BCC; the frequencies for these SNPs were also similar to the probands’. 
Therefore no evidence was found to implicate either PTCH inactivating mutations or SNPs in risk of 
BCC in these early-onset cases.  
5.2. Results 
5.2.1. dHPLC and sequencing analysis of the PTCH gene 
Twenty of the 23 PTCH exons were screened for mutations by dHPLC as described in Section 2.5.1 
and 2.6. These covered 97% of the coding sequence of PTCH, in which also 97% of all Gorlin 
syndrome-associated mutations have been found. The equipment and protocols used were identical 
to those used by a collaborating reference laboratory that has been screening Gorlin syndrome 
subjects for germline PTCH mutations by this method for several years. In six of the eight exons (2, 
3, 14, 15, 17, 18) that most commonly bear PTCH mutations in Gorlin syndrome two dHPLC 
temperatures were used to screen the 19 subjects with the highest probability of carrying a patched 
mutation. A single temperature was used for the other 14 exons and for screening the other 39 
subjects. All products were run with sequence proven wild-type controls and any test sample that 
gave a profile different from the control was submitted to bi-directional DNA sequencing. One 
variant-negative test sample at random from each exon analysed was sequenced in the forward 
direction to confirm presence of the wild type sequence. 
Exons 3, 7, 9, 13, 16, 17, 18, 20, 21, 22, and 23b did not show any variant elution profiles in any of 
the 58 subjects screened. In the other nine exons (2, 5, 6, 8, 11, 12, 14, 15 and 23a), dHPLC variants 
were seen in some of the samples. All these samples were confirmed to be heterozygous for 
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previously described single nucleotide polymorphisms (SNPs) as shown in table 5.1. dHPLC and 
sequence appearances of each SNP may be seen in appendix 7.9 and 7.10. 
 
Table 5.1 PTCH SNPs observed and comparison of relative frequencies with database population data 
Exon SNPa Amino acid 
change 
Proband 
heterozygote 
relative 
frequency 
(n=58) 
Population 
heterozygote 
relative 
frequency  
Source of 
population 
datac 
2 116C>T Leu>Leu 0.034 No data n/a 
5 80A>G Thr>Thr 0.103 No data n/a 
6 IVS6-55T>Cb N/A 0.450 0.267 HapMap 
project: USA 
European 
descent n=30  
   0.500 CCRd: USA 
European 
descent n=24  
   0.125 CCR: USA 
Han Chinese 
n=24 
   0.261 CCR: USA 
African 
American n=23 
8 IVS8+23G>A N/A 0.017 0.029 NIHPDRe: 
USA mixed 
descent n=450 
11 IVS11-50G>Cb N/A 0.431 0.468 CCR: USA 
Caucasians 
n=95 
   0.250 CCR: USA 
European 
descent n=24 
   0.267 NIHPDR: USA 
mixed descent 
n=450 
   0.167 CCR: USA 
Han Chinese 
n=24 
   0.087 CCR: USA 
African 
American n=23 
12 63T>Cb Asn>Asn 0.224 0.167 CCR: USA 
European 
descent n=24 
   0.250 CCR: USA 
Han Chinese 
n=24 
   0.304 CCR: USA 
African 
American n=23 
84C>T Ala>Ala 0.362 0.458 CCR: USA 
European 
descent n=24 
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   0.100 NIHPDR: USA 
mixed descent 
n=450 
   0.167 CCR: USA 
Han Chinese 
n=24 
   0.087 CCR: USA 
African 
American n=23 
14 351G>A Ser>Ser 0.017 No data n/a 
15 IVS15+9G>Cb N/A 0.483 0.500 CCR: USA 
European 
descent n=24 
   0.375 NIHPDR: USA 
mixed descent 
n=450 
   0.458 CCR: USA 
Han Chinese 
n=24 
   0.565 CCR: USA 
African 
American n=23 
23a 140C>T Pro>Leu 0.552 0.214 - 0.436 
(two reports on 
same 
population) 
WICVARf: 
USA mixed 
descent 
aAll SNPs are referred to in the forward direction 
bRefers to forward sequence; SNP database refers to complement reverse sequence  
cUsing ensembl human geneview (www.ensembl.org) and CHIP bioinformatics (http://snpper.chip.org) SNP databases 
dCCR= Coriell Cell Repository 
eNIHPDR= National Institute of Health Polymorphism Discovery Resource 
fWICVAR is a population submitted by the laboratory of the Centre for Genome Resarch at the Whitehead Institute, 
Cambridge MA 
 
In summary, the only variants observed had been previously described in various populations of 
normals and can be classified as single nucleotide polymorphisms (SNPs). None of the variants had 
known associations with Gorlin syndrome or any other disease. 
Each of the SNPs will be described in turn and their frequencies in the test probands compared with 
available data from the Ensembl Human Geneview (www.ensembl.org) and Children’s Hospital 
Informatics Program (CHIP) bioinformatics (http://snpper.chip.org) SNP databases. Table 5.1 
shows all population data available to date from these two databases and compares these with the 
dHPLC variant frequency observed in the test cohort. In brief, for the six of these variants where 
published data was available, dHPLC-detected SNP heterozygotes were seen at frequencies similar 
to those expected from the population frequencies observed in samples of similar ethnic 
background.  
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In the exon 2 assay, a C>T SNP was observed at position 116, synonymous Leu>Leu at the amino 
acid level. The heterozygote relative frequency in the early-onset BCC probands was 2/58 (0.034) 
and no population data were available for comparison. 
In the exon 5 assay, a A>G SNP was observed at position 80, synonymous Thr>Thr at the amino 
acid level. The heterozygote relative frequency in the early-onset BCC probands was 6/58 (0.103) 
and no population data were available for comparison. 
In the exon 6 assay, a SNP was observed at intron 6, position -55 (IVS6-55 T>C) in 26/58 probands 
(frequency of heterozygosity 0.45). A similar frequency of this SNP (12/24, 0.50) in healthy adults 
was seen among North Americans of European descent sampled in the Coriell Cell Repository. 
Population heterozygosity varies between samples of assumed similar genetic background, as the 
frequency of heterozygosity among another group of European descent was 0.267 (see table 5.1). 
Frequencies of this SNP in Chinese and African American groups have been lower than in the 
European samples. 
In the exon 8 assay, a G>A SNP was observed at intron 8, position 23 (IVS8+23 G>A), in 1/58 
probands (frequency of heterozygosity 0.017). This frequency was similar to that found in a 
population from North America of mixed descent (0.029). 
In the exon 11 assay, a G to C base substitution was found at intron 11, position -50 (IVS11-50 
G>C) in 25/58 probands (frequency of heterozygosity 0.431). The frequency of this SNP varied 
widely in other populations, ranging from 0.087 to 0.468. The frequency found in a North American 
population sample of 95 ‘Caucasians’ was 0.468, which differed little from our proband group who 
are mostly also of European descent.  
Two SNPs were seen in the exon 12 assays. A base substitution of T to C occurred at position 63 (63 
T>C) in 13/58 probands (frequency 0.224) and a C to T substitution occurred at position 84 (84 
C>T) in 21/58 probands (frequency 0.362). Neither of these SNPs changes the amino acid sequence. 
Five probands harboured both variants (see appendix 7.10 for sequence). SNP 63 T>C occurred at 
similar heterozygote frequencies of between 0.167 and 0.304 in mixed populations from the USA, 
with the most similar frequency seen in a group of 24 Han Chinese from North America. The SNP 
84 C>T was seen in varying rates of between 0.087 and 0.458 in populations of differing genetic 
backgrounds from the US. The most similar frequency of heterozygosity to that seen in our group of 
probands was seen in 24 North Americans of European descent. 
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In the exon 14 assay, a G>A SNP was observed at position 351, synonymous Ser>Ser at the amino 
acid level. The relative frequency of heterozygosity in the early-onset BCC probands was 1/58 
(0.017) and no population data were available for comparison. 
In the exon 15 assays a G>C SNP was commonly seen at intron 15, position 9 (IVS15+9 G>C), at a 
rate of 0.483. A similar frequency of heterozygosity was evident among populations previously 
studied (ranging from 0.375 to 0.565) from varied ethnic backgrounds.  
In exon 23a, a SNP was observed at position 140 (140 C>T) occurred commonly, with a base 
substitution of C for T in 32/58 probands (frequency of heterozygosity 0.552). This SNP alters 
proline to leucine at amino acid position 1315 of the protein. It has been reported to occur at a 
similar frequency in North American populations of mixed racial background, albeit at two different 
heterozygosity frequencies, 0.214 and 0.436. 
In summary, none of the SNPs observed in these exons, for which published population data existed, 
showed frequencies in this cohort that deviated from published values. Where there was no relevant 
data from other populations, control data was obtained from an Australian sample. 
5.2.2. Comparison with Australian population SNP frequency 
For the three exonic, synonymous SNPs observed in exons 2, 5, and 14, there was no population 
data available with which to compare the frequencies seen in the probands. In order to seek 
preliminary evidence as to whether these SNPs were associated with early-onset BCC, a 
‘convenience’ control group was sought. The set of control siblings would only have been suitable 
for this purpose in a much larger study, given the low frequencies observed in the probands. 
Age- and sex-matched controls (n=110) were selected from subjects in an Australian population-
based study of melanoma [410]. They were relatives of the probands (who were cases of early-onset 
melanoma in Sydney, Melbourne or Brisbane). The protocol of that study does not include 
collection of data from relatives as to previous diagnoses of NMSC, so their status with respect to 
BCC is unknown. However they are known to have 91% Anglo-Celtic ethnicity, a frequency similar 
to that expected in this cohort of BCC-affected probands. 
One hundred and ten control samples were screened for the exon 2, 5 and 14 SNPs and the results 
are shown in table 5.2. In addition, data are shown for the exon 15 SNP, which was screened (in an 
earlier, preliminary project) in 30 controls from this group age- and sex-matched to the 19 initial 
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probands that had been screened at two dHPLC temperatures for exon 15. Published data existed for 
this SNP, but this comparison was to rule out any possible large differences in frequency of PTCH 
SNPs between these Australian controls and other populations previously tested. 
 
Table 5.2 PTCH SNP frequency data comparison with Australian population sample 
Exon SNP Amino 
acid 
change 
Relative 
frequency 
early-
onset 
BCC 
probands 
Relative 
frequency 
Australian 
population 
sample  
p value: 
Fisher’s 
exact 
test (2-
sided) 
2 116C>T  Leu/Leu 0.034 
(2/58 ) 
0.028 
(3/105) 
1.000 
5 80A>G  Thr/Thr 0.103 
(6/58) 
0.047 
(5/106) 
0.197 
14 351G>A  Ser/Ser 0.017 
(1/58) 
0.020 
(2/102) 
1.000 
15 IVS15+9 
G>C 
N/A 0.483 
(28/58) 
0.519 
(14/27)* 
0.818 
*population frequency range 0.375 – 0.565 (see table 5.1) 
None of these SNPs were novel, but no data on their prevalence in the population was available. The 
purpose of the comparison of heterozygote frequencies in the BCC probands and a comparable, 
though not strictly controlled, Australian population sample was to rule out the possibility that these 
were otherwise rare SNPs with a potential association with BCC. This would have remained a 
possibility if they had not been observed in the ‘control’ sample, however all three were observed at 
similar frequencies in both samples (see table 5.2).  
The exon 2 116C>T SNP was observed with a relative frequency of 3.4% in the Australian controls 
(p=1.000, Fisher’s Exact Test for comparison with BCC proband sample). The exon 5 80A>G 
substitution (A>G 80) was observed with a relative frequency of 4.7% of the Australian controls (p= 
0.197, Fisher’s Exact Test). The exon 14 351G>A SNP was observed in 1.9% of controls (p=1.000, 
Fisher’s Exact Test). For the exon 15, IVS15+9G>C SNP, its frequency in the Australian population 
sample (51.9%), was similar to that in the BCC proband group (p=0.818, Fisher’s Exact Test), as 
well as within the range of published values (population frequency range 0.375 – 0.565, table 5.1). 
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5.3. Limits on PTCH mutation frequency in early-onset BCC probands 
Given that no mutations were found in this group of 56 early-onset probands, what can we infer 
about the general population from which this sample was drawn? 
We assume a Poisson distribution because PTCH mutation is considered to be a rare event and 
calculate the upper 95% confidence limit: 
P(X) =  e-λλx 
    X! 
 
Where P = 95%, X = 0, λ= rate of mutation 
0.95 = e-λλ0 
 0! 
 
0.95 = e-λ 
-λ = ln(0.95) 
λ = - 0.051 
The upper 95% confidence rate of the mutation frequency is 5.1%, meaning there is a 97.5% chance 
that PTCH mutations occur in fewer than 5.1% of Australians with early-onset BCC. 
5.4. Discussion 
Nine of the 20 exons screened were found to harbour single nucleotide polymorphisms (SNPs), seen 
on dHPLC as variant melting curves and confirmed on direct sequencing. In eight exons, only one 
SNP was seen, and in one, two SNPs were apparent. All SNPs produced non-coding variants except 
for one, the T>C 140 SNP on exon 23a causing a proline to leucine change, seen in 46% of the 
subjects screened. This SNP was seen in a similar frequency (43.6%) in a SNP database (CHIP) 
comprised of persons of European background who were likely to be of similar racial mix to this 
sample. Five more of the 9 exons harbouring SNPs had population SNP data for comparison, and in 
each, the proband SNP frequency was similar to the population SNP frequency. For the remaining 
three exons harbouring SNPs there were no population SNP data available. For these three exons, a 
control group was chosen from the Australian population for comparison of these exons in the 
PTCH gene. The frequency of SNPs in this group for each of the three exons lacking comparable 
population SNP frequency data was not significantly different to that found in the proband group 
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(see table 5.2). A subset of these controls was compared with the SNP frequency of one of the exons 
for which population SNP data was available (exon 15). This confirmed that Australian SNP 
frequency for PTCH is likely to be similar to that from international data on European-derived 
populations. 
The familial aggregation of BCC in nearly a fifth of all the families screened is suggestive of genetic 
susceptibility as a contributing factor to its cause. The tumour suppressor gene PTCH is a candidate 
as a contributor to genetic susceptibility. Gorlin syndrome is caused by the autosomal dominant 
inheritance of a gene that leads to marked susceptibility to BCC and a range of developmental 
defects. PTCH is the cell growth regulatory gene responsible for this disorder, and mice with 
knockouts of one copy of PTCH develop BCCs when exposed to UVR [4]. In addition, PTCH 
mutations are found very commonly within sporadic tumours suggesting a possible necessary 
involvement of this pathway in tumours outside of Gorlin syndrome. Importantly, it appears that no 
studies have previously looked at possible germline mutations of this gene in non-Gorlin families 
with susceptibility to BCC. Thus it is obligatory that this gene be examined when investigating 
possible genetic causes of familial aggregation of this tumour. 
Twenty PTCH exons (exons 2, 3, 5 to 18, and 20 to 23) were screened for mutations in this study. 
Together these exons account for 4196 coding base pairs (97% of the total of the 4345 coding base 
pairs) and for 97% (199/206) of the published mutations in PTCH. The only exon with published 
mutations not to be screened was exon 19, and this was excluded due to technical problems with 
amplification of the exon by PCR. The primers used amplified the full coding segment and the 
splice junctions next to each exon. dHPLC screening found variants in the introns adjacent to exons 
6, 8, 11 and 15, which confirms that those assays were effective. 
dHPLC identifies DNA variants mainly through detection of the altered affinity and mobility of any 
heteroduplexes formed between mismatched nucleotides in double stranded DNA during the 
reannealing phase at the end of PCR. The sensitivity of dHPLC to detect these heteroduplexes in 
amplicons sized 100 to 732 base pairs is estimated to be between 92-100% [400-402] and is 
increased by performing dHPLC at multiple temperatures. [402]. Thus for single temperature 
screening, the sensitivity is 92% at worst. Generally, dHPLC is a reliable technique to screen for 
single nucleotide substitutions, deletions and insertions [403]. 
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Screening of the PTCH gene was nearly complete in these patients. 97% of the coding regions were 
screened, and although this accounts for 97% of the Gorlin syndrome-associated mutations as 
reported in the literature, there is still a small part of the gene left that could harbour DNA variants. 
It is also possible that PTCH mutations causing non-Gorlin familial BCC might have a different 
mutation spectrum to those which cause Gorlin syndrome. In the interests of efficiency, those 
probands of highest risk were screened more thoroughly by the use of two dHPLC temperatures for 
the subjects with the highest probability of carrying a mutation (ie those with greatest familial 
aggregation). Taking into account the sensitivity of dHPLC and the coverage of the assays 
performed, the completeness of PTCH gene screening in this study is at least 95% (0.92 x 0.97) for 
known Gorlin mutations and 95% (0.92 x 0.97) for the coding sequence of PTCH. Therefore, based 
on the findings of this study it can not be completely excluded that some probands have pathogenic 
DNA variants in the PTCH gene, although given the completeness of the screen it is unlikely. 
Given that no mutations were found in any of the exons screened in any subject, no evidence was 
found to implicate either PTCH inactivating mutations or SNPs in risk of BCC in these early-onset 
cases. Combinations of polymorphisms (haplotypes) have been associated in the literature with 
particular phenotypes such as skin pigmentation and rate of accrual of tumours. Even silent 
substitution of nucleotides (effecting no amino acid change) could influence mRNA processes, 
including affecting splicing accuracy or efficiency [230] eg through effect on enhancer regions or a 
combination effect on protein function. They could also act as markers for other significant gene 
mutations/variants through linkage disequilibrium. The SNPs found here are classified as 
polymorphisms based on their frequency in controls, not on their possible functional significances. 
Given that the frequencies are similar in our subjects compared with controls, it is unlikely that these 
SNPs have any functional significance, and there is no evidence at present that they are associated 
with familial BCC. The potential role of uncommon SNPs as low penetrance alleles for BCC should 
be specifically tested in larger case-control studies.  
Assuming a Poisson distribution, and having observed no mutations in a sample of 56, we can be 
97.5% confident that if there are any PTCH mutations contributing to early-onset BCC in the 
Australian population, then their prevalence is less than 5.1%. Thus high penetrance germline 
mutations in this gene may still be responsible for a small proportion of the increased risk seen in 
this family study. This suggests that screening PTCH will be unlikely to prove relevant to clinical 
geneticists, given that it is a large and expensive gene to test for mutations [404]. Larger family 
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studies may be able to determine if this gene does contribute at all to increased risk of BCC, and 
multiple large studies showing a lack of association will be needed to exclude PTCH as a 
contributory factor to BCC.  
One proband (9125) was affected with Gorlin syndrome, although the clinical features of this family 
were atypical for Gorlin’s syndrome: the proband had pathognomonic Gorlin syndrome features 
(multiple early-onset BCC, palmar pitting, characteristic facies and calcification of the falx cerebri), 
but there were no typically affected first degree relatives. Clinical records show that the proband’s 
father had falx cerebri calcification, but no BCC. PTCH gene screening for this subject was also 
done in a clinical setting and this showed that no DNA variants were present in the PTCH gene of 
either individual. This confirms our finding (of no mutation in PTCH for this proband), and suggests 
a contribution to the disease of other genes in this family, most likely genes coding for proteins 
involved in the hedgehog signalling pathway (see section 1.5.2). To thoroughly exclude other 
members of the hedgehog pathway from involvement in population risk of BCC, other genes in this 
pathway should be screened for high risk families in the same way (eg smoothened, Gli1, Gli2, and 
Gli3). 
Functional studies of the SNP variants found could be performed to determine whether or not they 
are truly benign polymorphisms, although this is very unlikely as no associations with BCC 
susceptibility were seen here. Since all of the SNPs seen here except one are intronic or synonymous 
variants, the protein sequence will not be affected. To rule out an effect on the function of the 
protein however, a bioinformatics analysis of the relevant sequence should be undertaken. The 
involved regions of the gene would be examined to determine whether they are in evolutionarily 
conserved domains indicating a possible important role in the function of RNA processing or 
trafficking, for example altering splice junctions to cause a false splice site. If the involved domains 
are highly conserved, a study of mRNA splicing should be undertaken in cell lines from carriers and 
non-carriers of a similar genetic background.  
Examination of MC1R variant frequency is the next priority when considering genes that could be 
contributing to the BCC-specific aggregation occurring in this family study. This polymorphic gene 
codes for a receptor that is involved in individual differences in pigmentary characteristics such as 
skin, hair and eye colour. Studies have shown that variants of MC1R are also associated with BCC 
risk, and that this occurs independently of pigmentation phenotype (see section 1.7.6): it would be 
interesting to see the correlation between variants of this gene and phenotypes of patients in family 
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studies. As discussed in the previous chapter, correlation of MC1R genotype with skin colour 
parameters recorded by the BYK Gardner, or other full-spectrum reflectance, spectrophotometer 
will be necessary for their full interpretation (see sections 2.3.3 and 4.2.2.3). 
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Chapter 6: Discussion 
 
6.1. Introduction 
This family study aims to investigate the causes of BCC. People who had BCC before the 
age of 40 were recruited in order to study people who are enriched for risk factors: these 
are the youngest 7% of the population to have this disease. A study of 56 families of 
people with early-onset BCC has enabled an investigation into the causes of BCC and has 
confirmed the hypothesis that first degree relatives of people with early-onset BCC are at 
greater risk of NMSC and MM than the general Australian population. Despite no 
differential overall risk to relatives of BCC over SCC, there were nevertheless a subgroup 
of families with aggregation of BCC alone (to the exclusion of SCC), suggesting the 
existence of BCC-specific risk in some families.  
Examination of the probands and their unaffected siblings confirmed the hypothesis that 
identifiable phenotypic risk factors for early-onset BCC exist. These were found to be a 
mixture of pigmentary and sun-exposure-related risk factors and suggest that 
combinations of genetic and environmental factors are involved in BCC susceptibility. A 
study of the PTCH gene failed to find any mutations and does not support the hypothesis 
that mutations in this gene are responsible for the increased risk of BCC seen in the 
probands. Polymorphisms in this gene were found in a similar proportion to the general 
population, the significance of which to BCC risk is unclear.  
6.1.1. Context  
This family study is the first of its kind to look at familial aggregation of NMSC in any 
general non-syndromic population, and shows that this kind of research is an important 
addition to current cancer research in NMSC. Given the enormous burden of disease that 
BCC and SCC present to the Australian and international communities, it is surprising 
that this is the first time familial aggregation of NMSC has been examined in this way. 
NMSC does aggregate in families of probands with early-onset BCC, showing that some 
families exist that are enriched for risk factors to these tumours. These risk factors are 
made up of genetic and environmental factors, both of which have been examined to 
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some extent here, and that should be examined in further detail in future studies. A bank 
of DNA from these multiple-case BCC-affected families has been created for the first 
time by this project, and may be used and expanded upon for further studies on the 
genetics of skin cancer. 
Important additions to the understanding of the aetiology, prevention and treatment of 
other cancers such as breast cancer and colon cancer have been gathered from this type of 
research; in some cases the identification of high and medium-penetrance susceptibility 
genes. Despite its limited scale, this project has demonstrated the feasibility and 
efficiency of a strategy of recruitment of early-onset BCC cases. Further work with larger 
samples need to be done; this will allow for segregation and linkage analysis for further 
characterisation of the way this disease may be inherited.  
The current study also uses a novel approach to determining prevalence from recent 
nationwide Australian incidence data on NMSC, in lieu of cancer registry data on these 
cancers. The resulting estimate is not perfect, but is the best approximation to 
calculations performed using cancer registry data in other cancer studies. The success of 
this approach leads to several important conclusions: that such incidence studies on the 
Australian population are important for family studies in NMSC; that regular collection 
of this rapidly changing data will be important for genetic epidemiological studies 
involving NMSC in the future; and that prevalence may be estimated from incidence data 
for cancers not on cancer registries to allow comparison of sample populations with the 
general population.  
6.2. Hypothesis 1: First degree relatives of people with BCC are at increased risk of 
NMSC compared with the general population, with a differentially greater risk 
of BCC than SCC 
We have shown that first-degree relatives of people with early-onset BCC are at 
increased risk of BCC, SCC and malignant melanoma. The exact risk seen in this study 
varies by cancer, gender, and relative type. The risk of BCC was elevated in all relatives, 
but significantly elevated in brothers, sisters, and mothers of people with early-onset 
BCC, with the greatest risk seen to brothers who had a greater than five-fold increased 
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risk of also having this tumour. The risk of SCC to relatives of people with early-onset 
BCC was elevated in brothers, sisters and fathers of people with early-onset BCC, and 
significantly elevated in sisters and fathers. The greatest risk seen was in sisters of 
probands who had a greater than five-fold risk of having this tumour. The risk of 
malignant melanoma was also raised in all first-degree relatives, but significantly 
elevated for male relatives, the greatest risk seen to brothers who had over ten-fold 
increased risk of having this tumour.  
These figures should be interpreted with the knowledge that the cases were ascertained 
from the SCFA database which is not a statewide registry (see section 2.1.1) and as with 
all family cancer studies, there may be an ascertainment bias whereby people who have a 
history of cancer in the family may be more likely to consent to participate in cancer 
studies. As calculated in section 3.6, any overestimation due to this potential bias is likely 
to be less than two- to three-fold, and therefore the observed increased risk to relatives of 
all three types of skin cancer is likely to be true of early-onset BCC cases as a whole. 
However, given these limitations the results cannot be generalised to an estimation of 
prevalence of NMSC in the families of people in the general population with early-onset 
BCC.  
The hypothesis of a differentially increased overall risk of BCC specifically as compared 
with SCC in relatives of people with early-onset BCC was not supported by this study. 
Instead, risks for both types of NMSC were increased. Nevertheless, in one third of 
families affected by NMSC, clusters of BCC alone (to the exclusion of other skin cancer 
types) did occur. This suggests the possibility of BCC-specific risk factors operating in 
some families, despite the absence of a differentially increased risk for BCC overall in 
the whole sample of 56 families. This concept needs to be explored further with larger 
family studies that are likely to identify more families with clusters of BCC. Further 
genotypic and phenotypic analysis could be done on identified BCC-specific families. 
6.2.1. Estimation of population prevalence 
To determine how the subjects’ risk of skin cancer compares to the Australian population, 
we would ideally compare the incidence per year of each cancer in each subject with that 
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of the incidence of cancer in the same age and sex of the Australian population at the 
same period in time. This data is not available and instead we have estimated the risks for 
the Australian population based on a national incidence survey for NMSC from the year 
1995 [1] and cancer registry data for melanoma data, from the year 1996. 
The incidence figures from the nationwide survey used as a representative of Australian 
population cancer figures may not truly represent the current population incidence, as 
discussed in section 3.6. The Poisson model used to fit a curve to the incidence figures 
from the survey suggest that it provides a reasonable approximation to the whole 
population incidence. We have used the incidence figures from the year 1996 to estimate 
the expected prevalence of disease in our subjects and there are inherent problems in 
doing this.  
The estimated incidences relate to the risk of skin cancer in the population in 1996, and 
may differ from the risk in other years. It is clear that the incidence of both melanoma 
and nonmelanoma skin cancers in Australia have been increasing over the last several 
decades, at least in older persons, meaning that this “snapshot” of risk for skin cancers 
from 1996 may be an overestimate of the total risk of individual subjects in this study 
who have lived through many years where the risk was likely to have been significantly 
smaller. Consequently it is also likely that the overestimate will be smaller for younger 
persons as there has been less time in which to expect a change in the population’s 
incidence. In addition, incidence of BCC may actually be decreasing in younger people 
(under the age of 50 years), meaning that for siblings of probands, our population 
estimates could be slight underestimates [1]. 
Inferring individual risk of skin cancer from this data also assumes that the data is taken 
from a homogeneous population, that is, one where each member of the population’ risk 
is equal. The Australian population is obviously heterogenous with risks likely to be 
associated with skin phototype, other genetic influences, and environmental exposures of 
the individual. This data is likely to include individuals with multiple skin cancers who 
will represent a larger proportion of this risk than others. It will also include persons of 
skin phototype III or IV who are likely to contribute relatively little to the overall risk to 
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the population. As the subjects of the current study are largely of European background 
and born in Australia, the estimates of population incidence could provide an 
underestimate of the actual risk to the subjects of this study.  
Despite these possible biases, our approach to the estimation of population prevalence of 
NMSC provided a reasonable basis with which to compare subject cancer prevalence, 
and could be used as a model for determining population prevalence in future studies. 
6.3. Increased cancer risk in these families: possible causes? 
Overall, susceptibility to NMSC and MM is increased in these 56 families compared with 
the general population: this fact needs some explanation and warrants further investment 
into family studies in the area of NMSC. The fact that a proportion of families have a 
cluster of multiple BCC also suggests a susceptibility to this cancer specifically, 
separately to NMSC susceptibility. The root of all this increased susceptibility is to be 
found in a combination of environmental and genetic risks, some of which may be 
reflected in the phenotypic risk factors identified in probands. Family members usually 
share very similar environments and therefore environmental risks; they also share very 
common genetic backgrounds making differences in either easier to identify than simply 
among unrelated members of the same cohort in the general population.  
The possible causes of the familial aggregation of skin cancer seen in this study are due 
to a complex interaction of environmental and genetic risk factors. By looking at 
phenotypic differences between sibling pairs, the variance in environmental influences 
seen between members of the general population is reduced as siblings generally share 
similar environmental influences. This means that any differences between the 
individuals in the pairs are more likely to have a genetic basis. We looked at the 
phenotypic differences between affected probands and their oldest unaffected siblings 
(where available) in order to find out more about the possible basis for their increased 
risk of cancer. 
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6.3.1. Hypothesis 2: Identifiable pigmentary and sun exposure related risk 
factors are present in people with early-onset BCC compared with their 
unaffected siblings 
Differences seen on examination between people with early-onset BCC and their 
unaffected siblings suggest that genetic differences in combination with high risk sun 
exposure behaviours have contributed to the increased risk of BCC in probands. It is very 
difficult to disentangle the environmental from the genetic causes of these differences, as 
these risk factors are interactive. The term ‘sun sensitivity’ encompasses a mixture of 
inherited characteristics that make up a person’s skin colour, propensity to burn and 
ability to tan. Skin ‘phototype’ predicts BCC risk in our subjects and this confirms 
previous research: people with very fair skin (phototype I = always burn/never tan) have 
almost 10 times the risk of BCC compared with people with darker skin (phototype III = 
sometimes burn/usually tan). Phototype is relatively uncontaminated by environmental 
exposure as a risk and suggests a difference in genetic susceptibility. However, phototype 
is likely to affect sun exposure behaviour to some degree, although a lower phototype 
individual is likely to reduce their sun exposure and therefore cause an underestimation 
of risk at best. 
A similar effect with increased BCC risk for a decreased ‘ability to tan’ and increased 
‘propensity to burn’ was seen although significance was not achieved with this group. As 
seen in section 1.7, pigmentary characteristics are influenced by, but not directly related 
to an individual’s MC1R variant status: MC1R expression may be modified by other as-
yet-unknown genes and proteins to result in phototype. It is also possible that PTCH 
polymorphisms interact with MC1R variant status to affect NMSC risk as suggested by 
one research group [235]. MC1R variant status would be the next priority in genetic 
candidates to examine in such a group, and correlation with sun sensitivity factors and 
PTCH haplotype would be of interest as potential predictors of risk. 
Actinic keratoses are related to cumulative sun exposure and are both precancerous and a 
marker of SCC risk. Our study confirms other work [78] showing that they may also be 
considered a marker for BCC risk, with a three-fold risk for BCC seen with presence of 
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any actinic keratoses. As BCC seems to be associated more with intermittent exposure 
than cumulative, and SCC more to cumulative than intermittent [14], we would expect 
actinic keratoses to be better markers for SCC than BCC. Freckling and solar lentigines 
were also associated with small increased risks, and although significant only on the 
arms, given the trends seen here are likely to act as markers for BCC risk elsewhere on 
the body in larger samples. Presence of these lesions probably reflects a high risk level of 
intermittent or cumulative sun exposure in combination with high risk skin pigmentary 
types. Questionnaires indexed to lifetime residential and work history used by other 
research groups [38, 80] would be valuable in this context, and we would expect to see 
increased intermittent sun exposure in this group, and perhaps, but not necessarily, 
increased cumulative exposure compared with unaffected relatives. Administration of 
such questionnaires should take high priority in sufficiently-funded future family studies 
on NMSC, for the information on interaction of environmental, genetic, and phenotypic 
risk factors that this would provide.  
Red-green reflectance in constitutive skin colour was associated with decreased BCC 
risk, and this may be interpreted as a decreased risk of BCC with increased skin 
melanisation. Skin colour has shown less association with BCC risk than sun sensitivity 
in the literature, although firm conclusions have been difficult due to the lack of 
consistent and reliable measures of skin colour used to date. Few research groups have 
used the BYK Gardner spectrophotometer, and studies using similar instruments have 
reported single readings only, making comparisons with the present study’s results 
difficult [398].  
The BYK Gardner spectrophotometer needs to be calibrated to melanin content and 
perhaps a suitable marker such as MC1R variant status, and this correlation would be 
relatively simple in future studies where both measures are performed. This would allow 
important interpretation of spectrophotometer measurements with respect to genotype 
and phenotype. The influence of hair on the readings of this instrument should also be 
examined to ensure that systematic bias is not being introduced by the hairiness of the 
test site, as seen with the Minolta spectrophotometer [399]. 
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Hair and eye colour were not good measures of BCC risk in this study, reflecting 
previous trends [103, 112]. Importantly, it is noted that self-report of hair colour by 
naming the colour may be an unreliable and subjective measure, and that the use of hair 
swatches may allow a more objective assessment of this variable. Seborrhoeic keratoses 
were paradoxically associated with a trend towards decreased risk of BCC. Many 
probands and siblings were scored as having no seborrhoeic keratoses, and this is an 
unlikely result in an Australian population based on previous studies. This indicates that 
faint lesions were probably missed by the examiner. The validity of the examination for 
these lesions is questioned, and highlights the need for adequate training of the examiner 
in identification of all lesions.  It is unclear whether faint seborrhoeic keratosis lesions 
and pigmented seborrhoeic keratosis lesions are in a relatively constant proportion to 
each other between body sites and also between patients. Any undercounting is likely to 
have occurred systematically for all subjects and all body regions and therefore the 
unexpected paradoxical association with decreased risk of BCC would still require 
explanation. It should be considered that any genetic predisposition to early onset BCC in 
these subjects also in some way suppresses the development of these benign lesions. 
Solar elastosis and pterygium were so common as to lose sensitivity as markers, and 
broader spectra may be required in coding these variables in future. 
6.3.2. Possible environmental causes 
Environmental risks that are likely to increase risks of all three types of skin cancer 
include general sun exposure, with intermittent sun exposure probably predisposing more 
to BCC [101, 102] and MM, and cumulative exposure predisposing more to SCC [14]. 
Studies show that childhood and adolescent exposure may also contribute more to BCC 
and MM risk than later exposure, whereas for SCC risk the cumulative dose may be more 
important [81, 99, 103]. Questionnaires regarding sun exposure over the individuals’ 
lifetime may help to support or refute these hypotheses. Despite the known risk of UVR, 
other factors must be operating to give the 5- to 10-fold increased skin cancer risks seen 
in these family members, as sun exposure contributes relative risks in the low 1.0 to 2.0 
range, and cannot account entirely for the figures seen here. 
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Other environmental risk factors that may increase risks of NMSC include HPV infection 
or possibly other as-yet-unidentified viral agents. Infectious agents such as viruses may 
cluster in families. HPV is a common viral infection, and high risk genital types have 
recently been identified as possible risk factors for both BCC and SCC [308]. Several 
studies have shown that hair follicle reservoirs of HPV infection exist [323, 324, 405], 
and eyebrow hairs are a convenient source of these [324]. It is unclear if eyebrow hairs 
are an adequate marker of HPV infections elsewhere on the body or of the HPV-type 
within epidermal lesions. Collection of eyebrow hairs during examination of subjects is a 
reasonably non-invasive way of measuring sub-clinical HPV infection and conducting 
investigations into the possible association with skin cancer susceptibility. Several 
members the human herpes virus family contribute to human cancer pathogenesis, and 
CMV needs further investigation as a possible co-factor for NMSC [333]. 
Exposure to therapeutic ionising radiation also increases the risk of NMSC [151-153]. 
Surveillance of individuals and their families for all forms of skin cancer may also 
increase following the diagnosis of one member with any type of skin cancer. Arsenic 
exposure and sites of scars from physical trauma have also been reported to increase risk 
of BCC specifically. Theoretically these environmental predispositions could be shared 
by family members and contribute to their increased susceptibility.  
6.3.3. Hypothesis 3: Mutation in PTCH is responsible for some of the 
increased risk in early-onset non-syndromic BCC probands 
Candidate cancer susceptibility genes for NMSC and MM are likely to include MC1R: 
preliminary studies show that variants in this gene may increase risk of skin cancers 
independently of their effect on pigmentary characteristics [267, 274, 283]. It is possible 
that certain variant alleles negate the UVR protection usually afforded to people of higher 
phototype (darker skin) by their pigmentation.  
The tumour suppressor gene PTCH is an obvious candidate for BCC-specific cancer 
susceptibility given its role in Gorlin syndrome, a rare familial genodermatosis involving 
predisposition to multiple early-onset BCC (see section 1.5.4). The current study is the 
first to examine this gene in the context of non-syndromic population susceptibility to 
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BCC. We found no mutations in the PTCH gene in 58 early-onset probands with BCC, 
indicating that if PTCH mutations are causing population susceptibility to this tumour, 
then they are not a major contributing factor. Almost all of the coding sequence of PTCH 
in which Gorlin syndrome-associated mutations have been found was thoroughly 
screened and found to harbour no mutations. Given the numbers of subjects involved and 
the completeness of screening of this gene, we can be sure that if PTCH mutations are 
causing population susceptibility to BCC, that this is affecting less than 5% of the high 
risk non-syndromic early-onset cases in the community. This important result needs to be 
confirmed in larger studies. It does give preliminary evidence that PTCH is unlikely to be 
a major susceptibility gene to BCC outside the context of Gorlin syndrome. As the 
prevalence of any mutations causing general population BCC is likely to be less than 5%, 
this result also indicates that screening PTCH will be unlikely to prove relevant to clinical 
geneticists, given that it is a large and expensive gene to test for mutations of such a low 
yield. 
Single nucleotide polymorphisms in PTCH in these 58 subjects were seen at a similar 
frequency to that reported in other studies in SNP databases (see section 5.4). Most of the 
other studies are from small groups in the USA and all have different ethnic mixes to that 
seen in Australia, and as they have obviously been ascertained in different ways, are not 
an ideal comparison for the Australian sample examined here. The current polymorphism 
heterozygosity results for PTCH will add useful data to this bank of polymorphism data 
for comparison in the future for other studies on this gene in Australia and 
internationally. Given their similar frequency to that seen in controls, these SNPs are 
unlikely to be contributing to the BCC susceptibility seen in these families. However, 
functional studies of these SNPs would be required to rule out a role in susceptibility to 
BCC. 
6.3.4. Other possible genetic causes 
Other genes in the Hedgehog signalling pathway are still candidates for susceptibility 
genes for BCC, and should be further investigated in susceptible people. Activating 
smoothened mutations have been found in human BCC tumours themselves, and mice 
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overexpressing Gli1 or Gli2 develop BCC-like tumours. Overexpression of the hedgehog 
gene itself in human and mouse skin leads to BCC-like tumours also. Potential 
interactions of PTCH polymorphisms with other gene variants (eg MC1R) mutations 
would also be of interest before ruling out possible PTCH involvement in susceptibility 
to BCC.  
Germline mutations or variants that may be involved in NMSC susceptibility also include 
p53Arg, whereby a polymorphism at codon 72 of P53 replaces proline with arginine and 
results in a protein with increased susceptibility to HPV-mediated degradation. Since 
UVR-mediated mutation of p53 is known to occur commonly in BCC tumours 
themselves [292], this variant of p53 may be contributing to population susceptibility to 
BCC and SCC through infection with HPV. Conflicting evidence has been provided 
regarding this possibility [406-409]. The genetically polymorphic glutathione s-
transferase genes and cytochrome P450 enzyme genes are attractive candidates for cancer 
susceptibility because of the roles they play in metabolizing toxins. They have been 
studied with respect to NMSC susceptibility and again, no firm conclusions can be made. 
Further studies are needed to map and identify BCC susceptibility genes. These should 
include genome-wide linkage studies of dense family clusters in which PTCH mutations 
have been excluded, in order to exclude the presence of as yet undetected hign-
penetrance susceptibility gene mutations. It is likely that these will be more efficient if 
restricted to clusters with early median age of onset. In addition, genome-wide 
association studies are needed on large cohorts of cases and controls, and again it would 
seem prudent to restrict these to early age of onset in order to increase their sensitivity to 
genetic as opposed to environmental causes.. 
6.4. Clinical relevance 
We can now be more certain that when an individual in Australia is treated for BCC at an 
early age, their close relatives are more likely to get all three types of skin cancer than 
others in their community. This could have implications for general practitioners and 
dermatologists who may be able to advise patients and their relatives of a need for 
increased preventative measures and surveillance. Patients who have the phenotypic 
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features that are associated with an increased risk of BCC may also be identified by their 
treating doctor: large degrees of freckling or solar lentigines on the arms could indicate 
the need for a closer examination for early tumours, or reduce the threshold to investigate 
or biopsy suspicious lesions in younger people.  
6.5. Future research 
The probability of familial aggregation of BCC and other skin cancers seen in this study 
suggest that large-scale familial aggregation studies are needed on BCC affecting the 
general population (outside of rare hereditary syndromes): to enable an understanding of 
gene/environment interactions, and to allow genome-wide linkage studies to identify as-
yet unknown markers that may cosegregate with the disease. This could be followed by 
segregation analysis and linkage studies which could lead to the development of complex 
genetic models incorporating rare high-penetrance gene mutations, and common 
medium- and low- penetrance genetic variants. 
The design of future familial aggregation studies could mirror the current study with 
larger numbers of probands with early-onset BCC and their first-degree relatives. Subject 
questionnaires could include history of lifetime sun exposure linked to work history to 
better quantify the amount of sun exposure in probands and their relatives. Skin 
examinations for pigmentary and sun exposure characteristics could be repeated in a 
similar manner to the current study. The MC1R gene would be the next priority when 
screening genes likely to be responsible for any familial aggregation seen. As this is a 
relatively small gene, screening could be done with direct sequencing rather than dHPLC 
and sequencing. Eyebrow hairs could be plucked from subjects for examination of HPV 
presence, subtyping, and correlation with BCC risk.  
BCC is a very common human cancer that is likely to have complex interacting genetic 
and environmental causes that are as-yet poorly understood. Further investigation into 
these interactions are desperately needed to improve future monitoring, treatment and 
prevention of this incredibly burdensome disease. 
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Chapter 7: Appendices 
 
7.1. Appendix: Clinical Protocol for Questionnaire and Examination 
 
 
 
 
Westmead Institute for Cancer Research 
Westmead Hospital, Westmead NSW 2145 Australia 
      
 Basal Cell Carcinoma Genetics Project 
  
    
 
 
 
 
 
 
 
 
   Surname ___________________ 
 
   Given Name ________________ 
 
   Date of Birth ________________ 
 
   Identification no ______________ 
 
   Date of Examination ___________ 
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Genotype/Phenotype studies in Non-melanoma  skin cancer 
Clinical Protocol 
SECTION A 
Demographic Data 
 
 
 i. Sex:  M        F          
 
  
  ii. Age: ____ years 
  
 
  Body Surface Area = 71.84 x (h) 0.725 x (w) 0.425 
 
 
  iii. Height: _______ cm (h) 
 
 
 iv. Weight: _______ kg (w) 
 
 
  v. Skin Reflectance   
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L 
a b 
Outer upper 
arm 
   
Lateral wall 
axilla (inner 
upper arm) 
   
 178
SECTION B 
 
COLOURING, SKIN TYPE. 
Please circle one answer for each question below. 
1. Which colour best describes your natural hair colour at age 21?  
 Red (including Auburn) ............................................................................................ 1 
 Fair or Blonde (including White) ............................................................................. 2 
 Light or mouse brown ............................................................................................... 3 
 Grey .......................................................................................................................... 4 
 Dark brown ............................................................................................................... 5 
 Black ......................................................................................................................... 6 
 
2. Which colour best describes the colour of your eyes? 
 Blue or Grey ............................................................................................................. 1 
 Green or Hazel .......................................................................................................... 2 
 Brown or Black ......................................................................................................... 3 
 
3. Which colour type best describes your skin before tanning or on areas never exposed to 
the sun, such as the inside of your upper arm? 
 Very fair ...................................................................................................................... 1 
 Fair .............................................................................................................................. 2 
 Olive or Brown ........................................................................................................... 3 
 Asian ........................................................................................................................... 4 
 Black ........................................................................................................................... 5 
 Other (specify)  ........................................................................................................... 6 
 
Which statement best describes what would happen if your skin were exposed to bright 
sunlight for the first time in summer for one hour in the middle of the day without any 
protection? 
  Get a severe sunburn with blistering? ......................................................................... 1 
  Have a painful sunburn for a few days followed by peeling? .................................... 2 
  Get mildly burnt followed by some tanning? ............................................................. 3 
  Go brown without any sunburn?................................................................................. 4 
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Which of the following best describes what would happen to your skin if it were repeatedly 
exposed to bright sunlight in summer without any protection?  
 Go very brown and deeply tanned ............................................................................ 1 
 Get moderately tanned .............................................................................................. 2 
 Get mildly or occasionally tanned ............................................................................ 3 
 Get no suntan at all or only get freckled ................................................................... 4 
 
In general, how does your skin react to the sun ? 
 Always burns, never tans  1 
 Usually burns, sometimes tans 2 
 Sometimes burns, usually tans 3 
 Never burns, always tans  4 
 
Please look at the faces below. Each of the faces shows some degree of freckling, from none to many. 
Which of these faces best describes how many freckles you would have had at the end of 
summer during childhood? 
 None ......................................................................................................................... 1 
 Very few ................................................................................................................... 2 
 Few ........................................................................................................................... 3 
 Some ......................................................................................................................... 4 
 Many ......................................................................................................................... 5 
 Very many ................................................................................................................ 6 
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Which one of these faces best describes how many freckles you would have at the end of 
summer as an adult?  
 None ......................................................................................................................... 1 
 Very few ................................................................................................................... 2 
 Few ........................................................................................................................... 3 
 Some ......................................................................................................................... 4 
 Many ......................................................................................................................... 5 
 Very many ................................................................................................................ 6 
 
 
 
 
 
 
Have you ever had dental surgery for a cyst (or cysts) in your upper or lower jaw? 
 
      Yes      □ 
      No       □ 
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C. Clinical Phenotype 
 
 
1. Ephelides 
(with respect to freckling quantification chart) 
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2. Solar Lentigines 
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SL4 Upper 
Back/ 
Shoulders 
          
 
 
3. Actinic Keratoses 
 
 
 
  
Nil 
 
Sparse (0-
10) 
 
Moderate (10-
60) 
 
Extensive/confluent 
>60 
 
AK1 
Head/Neck 
    
 
AK2 Chest 
    
 
AK3 Dorsum 
Arms 
    
 
AK4 Dorsum 
Hands 
    
 
 
 
4. Actinic Damage/ Elastosis 
 
 
 
  
Absent 
 
Mild 
 
Severe 
 
Present 
 
AD1 Head, 
neck,  
Anterior Chest 
    
 
AD2 
Periorbital 
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AD3 Lips 
    
 
AD4 Dorsa 
Forearms 
    
 
AD5 Dorsa 
hands 
  
 
  
 
P1 Pterygium 
    
 
 
 
 
5. Seborrhoeic Keratoses 
 
 
  
Nil 
 
Sparse (0-
10) 
 
Moderate (10-
60) 
 
Confluent 
(>60) 
 
SK1 Head & 
Neck 
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6. Skin Cancers 
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Body Site 
 
Number 
 
SCC 
 
  
 
BCC 
 
  
 
Melanoma 
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7. Palmar Pitting 
 
 
 Absent Equivocal Present 
PP1 Palmar pitting 
   
 
 
8. Hair Colour 
 
Hair colour at 21 years use swatches provided  
   
Red ………………………………………………………………..1 
 
Blonde/fair ....................................................................................... 2 
 
Brown …………………………………………………………….3 
 
Black ……………………………………………………………....4 
 
9. Notes 
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7.2. Appendix: Protocol for DNA extraction from whole blood 
 
Take ~3-5 mL blood and add 5x the volume of QIAGEN Buffer EL. Vortex to mix. 
Place on ice for 15 min, vortexing after 10 min then again after a further 5 min. 
Centrifuge at 1400 rpm for 10 min at room temperature. Discard supernatant 
appropriately. 
Wash pellet with 2x the original volume of blood with Buffer EL and place on ice for 5 
min. 
Centrifuge at 1400 rpm for 10 min at room temperature. Discard supernatant 
appropriately. 
Repeat step 4 and 5 if the samples have been frozen. 
Rinse pellet with Buffer EL to remove all remaining red blood cells, using a transfer 
pipette. 
Resuspend the pellet in 5 mL Enzyme solution (after aliquoting the desired amount under 
sterile conditions) and add 50 μL Proteinase K (150 U/mg). 
Incubate at 55°C for at least 3 h, or 37°C overnight. 
Transfer digest to a 15 mL Falcon tube and add 3.5 mL 3M NaCl (1.2M final 
concentration) and shake vigorously 15 times. 
Centrifuge at 2500 rpm for 15 min at room temperature. 
Inverting only once, remove supernatant to a second 15 mL tube and repeat centrifugation. 
Again, inverting only once, remove the supernatant to a new tube and precipitate the DNA 
with 2 volumes of absolute EtOH. 
If no precipitate is present, spin the sample in a high-speed centrifuge at ~10 000rpm (_g) 
for 10-15 min. Remove the supernatant and reconstitute in 1 mL 70% ethanol (EtOH). 
Continue from step 15. 
Spool the DNA from the EtOH using a 1 mL pipette tip and carefully transfer to an 
eppendorf tube containing 70% EtOH and mix. 
Briefly centrifuge the sample to pellet the DNA and remove the EtOH by inverting only 
once then remove the remaining EtOH carefully with a suction line. 
Briefly air dry and resuspend in 200-600 μL sterile T10E1 (for 2 x 107 cells initial dilution 
should be ~300 μL) and place in a heating block at 50°C for 15 min to aid help dissolve 
the pellet.  
Leave at 4°C for at least one week to dissolve before quantitation and electrophoresis. 
 
(Adapted from: kCkonFab; Agha-Hamilton C, Biospecimen Manager at the Westmead 
Millennium Institute, Sydney; Personal communication) 
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7.3. Appendix: Nucleotide sequences of PTCH exons 
 
Nucleotide sequence of wild type PCR product of exons 2 to 4, and 5 to 23 of the PTCH 
gene. Forward and reverse primers are underlined. Exonic sequences are in capital letters, 
intronic sequences in small letters. The size of the amplicon is given between ( ). Sequence 
is from GenBank accession number U59464. 
 
 
Exon 2 PTCH (294 basepairs) 
 
actcctcccttctgcttcgtccccagGGGAAGGCTACTGGCCGGAAAGCGCCGCTGTGGCTGA
GAGCGAAGTTTCAGAGACTCTTATTTAAACTGGGTTGTTACATTCAAAAAAAC
TGCGGCAAGTTCTTGGTTGTGGGCCTCCTCATATTTGGGGCCTTCGCGGTGGGA
TTAAAAGCAGCGAACCTCGAGACCAACGTGGAGGAGCTGTGGGTGGAAGgtaag
agcgcccgccgcggcgcccgcgcccccggcccggtccctcctcgcggttgatagagatattcgccagcgc 
 
 
Exon 3 PTCH (313 basepairs) 
 
ctattgtgtatcctatggcaggtagtcagataacagataaaacatgagtttgcagtgattttgctattctaattaaacctgtacatatttgt
cagTTGGAGGACGAGTAAGTCGTGAATTAAATTATACTCGCCAGAAGATTGGAG
AAGAGGCTATGTTTAATCCTCAACTCATGATACAGACCCCTAAAGAAGAAGGT
GCTAATGTCCTGACCACAGAAGCGCTCCTACAACACCTGGACTCGGCACTCCA
GGCCAGCCGTGTCCATGTATACATGTACAACAGgtaaggcccgccgcgtccacctactaat 
 
 
Exon 5 PTCH (248 basepairs) 
 
gcaaaaatttctcaggaacaccccagtagtgtgccttaacctaacgcatggcctcttctttttaactttgacagATAATAGAA
TATCTTTACCCTTGTTTGATTATTACACCTTTGGACTGCTTCTGGGAAGGGGCG
AAATTACAGTCTGGGACAGCATACCTCCTgtaagtgtgtgatcatgctttctgatgtctgtgacttctctag
gactcagtgtttctaatgttgcttatcattgtttgttcc 
 
 
Exon 6 PTCH (335 basepairs) 
 
cctacaaggtggatgcagtgggcgcagccgtgttactttacgatgcgtttagaaggctcttttcatggtctcgtctcctaatttcttttgc
agAGGTAAACCTCCTTTGCGGTGGACAAACTTCGACCCTTTGGAATTCCTGGAA
GAGTTAAAGAAAATAAACTATCAAGTGGACAGCTGGGAGGAAATGCTGAATA
AGGCTGAGGTTGGTCATGGTTACATGGACCGCCCCTGCCTCAATCCGGCCGAT
CCAGACTGCCCCGCCACAGCCCCCAACAAAAATTCAACCAAAgtgagtaccagcagtga
gcgctctcagaagggtggagagcaaa 
 
Exon 7 PTCH (294 basepairs) 
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gtgacctgcctactaattcccataattatgtggctgtctttttattttagCCTCTTGATATGGCCCTTGTTTTGAA
TGGTGGATGTCATGGCTTATCCAGAAAGTATATGCACTGGCAGGAGGAGTTGA
TTGTGGGTGGCACAGTCAAGAACAGCACTGGAAAACTCGTCAGgtaagccagctcccg
aggacaatctatgccctgtagtcttcttcctttcctcaaaagccacttccctcctgacatcggcaagtgtatttgtattaatacttaaacc
gttatcctcgctagcc 
 
Exon 8 PTCH (256 basepairs) 
 
gaggcagtggaaactgcttcctgggaatactgatgatgtgccttcccttggactgtgctgcagCGCCCATGCCCTGCA
GACCATGTTCCAGTTAATGACTCCCAAGCAAATGTACGAGCACTTCAAGGGGT
ACGAGTATGTCTCACACATCAACTGGAACGAGGACAAAGCGGCAGCCATCCT
GGAGGCCTGGCAGAGGACATATGTGGAGgtaaacccaccttcgaatcggcgtgcagactcgctggtta
tgcaa 
 
Exon 9 PTCH (245 basepairs) 
 
gtgctgtcgaggcttgtggaagtgttcattgcatttgggcatttcgcattctgttgtgaccacagGTGGTTCATCAGAGT
GTCGCACAGAACTCCACTCAAAAGGTGCTTTCCTTCACCACCACGACCCTGGA
CGACATCCTGAAATCCTTCTCTGACGTCAGTGTCATCCGCGTGGCCAGCGGCT
ACTTACTCATGgtaacgctcgatgccatgctcctgggggctggagtttggtttggttgttttagtctttacttttccatgactg
ctcctgcttct 
 
Exon 10 PTCH (242 basepairs) 
 
ttcggcttttgttctgtgcccccattgttctgcttgcagCTCGCCTATGCCTGTCTAACCATGCTGCGCTG
GGACTGCTCCAAGTCCCAGGGTGCCGTGGGGCTGGCTGGCGTCCTGCTGGTTG
CACTGTCAGTGGCTGCAGGACTGGGCCTGTGCTCATTGATCGGAATTTCCTTTA
ACGCTGCAACAACTCAGgtactaaaggagccatttatctgctgtccgttgacaaatgccaccgg 
 
Exon 11PTCH (253 basepairs) 
 
ctgttaggtgctggtggcagagtcctaactagctttagaatcatctgaattgcatctcgcatgtctaatgccaccatcctctgtttttgct
gtagGTTTTGCCATTTCTCGCTCTTGGTGTTGGTGTGGATGATGTTTTTCTTCTGG
CCCACGCCTTCAGTGAAACAGGACAGAATAAAAGAATCCCTTTTGAGgtaatgcaa
aaacaaaagaagagagctttggggacatcacagcttcctctgttcctaag 
 
 
Exon 12 PTCH (211 basepairs) 
 
gaccatgtccagtgcagctctcagcgctgtgtttttttattcccagGACAGGACCGGGGAGTGCCTGAAGC
GCACAGGAGCCAGCGTGGCCCTCACGTCCATCAGCAATGTCACAGCCTTCTTC
ATGGCCGCGTTAATCCCAATTCCCGCTCTGCGGGCGTTCTCCCTCCAGgtgagcttct
ggtgatgaaggctgtggtgatcctgaacg 
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Exon 13 PTCH (222 basepairs) 
 
agtcctctgattgggcggaggcatgttggtgacctctgaattttttttctgctcccagGCAGCGGTAGTAGTGGTGT
TCAATTTTGCCATGGTTCTGCTCATTTTTCCTGCAATTCTCAGCATGGATTTATA
TCGACGCGAGGACAGGAGACTGGATATTTTCTGCTGTTTTACAAGgtacattttcagact
gctgtggccttttgattgggtgcagaatgg 
 
 
Exon 14 PTCH (540 basepairs) 
 
aaaatggcagaatgaaagcaccatttccctgtttcagcataacattgcaacatgtttcccctcctttcagCCCCTGCGTCAG
CAGAGTGATTCAGGTTGAACCTCAGGCCTACACCGACACACACGACAATACCC
GCTACAGCCCCCCACCTCCCTACAGCAGCCACAGCTTTGCCCATGAAACGCAG
ATTACCATGCAGTCCACTGTCCAGCTCCGCACGGAGTACGACCCCCACACGCA
CGTGTACTACACCACCGCTGAGCCGCGCTCCGAGATCTCTGTGCAGCCCGTCA
CCGTGACACAGGACACCCTCAGCTGCCAGAGCCCAGAGAGCACCAGCTCCAC
AAGGGACCTGCTCTCCCAGTTCTCCGACTCCAGCCTCCACTGCCTCGAGCCCCC
CTGTACGAAGTGGACACTCTCATCTTTTGCTGAGAAGCACTATGCTCCTTTCCT
CTTGAAACCAAAAGCCAAGgtaatctgccacaacttaaggctcttcctgtcttcaaaaaaataacagaacctttgg
agttcatcag 
 
 
Exon 15 PTCH (425 basepairs) 
 
gacagcttctctttgtccaggaagagtcagtggtgctccctggggtctgaccttgtgcctcttctgttccagGTAGTGGTGA
TCTTCCTTTTTCTGGGCTTGCTGGGGGTCAGCCTTTATGGCACCACCCGAGTGA
GAGACGGGCTGGACCTTACGGACATTGTACCTCGGGAAACCAGAGAATATGA
CTTTATTGCTGCACAATTCAAATACTTTTCTTTCTACAACATGTATATAGTCAC
CCAGAAAGCAGACTACCCGAATATCCAGCACTTACTTTACGACCTACACAGGA
GTTTCAGTAACGTGAAGTATGTCATGTTGGAAGAAAACAAACAGCTTCCCAAA
ATGTGGCTGCACTACTTCAGAGACTGGCTTCAGGgtaagacggcgtgggaggctctcgtcctttc
ggtcttttgcgt 
 
Exon 16 PTCH (219 basepairs) 
 
agggtccttctggctgcgagttataatgtgttacaatcatttgccatttctagGACTTCAGGATGCATTTGACAG
TGACTGGGAAACCGGGAAAATCATGCCAAACAATTACAAGAATGGATCAGAC
GATGGAGTCCTTGCCTACAAACTCCTGGTGCAAACCGGCAGCCGCGATAAGCC
CATCGACATCAGCCAGgtactccagctgctgggcactga 
 
Exon 17 PTCH (268 basepairs) 
 
aaccccattctcaaaggcctctgttcttcccgtttttgtagTTGACTAAACAGCGTCTGGTGGATGCAGA
TGGCATCATTAATCCCAGCGCTTTCTACATCTACCTGACGGCTTGGGTCAGCAA
CGACCCCGTCGCGTATGCTGCCTCCCAGGCCAACATCCGGCCACACCGACCAG
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AATGGGTCCACGACAAAGCCGACTACATGCCTGAAACAAGGCTGAGAAgtaagta
gcgttttatcgggaggtctgggaacttacagaggtg 
 
Exon 18 PTCH (410 basepairs) 
 
aactgtgatgctcttctaccctgggctgctcctaacctgtgcccttctctgtccagTCCCGGCAGCAGAGCCCATC
GAGTATGCCCAGTTCCCTTTCTACCTCAACGGCTTGCGGGACACCTCAGACTTT
GTGGAGGCAATTGAAAAAGTAAGGACCATCTGCAGCAACTATACGAGCCTGG
GGCTGTCCAGTTACCCCAACGGCTACCCCTTCCTCTTCTGGGAGCAGTACATCG
GCCTCCGCCACTGGCTGCTGCTGTTCATCAGCGTGGTGTTGGCCTGCACATTCC
TCGTGTGCGCTGTCTTCCTTCTGAACCCCTGGACGGCCGGGATCATTgtgagtgtatta
taaggggctttgtggaagtcaaattcctttcagcatagctctttctgcagccgggaagttt 
 
 
Exon 19 PTCH (305 basepairs) 
 
tttgatctgaaccgaggacaccttagccctctggcgacctcccttgtgggcagccccagagggtgacctgcccgcccactgacca
ctgtgtgccctgctccagGTGATGGTCCTGGCGCTGATGACGGTCGAGCTGGCATAGGAG
TGGAGTTCACCGTTCACGTTGCTTTGTTCGGCATGATGGGCCTCATCGGAATCA
AGCTCAGTGCCGTGCCCGTGGTCATCCTGATCGCTTCTGTTGgtatgggagacatttgaag
caaaaactttgtgaaaaaacaacccatttcctctggctctgtttg 
 
Exon 20 PTCH (214 basepairs) 
 
catttaggacagagctgagcatttaccaggtgaagtccagcaacctgatcttgtgaacatcctcattgcacagGCCTTTCTG
ACGGCCATCGGCGACAAGACCGCAGGGCTGTGCTTGCCCTGGAGCACATGTTT
GCACCCGTCCTGGATGGCGCCGTGTCCACTCTGCTGGGAGTGCTGATGCTGGC
GGGATCTGAGTTCGACTTCATTGTCAGGTAAGCAGGCGTGTGCAAGGAGACAT
GTTTTAGAAATCATTGTGATTGGGCC 
 
Exon 21 PTCH (187 basepairs) 
 
tgttcccgtttcctcttgatctcccagGTATTTCTTTGCTGTGCTGGCGATCCTCACCATCCTCGG
CGTTCTCAATGGGCTGGTTTTGCTTCCCGTGCTTTTGTCTTTCTTTGGACCATAC
CTGAGgtcagtagtgacacggggatgtcccacgtgtaggccggctgaatgctgtgtttcctgtgc 
 
Exon 22 PTCH ( 371 basepairs) 
 
agtgtggccagcaggtaaatggacaagaacacttttaacatggaatccccttaaatagGTGTCTCCAGCCAACGG
CTTGAACCGCCTGCCCACACCCTCCCCTGAGCCACCCCCCAGCGTGGTCCGCTT
CGCCATGCCGCCCGGCCACACGCACAGCGGGTCTGATTCCTCCGACTCGGAGT
ATAGTTCCCAGACGACAGTGTCAGGCCTCAGCGAGGAGCTTCGGCACTACGAG
GCCCAGCAGGCGCGGGAGGCCCTGCCCACCAAGTGATCGTGGAAGCCACAGA
AAACCCCGTCTTCGCCCACTCCACTgtaagtgactctgcagaaccagggggaggggtcttcccaccgtgg
tagtgggcctggag 
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Exon 23a PTCH (331 basepairs)  
 
aaacccaaggagggaagtgtgggagctgcggggaccatgcccagcctgggataccacccttctaacccaccctcaccctctgc
agGTGGTCCATCCCGAATCCAGGCATCACCCACCCTCGAACCCGAGACAGCAG
CCCCACCTGGACTCAGGGTCCCTGCCTCCCGGACGGCAAGGCCAGCAGCCCCG
CAGGGACCCCCCCAGAGAAGGCTTGTGGCCACCCCTCTACAGACCGCGCAGA
GACGCTTTTGAAATTTCTACTGAAGGGCATTCTGGCCCTAGCAATAGGGCCCG
CTGGGGCCCTCGCGGGGCCCGTTCTCACAACCCTCGG 
 
Exon 23b PTCH (406 basepairs) 
 
GCATTCTGGCCCTAGCAATAGGGCCCGCTGGGGCCCTCGCGGGGCCCGTTCTC
ACAACCCTCGGAACCCAACGTCCACTGCCATGGGCAGCTCCGTGCCCGGCTAC
TGCCAGCCCATCACCACTGTGACGGCTTCTGCCTCCGTGACTGTCGCCGTGCAC
CCGCCGCCTGTCCCTGGGCCTGGGCGGAACCCCCGAGGGGGACTCTGCCCAGG
CTACCCTGAGACTGACCACGGCCTGTTTGAGGACCCCCACGTGCCTTTCCACG
TCCGGTGTGAGAGGAGGGATTCGAAGGTGGAAGTCATTGAGCTGCAGGACGT
GGAATGCGAGGAGAGGCCCCGGGGAAGCAGCTCCAACTGAGgtgagtgccactgacaa
gggcagcaagggacctagagccaggcaaaga 
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7.4. Appendix: DHPLC melting profiles 
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Predicted dHPLC melting profile for PTCH exon 2, wild type 
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Predicted dHPLC melting profile for PTCH exon 3, wild type 
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Predicted dHPLC melting profile for PTCH exon 5, wild type 
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Predicted dHPLC melting profile for PTCH exon 6, wild type 
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Predicted dHPLC melting profile for PTCH exon 7, wild type 
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Predicted dHPLC melting profile for PTCH exon 8, wild type 
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Predicted dHPLC melting profile for PTCH exon 9, wild type 
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Predicted dHPLC melting profile for PTCH exon 10, wild type 
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Predicted dHPLC melting profile for PTCH exon 11, wild type 
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Predicted dHPLC melting profile for PTCH exon 12, wild type 
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Predicted dHPLC melting profile for PTCH exon 13, wild type 
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Predicted dHPLC melting profile for PTCH exon 14, wild type 
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Predicted dHPLC melting curve for PTCH exon 15, wild type 
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Predicted dHPLC melting curve for PTCH exon 16, wild type 
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Predicted dHPLC melting curve for PTCH exon 17, wild type 
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Predicted dHPLC melting curve for PTCH exon 18, wild type 
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Predicted dHPLC melting curve for PTCH exon 20, wild type 
 
 197
0
50
100
0 20 40 60 80 100 120 140 160 180 200
Bas e Pos ition
61.7 ºC
 
Predicted dHPLC melting curve for PTCH exon 21, wild type 
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Predicted dHPLC melting curve for PTCH exon 22, wild type 
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Predicted dHPLC melting curve for PTCH exon 23, wild type 
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Predicted dHPLC melting profile for PTCH exon 23a, wild type 
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7.5. Appendix: Protocol for PCR-product purification 
 
Using QIAquick PCR Purification Kit and a conventional tabletop microcentrifuge, at 
13,000 rounds per minute: 
 
Suck up the total volume of PCR product using a pipette. 
Add  5 volumes of  Buffer PB to 1 volume of PCR sample and mix. 
Place a QIAquick spin column in a provided 2 ml collection tube. 
To bind DNA, apply the sample to the QIAquick column and centrifuge for 30-60 sec. 
Discard the flow-through. Place the QIAquick column back into the same tube. 
To wash, add 0.75 ml Buffer PE (with added ethanol) to the QIAquick column and 
centrifuge for 30-60 sec. 
Discard flow-through and place the QIAquick column back in the same tube. Centrifuge 
the column for an additional 1 min at maximum speed. 
Place QIAquick column in a clean 1.5 ml microcentrifuge tube. 
To elute DNA from the column, add 50 µl elution buffer (EB) (10 mM Tris-CL, pH 8.5) 
or H2O to the center of the QIAquick membrane and centrifuge the column for 1 min. 
Alternatively, for increased DNA concentration, add 30 µl elution buffer to the center of 
the QIAquick membrane, let the column stand for 1 min, and then centrifuge. The 
average eluate volume is 48 µl from 50 µl elution buffer volume, and 28 µl from 30 µl 
elution buffer. 
Store DNA at -20ºC until use, as DNA may degrade otherwise.  
 
(Adapted from: Qiagen. QIAquick Spin Handbook. USA: Instructions manual; 07/2002. 
p11-8) 
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7.6. Appendix: subjects excluded from analysis 
Table 7.1. Subjects excluded from analysis of comparison with population prevalence (due to death or 
age>70 years) 
ID Family ID  Cancers 
9129 29125 - 
8838 28762 Colorectal 
8827 28763 MM 
8930 28767 Renal Cell 
9331 28775 - 
9332 28775 SCC 
9411 28779 Ovarian 
9115 28797 Colorectal, SCC, BCC 
8892 28816 Renal Cell 
8823 28818 Breast 
8824 28818 - 
8859 28857 Laryngeal SCC 
9042 29022 BCC 
9128 29125 SCC 
9169 29168 Colorectal 
9170 29168 Squamous Cell Lung 
9430 29240 Malignant fibrous 
histiocytoma (sarcoma) 
9289 29275 Breast 
8817 28762 Prostate 
8801 28763 SCC 
8811 29764 - 
8765 28764 - 
8867 28776 - 
8929 28767 - 
8796 28770 BCC, SCC, MM 
8793 28771 - 
8792 28771 SCC 
8985 28773 BCC 
8986 28773 - 
9066 28794 - 
9067 28794 - 
9116 28797 - 
9303 28800 - 
9304 28800 BCC, SCC 
8891 28816 BCC, SCC 
8829 28825 SCC, MM 
8830 28825 Colorectal, BCC 
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9041 29022 BCC 
9096 29094 SCC 
9127 29125 - 
9429 29240 - 
9455 29445 BCC 
9456 29445 BCC, SCC 
9447 29446 - 
9448 29446 SCC 
9461 29459 SCC 
9530 29527 - 
Note: all deceased parents except two had a cancer diagnosis (likely to be bias of 
inclusion in study of people with family history of cancer?) 
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7.7. Appendix: Pedigrees for all families with cancer affected first degree relatives 
 
 
 
 
 
 
 
 
25
67
38m
29125 
37m 
   9127   9128 
16/2/1932     11/6/1928 
SCC 7/11/1995
 
  
   9126    9129   9125   9130
     19/3/1956 
 BCC 5/2/1994
SCC24/8/1999 
6/8/1957    12/8/1961 
 BCC  1/2/2000
 
 3/8/1964 
 BCC 2/12/1989
 
   
43 
28770 
69
39m 
8795 8796 
8770 8807 
29/6/1933 
BCC 
11/03/2003 
23/4/1963 
77m 
               2/4/1922 
BCC 8/9/1992 
SCC 19/11/1997 
            MM 7/7/2000 
Laryngeal SCC 22/09/1999 
 
8806
22/9/1944 
70m 
75m 78
33
28846 
56
26m
8847 8848 
8846 8849 
28/12/1944 
BCC 
1/5/2001 
11/2/1974 
BCC 17/2/2000 
30/12/1976 
10/12/1943 
BCC 27/11/1999 
55m 
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34m 
  8919   8920 
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7.8. Appendix: Raw data 
Raw, semi-quantitative data collected on each variable is displayed below as referred to 
in the text. 
Table 7.2 Self reported hair colour crosstabulation: by questionnaire and hair swatch selection 
  Hair colour by swatch  
  Red  Fair/Blonde Brown Total 
Hair colour by 
questionnaire 
Red 6 0 0 6 
Fair/Blonde 1 16 0 17 
Light or 
mouse brown 
5 20 8 33 
Dark Brown 1 3 27 31 
Black 0 0 1 1 
Total  13 39 36 88 
 
Table 7.3 Single  exposure to the sun (“sun sensitivity”) raw data 
Self-reported 
category 
n (%) 
Severe 
sunburn/blistering 
9 (10.2) 
Painful 
sunburn/peeling 
53 (60.2) 
Mild sunburn/tanning  23 (26.1) 
No sunburn/tanning 3 (3.4%) 
Total 88 (100) 
 
Table 7.4 Repeated exposure to the sun (“ability to tan”) raw data 
Self-reported 
category 
n (%) 
Very brown/deeply 
tanned 
6 (6.8) 
Moderately tanned 34 (38.6) 
Mildly/occasionally 
tanned 
32 (36.4) 
No tan/only 
freckled 
16 (18.2) 
Total  88 (100) 
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Table 7.5 General reaction to the sun (“phototype”) raw data 
Self-reported 
category 
n (%) 
Always burns, never 
tans 
8 (9.1) 
Usually burns, 
sometimes tans  
46 (52.3) 
Sometimes burns, 
usually tans 
34 (38.6) 
Total 88 (100) 
 
Table 7.6 Actinic Keratoses (AK’s) raw data 
Number lesions Head/Neck  
n (%) 
Chest 
n (%) 
Dorsum Arms 
n (%) 
Dorsum Hands 
n (%) 
Nil 59 (67) 84 (95.5) 70 (79.5) 73 (83) 
Sparse (0-10) 27 (30.7) 3 (3.4) 16 (18.2) 13 (14.8) 
Moderate (10- 60) 2 (2.3) 1 (1.1) 2 (2.3) 2 (2.3) 
Total 88 88 88 88 
 
Table 7.7. Solar elastosis raw data 
Actinic 
Damage/Elastosis 
Score 
Head/Neck/ 
Anterior Chest 
n (%) 
Periorbital 
n (%) 
Lips 
n (%) 
Dorsa 
Forearms 
n (%) 
Dorsa 
Hands 
n (%) 
Absent - - - - - 
Mild - moderate 6 (6.9) 6 (6.9) 18 (20.7) 17 (19.5) 15 (17.2) 
Severe 81 (93.1) 81 (93.1) 69 (79.3) 70 (80.5) 72 (82.8) 
Total 87 (100) 87 (100) 87 (100) 87 (100) 87 (100) 
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Table 7.8 Solar lentigines raw data 
Solar lentigines 
semi-quantitative 
score 
Face 
n (%) 
Forehead 
n (%) 
Dorsal Upper 
Limbs 
n (%) 
Upper 
back/shoulders 
n (%) 
0-10 10 (11.4) 16 (18.2) 5 (5.7) - 
10-20 19 (21.6) 31 (35.2) 5 (5.7) 3 (3.4) 
20-30 14 (15.9) 9 (10.2) 9 (10.2) 4 (4.5) 
30-40 17 (19.3) 10 (11.4) 11 (12.5) 5 (5.7) 
40-50 14 (15.9) 10 (11.4) 16 (18.2) 8 (9.1) 
50-60 6 (6.8) 7 (8.0) 11 (12.5) 5 (5.7) 
60-70 7 (8.0) 3 (3.4) 12 (13.6) 18 (20.5) 
70-80 - 1 (1.1) 9 (10.2) 14 (15.9) 
80-90 1 (1.1) 1 (1.1) 9 (10.2) 22 (25.0) 
90-100 - - 1 (1.1) 9 (10.2) 
Total 88 (100) 88 (100) 88 (100) 88 (100) 
 
Table 7.9 Freckling raw data 
Self-reported 
childhood freckling 
Proband  
n (%) 
Sibling 
n (%) 
Total 
n (%) 
None 4 (12.1) 4 (7.3) 8 (9.1) 
Very Few 13 (39.4) 18 (32.7) 31 (35.2) 
Few 8 (24.2) 10 (18.2) 18 (20.5) 
Some 2 (6.1) 13 (23.6) 15 (17.0) 
Many 6 (18.2) 10 (18.2) 16 (18.2) 
Total 33 (100.0) 55 (100.0) 88 (100.0) 
 
Self-reported adult 
freckling 
Proband  
n (%) 
Sibling 
n (%) 
Total 
n (%) 
None 7 (21.2) 8 (14.5) 15 (17.0) 
Very Few 15 (45.5) 28 (50.9) 43 (48.9) 
Few 6 18.2) 7 (12.7) 13 (14.8) 
Some 3 (9.1) 8 (14.5) 11 (12.5) 
Many 2 (6.1) 4 (7.3) 6 (6.8) 
Total 33 (100.0) 55 (100.0) 88 (100.0) 
 
Freckling semi-
quantitative score 
Face 
n (%) 
Forehead 
n (%) 
Dorsal Upper 
Limbs 
n (%) 
Upper 
back/shoulders 
n (%) 
0-10 9 (10.2) 8 (9.1) - - 
10-20 17 (19.3) 16 (18.2) 1 (1.1) 3 (3.4) 
20-30 11 (12.5) 15 (17.0) 2 (2.3) 1 (1.1) 
30-40 11 (12.5) 12 (13.6) 3 (3.4) 2 (2.3) 
40-50 12 (13.6) 10 (11.4) 7 (8.0) 6 (6.8) 
50-60 15 (17.0) 12 (13.6) 6 (6.8) 7 (8.0) 
60-70 5 (5.7) 5 (5.7) 15 (17.0) 17 (19.3) 
70-80 5 (5.7) 4 (4.5) 14 (15.9) 19 (21.6) 
80-90 3 (3.4) 6 (6.8) 37 (42.0) 24 (27.3) 
90-100 - - 3 (3.4) 9 (10.2) 
Total 88 (100)  88 (100)  88 (100)  88 (100)  
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Table 7.10 Seborrhoeic keratoses raw data 
Seborrhoeic Keratoses 
semi-quantitative 
score 
Head/Neck 
n (%) 
Upper 
Limbs 
n (%) 
Chest 
n (%) 
Abdomen 
n (%) 
Back 
n (%) 
Lower 
Limbs  
n (%) 
Nil 73 (83.0) 59 (67.0) 66 (75.0) 63 (71.6) 54 (61.4) 58 (65.9) 
Sparse (0 – 10) 15 (17.0) 28 (31.8) 22 (25.0) 22 (25.0) 32 (36.4) 28 (31.8) 
Moderate (10 – 60) - 1 (1.1) - 3 (3.4) 2 (2.3) 2 (2.3) 
Confluent - - - - - - 
Total 88 (100.0) 88 (100.0) 88 (100.0) 88 (100.0) 88 (100.0) 88 (100.0)
 
Table 7.11 Month of examination crosstabulation (all subjects) 
Month No. siblings examined No. probands 
examined  
Total 
January 4 6 10 
February 4 4 8 
March 3 6 9 
April 2 4 6 
May 6 12 18 
June 2 4 6 
July 2 7 9 
August 6 4 10 
September 2 2 4 
October - - - 
November - - - 
December 2 6 8 
Total 33 55 88 
 
Table 7.12 Season of examination of case-control pairs 
  Examination season proband Total 
  Summer Autumn Winter Spring  
Examination 
season sibling 
Summer 6 2 1 0 9 
Autumn 2 8 1 0 11 
Winter 5 1 4 0 10 
Spring 0 1 0 1 2 
Total  13 12 6 1 32 
Note: number of pairs examined in different seasons compared by taking number pairs below and above the 
diagonal (where season matched) and comparing these two numbers (4 above, 9 below) by McNemar Test. 
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Table 7.13 Comparison of Minolta Spectrophotometer and BYK Gardner spectrophotometer L*a*b* 
readings on three subjects 
Subject  Minolta CM-508d BYK Gardner CGSS 
 n=10 Mean SD Mean SD 
A L* 60.099 1.284 60.931 0.263 
 a* 10.473 0.718 11.026 0.297 
 b* 18.719 0.96 19.43 0.158 
B L* 61.192 0.205 62.516 0.261 
 a* 9.451 0.087 9.123 0.093 
 b* 15.966 0.241 16.105 0.357 
C L* 62.504 0.211 64.354 0.26 
 a* 9.408 0.45 8.834 0.349 
 b* 15.102 0.263 15.659 0.148 
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7.9. Elution profiles PTCH exons without variants (exons 3, 7, 9, 20, 13, 16, 17, 18, 
20, 21, 22, 23b) 
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Figure 7.1 dHPLC elution profiles for PTCH exons 3, 7, 9, 13, 16, 17, 18, 20, 21, 22, and 23b s. 
Elution time in minutes (X-axis) versus absorbance of the eluate in mV (Y-axis). The first peak is the 
sample injection peak; the second peak represents the PCR product elution peak, ideally found between 4-6 
minutes; the third peak is an acetonitrile wash-peak. Some of the elution peaks appear to have a ‘shoulder’; 
this is usually caused by the presence of AmpliTaq Gold. The small irregularities between the sample 
injection peak and the sample elution peak are primer-dimer artefacts [403] . 
 
 
7.10. Elution profiles and sequences for PTCH exons with variants 
 
 Exon 6 
A 
w ild type exon 6
PTCH exon 6 w ild type at 59.2º
Time (Minutes)
109876543210
Ab
so
rb
an
ce
 (m
V)
20
18
16
14
12
10
8
6
4
2
0
 
B 
variant exon 6
PTCH exon 6 variant at 59.2º
Time (Minutes)
109876543210
Ab
so
rb
an
ce
 (m
V)
20
18
16
14
12
10
8
6
4
2
0
 
Figure 7.2 A-B dHPLC elution profile for PTCH exon 6, wild type (A) and variant (B).  
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B. Similar elution profiles to this were obtained for 26 samples  
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Figure 7.3 A-B Reverse sequence exon 6 wild type (A) and variant (B) 
B The arrow indicates the IVS6-55 A>G variant. 
NOTE: This section of forward sequence not visualized on sequencing therefore reverse shown 
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Figure 7.4 A-B dHPLC elution profile for PTCH exon 8, wild type (A) and variant (B).  
Heteroduplexes have different retention properties to the dHPLC column than homoduplexes, creating an 
aberrant sample elution peak. The heteroduplexes are eluted from the colomn prior to the homoduplexes 
because of their reduced melting temperatures [403]. 
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Figure 7.5 A-B dHPLC elution profile for PTCH exon 11, wild type (A) and variant (B) 
B Similar elution profiles to this were obtained for 25 samples  
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Figure 7.6 A-B Reverse sequence exon 11 wild type (A) and variant (B) 
B The arrow indicates the IVS11-50 C>G variant. 
 
 Exon 12 
w ild type exon 12
PTCH exon 12 w ild type at 62.6º
Time (Minutes)
109876543210
Ab
so
rb
an
ce
 (m
V)
20
18
16
14
12
10
8
6
4
2
0
 
A    T      T   C   A  C/G  A  T   G    A   T 
  A       T    T   C   A   C   A   T   G    A   T 
 222
variant 1 exon 12
PTCH exon 12 variant 1 at 62.6º
Time (Minutes)
109876543210
Ab
so
rb
an
ce
 (m
V)
10
9
8
7
6
5
4
3
2
1
0
 
variant 2 exon 12
PTCH exon 12 variant 2 at 62.6º
Time (Minutes)
109876543210
Ab
so
rb
an
ce
 (m
V)
12
10
8
6
4
2
0
 
variant 3 exon 12
PTCH exon 12 variant 3 at 62.6º
Time (Minutes)
10987654321
Ab
so
rb
an
ce
 (m
V)
20
18
16
14
12
10
8
6
4
2
0
 
Figure 7.7 A-D dHPLC elution profiles for PTCH exon 12, wild type (A),  variant 1(B), variant2 (C), and 
variant 3 (D) 
B Similar elution profiles to this were obtained for 8 samples [give all ID numbers?]  
C Similar elution profiles to this were obtained for 16 samples 
D Similar elution profiles to this were obtained for 5 samples 
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E 
Figure 7.8 A-E Forward sequence exon 12 wild type (A, C) and variants (B,D,E) 
B  The arrow indicates T>C 63. 
D  The arrow indicates C>T 84 
E  The arrows indicate a combination of T>C 63 and C>T 84 within the same sequence. This occurred in 5 
proband samples 
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Figure 7.9 A-B dHPLC elution profile for PTCH exon 23a, wild type (A) and variant (B) 
B Similar elution profiles to this were obtained for 26 samples  
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Figure 7.10 A-B. Forward sequence exon 23a, wild type (A) and variant (B) 
B The arrow indicates the T>C 140 variant 
 
 
 
7.10.1. Elution profiles and sequences for exons with Australian control data  
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Figure 7.11 A-B dHPLC profile for PTCH exon 2, wild type (A) and variant (B) 
B Similar elution profiles to this were obtained for both 8784 and 9208 
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Figure 7.12 A-B. Forward sequence exon 2, wild type (A) and variant (B) 
B The arrow indicates the C>T 116 variant 
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Figure 7.13 A-B dHPLC elution profiles for AMFS controls PTCH exon 2; wild type (A) and variant (B) 
B Variant looks similar to variant profile of probands 
 
 
 
 
Figure 7.14 Forward sequence exon 2 AMFS control, variant 
The arrow indicates the C>T 116 variant 
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Figure 7.15 A-B dHPLC elution profiles for PTCH exon 5, wild type (A) and variant(B) 
B Similar elution profiles as this were obtained for samples with ID numbers 8781, 8825, 9094, 9273, 
9274, and 8779 
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Figure 7.16 A-B dHPLC elution profiles for AMFS controls PTCH exon 5; wild type (A) and variant (B) 
B Similar elution profiles to this were obtained for samples with ID numbers 11089, 21027, 7877, 6658, 
and 310 
 
 
Figure 7.17 Forward sequence exon 5 AMFS control, variant 
The arrow indicates the A>G 80 variant 
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Figure 7.18 A-B Forward sequence exon 5, wild type (A) and variant (B) 
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B The arrow indicates the A>G 80 variant 
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Figure 7.19 A-B dHPLC profile for PTCH exon 14, wild type (A) and variant (B) 
B Elution profile for sample ID 9465 
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Figure 7.20 A-B Forward sequence exon 14, wild type (A) and variant (B) 
B  The arrow indicates the A>G 351 variant 
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Figure 7.21 A-B dHPLC elution profiles for AMFS controls PTCH exon 14; wild type (A) and variant 
(B) 
B Similar elution profiles to this were obtained for samples with ID numbers 12835 and 12836 
 
 
Figure 7.22 Forward sequence exon 14 AMFS control, variant 
The arrow indicates the G>A 351 variant 
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Figure 7.23 A-D dHPLC elution profile for PTCH exon 15, wild types (A, B) and variants (C, D) 
C, D Same sample seen at two temperatures. Similar elution profiles seen at both temperatures for all 8 
variants. 
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Figure 7.24 A-B. Forward sequence exon 15, wild type (A) and variant (B) 
B The arrow indicates the IVS15+9 G>C variant 
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